Immunogene op oxidatietherapie-gebaseerde tweede generatie dendritische celvaccins voor de behandeling van hooggradige gliomen by Vandenberk, Lien
  
KU Leuven 
Biomedical Sciences Group 
Faculty of Medicine 
Department of Microbiology and Immunology 
Laboratory of Pediatric Immunology 
 
  
IMMUNOGENIC OXIDATIVE THERAPY-BASED 
NEXT-GENERATION DENDRITIC CELL 
VACCINES AGAINST HIGH-GRADE GLIOMA 
Lien VANDENBERK 
Jury: 
Promoter: Prof. Dr. Stefaan W. Van Gool 
Co-promoter: Dr. Abhishek D. Garg 
Co-promoter: Prof. Dr. Adrian Liston 
Chair: Prof. Dr. Marc Van Ranst 
Secretary: Prof. Dr. Paul Proost 
Jury members:  Prof. Dr. Jacques Piette 
Prof. Dr. Matthias Eyrich 
Prof. Dr. Paul Proost 
Prof. Dr. Carine Wouters        
 
 
 Leuven, March 2016 
Dissertation presented in 
partial fulfilment of the 
requirements for the 
degree of Doctor in 
Biomedical Sciences 
  
  
  
 
 
 
 
 
 
This work was mainly supported by the Olivia Hendrickx Research Fund vzw 
 
www.olivia.be 
  
  
 
 i 
 
Acknowledgements 
Meer dan 5 jaar geleden begon ik aan met doctoraat vanuit de idealistische overtuiging “ik wil 
mijn steentje bijdrage aan een hoopgevende behandeling voor kankerpatiënten”. Nu, 
duizenden cultuurflessen, honderden dendritische celvaccins en al evenveel muisjes later 
besef ik dat deze opgave moeilijker was dan verwacht. De quote die voor mij deze periode 
perfect omschrijft luidt: “If the plan doesn’t work, change the plan, but never the goal 
(Tupac).” Ik ben dan ook ontzettend trots dat ik vandaag aan jullie deze thesis mag 
voorstellen. In dit dankwoord wil ik vanuit de grond van mijn hart de mensen bedanken die op 
welke manier dan ook hebben bijgedragen aan dit werk.  
First of all, I would like to thank my promoter Prof. Dr. Stefaan Van Gool and my co-
promoters Dr. Abhishek D. Garg and Prof. Dr. Adrian Liston. Stefaan, vanaf de eerste keer 
dat ik je ontmoette heb je een ongelooflijke indruk op mij nagelaten. Jouw sterke geloof in 
immuuntherapie, jouw positieve ingesteldheid, jouw inzet voor je patiënten en jouw 
onophoudelijke zoektocht naar onderzoeksgeld zijn werkelijk inspirerend. Je hebt me steeds 
de nodige vrijheid gelaten om het onderzoek op mijn manier aan te pakken en hebt me geleerd 
om negatieve resultaten vanuit een ander oogpunt te bekijken. Bedankt om steeds tijd vrij te 
maken om resultaten te bespreken, alsook voor je onvoorwaardelijke steun over de jaren heen. 
Abhishek, the start of our collaboration was really a turning point in my PhD research. I‟m so 
thankful to have you as a co-promotor and for giving me the chance to work with you on the 
Hypericin-PDT project.  Your ingenuity and passion for science have truly made me a better 
scientist in so many ways; you thought me how to put results in a bigger perspective, how to 
critically design new experiments and how to deal with publishing issues (to name some). As 
a team, we made the PDT story grow, ending up in a high-impact journal and hopefully 
bringing a positive perspective to the patients in the near future. I wish you the best of luck 
with your further academic career and beyond. Adrian, thank you so much for your scientific 
input in my original project proposals and for critically reviewing my final plan and thesis 
manuscript.  
Ongelooflijk veel dank gaat ook uit naar het Olivia Fund (www.olivia.be). Vele mensen 
beseffen niet hoeveel financiële steun er nodig is om kleine kinderstapjes vooruit te zetten in 
de behandeling van kanker. Omdat reguliere financieringskanalen hiertoe ontoereikend zijn, 
zijn initiatieven als het Olivia Fund, opgericht vanuit persoonlijke beweegredenen, van 
onmisbare waarde. Mevrouw Ilse De Reze, ik wil u en uw organisatie dan ook van harte 
bedanken voor de continue steun en het vertrouwen in ons team en onze projecten. Dankjewel 
ook aan het Agentschap voor Innovatie door Wetenschap en Technologie (IWT) voor de 
financiële steun gedurende vier jaren. A big thank you also goes to the James E. Kearney 
Foundation and the many individual donors for your faith in our team and our projects.  
I would also like to sincerely thank the members of the jury for their careful review of this 
manuscript. Your comments helped me to further optimize this work, bringing it to a level I 
can be truly proud of. Ik bedank ook graag de professoren Jan Ceuppens, Steven De 
Vleeschouwer, Dominique Bullens en Peter Hellings voor hun waardevolle commentaren en 
 ii 
 
aanbevelingen tijdens de wekelijkse datasessies. Professor Ceuppens, jouw wil ik in het 
bijzonder bedanken om mij toe te laten om mijn experimenteel werk in uw labo uit te voeren.  
Although a personal motivation is really important, a PhD is not completed within the 
confines of a single person or a single lab. Several persons or groups deserve a special “thank 
you” note here. First of all, professor Patrizia Agostinis and doctor Abhishek Garg 
(Laboratory of Cell Death Therapy & Research), thank you so much for giving me the 
opportunity to join the Hypericin-PDT project.  Thanks to your excellent insights in the 
molecular and cell death-related data and our experience with the model, the DC vaccines and 
the clinical considerations, we can be really proud of this project. Our story is really a prime 
example of what you can accomplish with great teamwork! It has been a pleasure to work 
with you. I truly believe in the translational relevance of Hyp-PDT-based DC vaccines and I 
wish you the best of luck with the continuation of this project and others. Louis Boon 
(EPIRUS Biopharmaceuticals), ook jou wil ik bedanken voor het ter beschikking stellen van 
het depleterende anti-CD8 antilichaam. Professor Gianluca Matteoli, Iwant to thank you for 
providing us with the Rag1 knockout mice. They turned out very helpful for clarifying the 
contribution of the adaptive immune system to the response induced by the DC vaccines. 
Professor Monique Beullens, een welgemeende dankjewel om mee te brainstormen over de 
mogelijke moleculaire verschillen tussen de lysaatbereidingen, alsook voor het laten uitvoeren 
van de nodige gels. I would also like to thank professor Uwe Himmelreich and his team at the 
MoSAIC, especially Cindy, Tom and Ann, for their guidance and excellent problem-solving 
skills during the MRI sessions.  Als laatste wil ik ook nog een dikke merci zeggen aan Karin, 
Kelly en Griet van het animalium voor jullie fantastische zorgen over mijn muisjes. Karin, ik 
ga onze toffe babbels echt missen. We houden zeker nog contact!  
Dankzij dit doctoraat heb ik het geluk gehad om vele nieuwe collega‟s te ontmoeten, ieder 
uniek op zijn eigen manier. Ik wil jullie allemaal bedanken om mijn tijd als doctoraatsstudent 
zo onvergetelijk te maken. Tina, Carolien, Sofie, Matteo, Sofie, Valerie, Sonja, Christine, 
Laura, Zhe, Ina, Emily, Femke, Kelly, Kim, Valentina, Goedele, Danny, Lien, Joost, Thaïs, 
An, Kasran, Sven, Jochen, Matthias, Jonathan, Ellen, Lieve, Brecht Creyns, Brecht Steelant, 
Isabelle, Inge, Isabel, Liana & Jeroen, bedankt voor de aangename babbels, voor de hulp met 
experimenten en voor alle toffe momenten samen.  
Enkele collega‟s zou ik toch graag in het bijzonder bedanken. Liefste Tina, jij hebt mij 
geïntroduceerd in de wondere wereld van de immuuntherapie. Dankzij jouw aanstekelijke 
motivatie heb ook ik de onderzoeksmicrobe te pakken gekregen. Ik wil je vanuit de grond van 
mijn hart bedanken voor je geduld bij het aanleren van nieuwe technieken, voor je kritische 
blik op verkregen resultaten en op de planning van nieuwe experimenten en voor het bieden 
van een luisterend oor bij frustraties en negatieve resultaten. Maar bovenal wil ik je bedanken 
om zo een geweldige vriendin te zijn. Ik zou je echt niet meer kunnen missen. Ik wens je heel 
erg veel succes met je verdere carrière en daarbuiten natuurlijk ook! Carolientje, ook jou wil 
ik bedanken voor al je hulp en steun. Met zen drietjes hebben we ons vaak aan elkaar kunnen 
optrekken, dat schept een band. De congressen die we samen hebben mogen meepikken gaan 
me ook steeds bijblijven. Jochen en Matthias, een dikke merci ook aan jullie om af en toe in te 
springen voor celculturen en voor jullie nuttig advies. Ik wens jullie veel succes met het 
 iii 
 
afwerken van jullie doctoraat en nadien een schitterende toekomst in het onderzoek. Matteo, 
our Italian gentlemen, I have really enjoyed having you around in the lab. I will always 
remember your warm character, your sincere interest in me and my project and your positive 
attitude. You survived a though start in the lab, and I‟m convinced that you will finish your 
PhD, as well as your training as a neurosurgeon with magna cum laude! Brecht, als entertainer 
eersteklas was jij een echte sfeermaker in het labo. Blijf vooral zoals je bent! Inge, gelukkig 
was jij er de laatste jaartjes voor een beetje vrouwenklets. Aan jou nu om de girlpower 
staande te houden in het labo! Ik wens je nog heel veel geluk met je boys thuis en “held og 
lykke” (dat zou veel succes in het Deens moeten betekenen) met je doctoraat. Jeroen, iedereen 
zou zo een zachtaardige en grappige collega als jou moeten hebben. Ik wens je veel succes bij 
je zoektocht naar een nieuwe professionele uitdaging. Lieve, Jonathan en Ellen, heel erg 
bedankt voor de nodige experimentele ondersteuning. Jullie waren altijd bereid om hulp te 
bieden en dat heb ik erg geapprecieerd. Zonder jullie zou het labo nogal een zootje ongeregeld 
zijn. Kasran, ook jij bent bedankt voor je bijstand bij ELISA‟s en ELISPOTs en voor je 
sfeervolle muzikale intermezzo‟s tijdens de labouitstapjes. Caroline Lenaerts, voor jou ook 
een woordje van dank om de administratieve rompslomp op jou te nemen. Omer en Isabelle, 
jullie verdienen ook nog een dikke pluim voor de verwerking van de miltjes tijdens 2 cruciale 
experimenten. Isabelle, jouw spontaniteit en toffe babbels heb ik altijd super gevonden. Ik 
wens je heel erg veel succes met je nieuwe projectwending. Denk maar af en toe aan mijn 
quote in het begin van dit dankwoord.  
Vele mensen zouden denken dat het behalen van je doctoraat een eigen verdienste is. Niets is 
minder waar! De steun, liefde en vrienschap van familie en vrienden zijn voor mij heel erg 
belangrijk geweest in deze periode. Mijn Leuven-Ladies (Jolien, Anke, Lise, Nathalie, Lore & 
Myra) waren er al bij vanaf de onvergetelijke kotperiode. Bedankt voor alle toffe momenten 
samen. We gaan de birthday-diners zeker in stand houden! Nathalie meid, ik kan niet wachten 
om jou te zien schitteren als je je doctoraat verdedigt. Heel erg veel succes nog! Liefste Silke, 
wat bewonder ik jou ”spring-in-het-veld-mentaliteit” en je spontaniteit! Dikke merci voor de 
sfeervolle etentjes, deugdoende babbels en overgetelijke vakanties samen! Dorientje, in jou 
heb ik ook een echte vriendin gevonden. Bedankt voor de gezellige uitjes met en vooral ook 
zonder onze ventjes (ik denk maar aan onze onvergetelijk vrijgezellenweekends). Eveline en 
Esther, mijn 2 vriendinnetjes die al meegaan van in het middelbaar. Wat ben ik blij dat ik 
terug naar mijn roots ben gekomen in Lommel, ondermeer om vaker tijd met jullie door te 
brengen. Dankjewel voor al die jaren echte vrienschap.   
Dan kom ik nu aan misschien wel het moeilijkste deel van heel mijn thesis. Want hoe kan je 
nu je dankbaarheid voor je familie uitten in slechts een aantal zinnen. Ik ga beginnen met mijn 
schoonfamilie. Hilde, Bert, Eva, Laure en toekomstige schoonzonen Joeri en Bram, wat zijn 
jullie een schitterende bende! Jullie hebben mij zo liefdevol opgenomen in jullie gezin, als 
was ik jullie eigen dochter. Hilde, je stond altijd voor me klaar met een luisterend oor, met 
gouden raad of met een tasje met-liefde-gemaakte soep. Betteke, google-man, eersteklasse 
para, wellicht staat er in deze thesis niets dat je nog niet wist maar misschien is dit een nieuw 
gegeven “Ik ben echt ongelooflijk blij met zo een onvoorspelbare en spontane schoonpa zoals 
jij!”. Eefke en Lauke, jullie zijn echte zusjes geworden voor mij. Ik wil jullie bedanken voor 
 iv 
 
jullie spontaniteit en eerlijkheid en vooral ook voor jullie hilarische flapuit-uitspraken. Eefke, 
naast een nieuwe zus heb ik er aan jou ook een prachtige vriendin over gehouden. Jij betekent 
echt heel veel voor mij. Wat kijk ik al uit naar uit om je te zien stralen op jullie trouwdag! 
Allerliefste mama, papa, zusje & Jan. Mijn traantjes vloeien nu al, nog voor ik een woord heb 
getypt. Mam en pap, ik wil jullie vanuit de grond van mijn hart bedanken voor alle 
mogelijkheden, steun en liefde die ik van jullie gekregen heb. Mijn studies, het vele 
verhuizen, mijn doctoraat, de trouw, de bouw, noem maar op. Jullie hebben mijn keuzes nooit 
in vraag gesteld en stonden altijd voor me klaar. Ik kan niet uitdrukken hoeveel dat voor mij 
betekent. Mamske, wat heb ik je gemist als we in Leuven of Grimbergen woonden. Je 
telefoontjes ‟s avonds deden echt deugd. Bedankt ook om ons zo liefdevol te verwennen 
tijdens de bouw en om papa zo vaak aan ons uit te lenen! Papske, ik herken zoveel 
eigenschappen van jou in mij en daar ben ik zo enorm trots op. Het is grotendeels dankzij jou 
doorzettermentaliteit en oplossend vermogen dat ik hier vandaag sta. Die eigenschappen heb 
je nog maar eens bewezen tijdens de bouw. Dankzij jou is onze bouw zo vlotjes kunnen 
verlopen en kunnen we echt trots zijn op ons droomhuis dat we grotendeels zelf hebben 
kunnen neerzetten. Liefste zusje, we kunnen wel zeggen dat het vroeger niet altijd zo boterde 
tussen ons. Maar wat ben ik blij dat we naar elkaar toe gegroeid zijn de laatste jaren. Bedankt 
ook voor je oprechte medeleven als je wist dat ik belangrijke presentaties of deadlines had. Ik 
wens jou en Jan heel erg veel succes met de bouw van jullie prachtige droomhuis en kijk 
ernaar uit om als overbuurvrouw, maar vooral als zusje nog vele gezellige momenten samen 
te beleven.  
Woutje, mijne sjoeter, mijn held! Jij biedt me zoveel steun en liefde, ongelofelijk. Op 
momenten dat ik mijn doctoraat echt niet meer zag zitten of in andere panieksituaties heb je 
me altijd terug weten te motiveren. Als je me dan vertelde hoe trots je wel niet op mij was, 
bloeide ik weer helemaal open. Maar je moet weten dat ik ook supertrots ben op jou! Jouw 
leergierigheid, doorzettingsvermogen en onverwachte ingenieuze ingevingen blijven me 
verbazen. Ook je inzet en geduld tijdens de bouw hebben mij en iedereen uit onze omgeving 
versteld doen staan. Er wacht ons een schitterende toekomst samen, daar ben ik zeker van!  
Wie ik vandaag ben en waar ik vandaag sta, dank ik aan jullie allemaal!  
  
 v 
 
Table of contents 
 
Acknowledgements……………………………………………………………………………i 
Table of contents……………………………………………………………………………...v 
List of abbreviations………………………………………………………………………...vii 
1. GENERAL INTRODUCTION ....................................................................................... 1 
1.1 High-grade glioma: a devastating disease in dire need of therapeutic 
advancement ......................................................................................................................... 1 
1.1.1 Classification, epidemiology and risk factors ...................................................... 1 
1.1.2 Standard of care and major breakthroughs ........................................................... 2 
1.2 Cancer immunoediting: from immune surveillance to immune escape ............... 4 
1.3 Immune contexture in HGG ..................................................................................... 5 
1.3.1 The CNS as an immunologically specialized site ................................................ 5 
1.3.2 The presence of glioma-infiltrating lymphocytes and their prognostic relevance 6 
1.4 Immune escape mechanisms at play in HGG ......................................................... 7 
1.4.1 HGG intrinsic mechanisms .................................................................................. 8 
1.4.2 HGG extrinsic mechanisms ................................................................................ 10 
1.5 Immunotherapy to tilt the balance in favor of anti-glioma immunity ................ 12 
1.5.1 Checkpoint blockade to unleash the brakes of the immune system ................... 13 
1.5.2 Passive immunization with adoptive T-cell therapy .......................................... 14 
1.5.3 Active vaccination therapy ................................................................................. 14 
1.6 DC-based immunotherapy for HGG: clinical status and prognostic markers .. 16 
1.7 The impact of DC biology on the efficacy of DC vaccines ................................... 17 
1.8 Immunogenic treatment modalities to establish a more productive DC-cancer 
cell interphase ..................................................................................................................... 21 
1.8.1 Ultraviolet irradiation ......................................................................................... 25 
1.8.2 Oxidation-inducing modalities ........................................................................... 26 
1.8.3 Heat shock treatment .......................................................................................... 26 
1.9 ICD: ignited by ROS-based ER stress and executed by DAMPs ........................ 27 
1.9.1 ROS-based ER stress .......................................................................................... 28 
1.9.2 DAMPs ............................................................................................................... 29 
1.10 ICD-based DC vaccines ........................................................................................... 31 
1.10.1 Radiotherapy ...................................................................................................... 32 
 vi 
 
1.10.2 Shikonin ............................................................................................................. 33 
1.10.3 High-hydrostatic pressure .................................................................................. 33 
1.10.4 Oncolytic viruses ................................................................................................ 34 
1.10.5 Photodynamic therapy ........................................................................................ 36 
1.11 Hyp-PDT-based ICD in the spotlight ..................................................................... 38 
1.11.1 Hyp-PDT: an evolutionary conserved elicitor of host-defense mechanisms? ... 38 
1.11.2 Hyp-PDT as an ideal ICD inducer for application in DC vaccines? .................. 39 
2. AIMS AND OBJECTIVES ........................................................................................... 41 
3. RESULTS – PART I: Irradiation of necrotic cancer cells, employed for pulsing 
dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against 
high-grade glioma……………………………………………………………………..43 
4. RESULTS – PART II: Immunotherapy with dendritic cell vaccines based on 
immunogenic cell death elicit danger signals and T cells-driven rejection of high-grade 
glioma…………………………………………………………………………………67 
5. FINAL DISCUSSION AND PERSPECTIVES ......................................................... 115 
5.1. Oxidation in cancer cells as driver of potent DC vaccines ................................. 115 
5.2. Are Th1/Th17-driving DC vaccines the next generation glioma vaccines? ..... 116 
5.3. DAMPs as molecular regulators of potent ICD-based DC vaccines ................. 118 
5.4. How to reduce the chance of clinical failure of promising preclinical DC       
vaccines?………………..………………………………………………………………..118 
5.5. Towards the clinical implementation of Hyp-PDT-based DC vaccines ............ 119 
 
Abstract…………………………………………………………………………………......121 
Summary/Samenvatting……………………………………………………………….…..123 
References…………………………………………………………………………………..127 
Curriculum Vitae…………………………………………………………………………..143 
Bibliography and awards………………………………………………………………….145 
 
 
  
 vii 
 
List of abbreviations 
5-ALA 5-aminolevulinic acid     
APC(s) antigen presenting cell(s) 
ATP  adenosine triphosphate 
BBB  blood brain barrier 
CAR  chimeric antigen receptor 
CD  cluster of differentiation 
CMV  cytomegalovirus 
CNS  central nervous system 
CNTR  control 
COX  cyclo-oxygenase 
CRT  calreticulin 
CSF  colony stimulating factor 
CTL(s) cytotoxic T lymphocyte(s) 
CTLA-4 cytotoxic T lymphocyte-associated protein 4 
DAMP(s) damage-associated molecular pattern(s) 
DC(s)  dendritic cell(s) 
Ecto  surface exposed 
EGFRvIII epidermal growth factor receptor variant III 
eIF2α  eukariotic inititiation transcription factor 2-alpha 
ER  endoplasmatic reticulum 
Exo  secreted 
FasL  Fas ligand 
FDA  food and drug administration 
F/T or FT freeze-thawing or freeze-thaw or freeze-thawed  
GBM  glioblastoma multiforme 
GITR  glucocorticoid-induced TNFR family related gene 
 viii 
 
GM  GentleMACS® 
GM-CSF granulocyte/macrophage colony-stimulating factor 
HGG  high-grade glioma 
HHP  high hydrostatic pressure 
HMGB high-mobility group box 
HSP(s) heat shock protein(s) 
Hyp-PDT hypericin-based photodynamic therapy 
ICD  immunogenic cell death 
IDO  indoleamine 2, 3-dioxygenase 
IFN  interferon 
IL  interleukin 
i.p.  intraperitoneal 
IR  irradiation or irradiated 
KO  knockout 
L-Hist  L-Histidine 
LN  lymph node  
LPS  lipopolysaccharide 
mAb  monoclonal antibody 
MDSC (s) myeloid-derived suppressor cell(s) 
MGMT O
6
-methylguanine methyltransferase 
MHC  major histocompatibility complex 
MyD88 myeloid differentiation primary response gene 88 
NAC  N-acteylcysteine 
NK  natural killer  
OAMP(s) oxidation-associated molecular pattern(s) 
OS  overall survival 
PD-1  programmed cell death protein 1 
 ix 
 
PD-L1  programmed death-ligand 1 
PERK  PKR-like ER kinase 
PFS  progression-free survival 
PGE2  prostaglandin E2 
PI3K  Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PTEN  phosphatase and tensin homolog 
SPLs  splenocytes 
TAA(s) tumor-associated antigen(s) 
TAM(s) tumor-associated macropage(s) 
TGF  transforming growth factor 
Th1 or Th17 T helper type-1 polarized cells or T helper IL17A-secreting cells 
TIL(s)  tumor-infiltrating lymphocyte(s) 
TLR  toll-like receptor 
TMZ  temozolomide 
TP53  tumor protein p53 
Treg(s) regulatory T cell(s) 
TSA(s) tumor-specific antigen(s) 
TTF(s)  tumor treating field(s) 
TUDCA Tauroursodeoxycholic acid 
UPR  unfolded protein response 
UV  ultraviolet 
Vacc  vaccine 
VEGF  vascular endothelial growth factor 
WHO  world health organization 
  
 x 
 
  
 1 
 
 
1. GENERAL INTRODUCTION 
"There is no medicine like hope, no incentive so great, and no tonic so powerful as 
expectation of something tomorrow." 
- Orison Swett Marden 
1.1 High-grade glioma: a devastating disease in dire need of therapeutic 
advancement 
1.1.1 Classification, epidemiology and risk factors 
High-grade glioma (HGG) is a terrible disease with a universally dismal prognosis in children 
and adults. Gliomas in general are the most common primary intracranial tumor, representing 
81% of malignant brain tumors. The term glioma refers to a group of central nervous system 
(CNS) tumors that occur primarily in the brain. Gliomas are either astrocytic (most frequent), 
oligodendrocytic or mixed oligoastrocytic, depending on the glial cell type from which they 
originate (1, 2). The World Health Organization (WHO) classifies gliomas into different 
grades (from I to IV) based on several histopathological criteria such as presence or absence 
of necrosis, endothelial proliferation, extend of cellular and nuclear polymorphism and 
frequency of mitotic activity (1). Grade III (anaplastic astrocytoma, anaplastic 
oligodendroglioma and anaplastic oligoastrocytoma) and grade IV (glioblastoma multiforme/ 
GBM) represent the most aggressive HGGs. Of these, GBM is not only the most frequent but 
also the most malignant tumor type (1). GBM can either occur as a primary de novo lesion (in 
90% of the cases) or it can progress from a low grade astrocytic tumor (secondary GBM). In 
comparison to anaplastic astrocytoma, GBM shows more microvascular proliferation and 
necrosis. GBM tumors rarely metastasize outside the brain and are most frequently located in 
the white matter of the frontal or temporal lobes. Patients often present with progressive 
neurological deficit, headache and to a lesser extent with seizures, local edema and increased 
intracranial pressure.   
The overall age-adjusted incidence rates for glioma range from 4.67 to 5.73 per 100,000 
persons per year (2). Although this is a relatively smaller number as compared to certain other 
cancer types, the years of life lost from brain tumors are the highest amongst all cancer types. 
HGG is often diagnosed at a young age and results in short term fatal outcomes (3). Both 
anaplastic astrocytoma and GBM increase in incidence with age, peaking in the 75-84 age 
groups (2). Gliomas are more common in men than in women and it seems that glioma 
incidence rates do not increase over time (2).  
With regards to glioma risk factors, they can be subdivided into environmental and genetic 
factors. To date, the only proven environmental risk factor for glioma is ionizing radiation (4). 
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On the other hand, epidemiologic studies of large and diverse groups of cases and controls 
consistently suggest that allergic conditions (asthma, hay fever, eczema and food allergies) 
can reduce glioma risk (2). Other exogenous causes like smoking, non-ionizing radiation 
(cellular phone use), high dose chemotherapy and occupational chemical exposures have also 
been linked to glioma, but with inconclusive results (4, 5). When it comes to genetic risk 
factors, several monogenic Mendelian disorders (e.g. Li-Fraumeni syndrome, Lynch 
syndrome, Neurofibromatosis 1 and 2) are associated with increased risk of GBM and glioma 
in general (2). However, these disorders can only account for a small proportion of adult 
glioma incidence. To characterize other genetic contributors to adult glioma, five genome-
wide association studies were performed. These studies have identified eight independently 
significant germline DNA single nucleotide polymorphism associations located in seven 
genes (i.e., TERT, RTEL1, EGFR, TP53, CDKN2B, PHLDB1 and CCDC26) (6). Although 
no single molecular factor or signature has been determined to drive gliomagenesis, these 
genetic mutations can provide an excellent basis to unravel the main signaling pathways 
underlying this disease. 
In spite of multidisciplinary treatment, the median prognosis of GBM patients is limited to 
14.6 months, with less than 10% of patients surviving 5 years post diagnosis (7). Relapse is 
universal and upon relapse, prognosis is even worse. Relapsed GBM patients have a median 
survival expectancy of only 9 months and almost all patients succumb within 18 months (8). 
The treatment failure is attributed to the diffuse infiltration of therapy-resistant tumor cells 
into healthy tumor tissue. This results in recurrent tumor growth which, in 95% of the cases, 
develops very close to the resection cavity.  
1.1.2 Standard of care and major breakthroughs 
Despite therapeutic advances, HGG remains an incurable disease with no change in the 
standard of care for already a decade. This standard of care is based on a protocol first 
reported by Stupp et al. in 2005 (7). It involves maximal safe surgical resection followed by 
postoperative radiotherapy with concomitant temozolimide (TMZ) chemotherapy and 
continued use of adjuvant TMZ for 6 to 12 months. As compared to patients treated with 
radiotherapy alone, this treatment protocol could prolong the median overall survival (OS) of 
over 500 newly diagnosed GBM patients by 2.5 months (from 12.1 to 14.6 months) and could 
improve the 2-year and 5-year survival rates (7, 9). TMZ is an oral alkylating agent that adds 
a methylgroup on the O
6
 position of guanine in the DNA. As a consequence, this methylated 
guanine residue can no longer basepair with thymine during the following DNA replication 
cycle, resulting in the G2/M arrest and subsequent autophagy followed by apoptosis (10).  
The most decisive prognostic factors for GBM are age at the moment of diagnosis, Karnofsky 
performance status and the degree of tumor resection (2). In view of the latter, fluorescence-
guided resection with 5-aminolevulinic acid (5-ALA) is introduced since 2006, resulting in a 
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higher rate of complete resection and an improved 6-month progression free survival (PFS) in 
patients diagnosed with HGG (11).  
Another important milestone in HGG therapy is the discovery that patients with a methylated 
O
6
-methylguanine-DNA methyltransferase (MGMT) promoter have better responses to 
chemotherapy with alkylating agents like temozolomide (12). MGMT is a DNA repair 
enzyme that can remove alkyl groups from the DNA, enabling the prevention of DNA 
mismatch during replication and transcription. Methylation of the genetic promoter of this 
enzyme inhibits its activity. Hence, MGMT promoter methylation is considered a very 
valuable predictive biomarker for therapy response to TMZ that can be tested on a routine 
basis for therapeutic decision making. 
Given the recent advances in molecular diagnostics, alternative tumor classification methods 
(other than the WHO histological classification) are proposed based on molecular 
abnormalities and signaling pathways that play a role in glioma. These molecular subtypes 
show distinct prognosis and therapy responses. While there is significant correlation between 
traditional pathologic groupings and the newer molecular subtypes, this overlap is incomplete. 
Three core pathways have been proven to be targeted in GBM patients: retinoblastoma 
signaling, tumor protein 53 (TP53) signaling and receptor tyrosine kinase signaling (2). 
Subsequent to the characterization of the main signaling pathways, a GBM categorization 
based on gene expression profiles was proposed containing the following subtypes: classical, 
neural, proneural and mesenchymal (13). The most frequent classical subtype harbors 
hallmark epidermal growth factor receptor (EGFR) alterations and deletion of cyclin 
dependent kinase inhibitor 2A. Recently, the proneural subtype of GBM (characterized by 
isocitrate dehydrogenase mutations and hypermethylation across the genome) was shown to 
be the only subgroup with improved survival (2). Hence, molecular classification opens the 
door for personalized treatment of HGG by transforming diagnosis, dictating survival and 
elucidating subgroups that may respond better to specific therapies.  
Unfortunately, targeted molecular therapies have not been really successful thus far with the 
exemption of the antiangiogenic agent bevacizumab (a neutralized monoclonal antibody 
against VEGF, a key regulator of angiogenesis) (14). In 2009, bevacizumab received approval 
from the Food and Drug administration (FDA) for recurrent GBM based on an uncontrolled 
phase II trial demonstrating improved PFS at 6 months (15).  
Another therapy that was recently approved by the FDA for recurrent GBM is Nova-TFF 
(14). This treatment consists of tumor treating fields (TTFs) that are low amplitude alternating 
electric fields that can disturb cell division and tumor development.  
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1.2 Cancer immunoediting: from immune surveillance to immune escape 
Despite the heterogeneity of different cancer types, they all appear to share six hallmarks: 
angiogenic capacity, unlimited replication, resistance to apoptosis, autonomous growth, 
unresponsiveness to inhibitory growth signals and the ability to metastasize (16). In the last 
decade, it was proposed that the ability of tumors to evade immunological pressure can be 
considered an extra characteristic of tumorigenesis (16, 17). The rationale for this constatation 
lies within the immunoediting hypothesis originally proposed by Dunn et al. (17) 
The idea that the immune system can control tumor growth without therapeutic intervention 
(also termed immunosurveillance) is being discussed since the 1950s. Three main findings 
have meanwhile confirmed its existence (17). First, the incidence of chemically-induced, 
spontaneous and genetically engineered tumors is increased in immune compromised mice. 
Also in immunosuppressed or immunocompromised humans, both virus-induced and non-
virus-induced tumors develop at higher incidences. Second, the presence of tumor-infiltrating 
lymphocytes (TILs) can correlate with improved survival in cancer patients. Finally, owing to 
the discovery of tumor-specific antigens, it became clear that cancer patients can develop 
tumor-antigen specific immune responses.  
However, the interplay between the cancer and the immune system was not completely 
resolved with this concept of immunosurveillance. How would immunosurveillance then alow 
cancers to develop in immunologically intact individuals? The immunoediting paradigm gives 
a plausible explanation to this question (Figure 1). In this concept the tumor progresses 
through three different phases during its interplay with the immune system: elimination, 
equilibrium and escape (17).  In the first phase, the innate and adaptive immune system work 
together to recognize and destroy the malignant cells before they become a clinically apparent 
entity. However, cancer cells that manage to survive elimination are subjected to continuous 
immune selection pressure. This causes the tumor cells to genetically adapt, giving rise to new 
variants with increased resistance to immune attack. This equilibrium phase is considered a 
latent period in which those tumor cells that are not eliminated in the elimination phase persist 
in a dynamic interaction with immunity (18). Finally, in the escape phase, the edited tumor 
cells can outstrip the immune pressure to constrain tumor growth and become clinically 
detectible. A broad spectrum of tumor escape mechanisms have been discovered that can be 
grouped into two categories: tumor cell intrinsic and tumor cell extrinsic mechanisms. The 
most relevant mechanisms for immune escape in the context of HGG will be discussed in 
chapter 1.4. 
A key feature of cancer immune editing is that tumors express tumor-associated antigens 
(TAAs) and tumor-specific antigens (TSAs) that can be targeted by T cells, leading to their 
destruction and/or selection of tumor escape clones. Indeed the importance of T cells, in 
particular CD8
+
 T cells in cancer immune editing has long been recognized, with large 
 5 
 
annotated data sets often demonstrating favorable prognosis in patients with strong CD8
+
 T 
cell infiltrates. In addition to CD8
+
 T cells, other adaptive and innate immune cells and 
parameters eventually orchestrate the antitumor immune response. The term immune 
contexture defines this complex immunological composition of the tumor microenvironment 
in which the location, density and functional orientation of infiltrating hematopoietic cells 
correlates with the clinical outcome of patients. Although this human immune contexture can 
only be evaluated at the stage of tumor escape (when the tumor is clinically apparent), it can 
predict the ability of the natural immune reaction or therapies to drive the tumor into 
equilibrium or to even destroy the tumor.  
 
Figure 1: An overview of the cancer immunoediting process in high-grade glioma. Cancer 
immunoediting encompasses three main phases, i.e. elimination, equilibrium and escape. 
Tumors can be eliminated in either the elemination or equilibrium phase. However, due to 
immune selection pressure and genemic instability, tumors may ultimately escape immune 
protection and become clinically apparent in the escape phase. The molecular basis of 
several immune escape mechanisms is discussed in chapter 1.4 of this work. NK, natural 
killer; NKT, NK T cell; PTEN, phosphate and tensin homolog; Treg, regulatory T cell. 
(Modified adapted from Dunn et al. (19)). 
1.3 Immune contexture in HGG 
1.3.1 The CNS as an immunologically specialized site 
The brain has long been envisaged as an immunoprivileged site due to the presence of the 
tight blood-brain barrier (BBB) and the absence of a conventional lymphatic drainage system. 
Later experiments have invalidated this dogma by revealing that the CNS is 
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immunocompetent and can exhibit dynamic interactions with the peripheral immune system. 
Although the cellular biology of the BBB remains poorly understood, it is now a certainty that 
this barrier is deteriorated in the context of malignant glioma (20). In addition, it is now well 
recognized that intracerebral antigens and T cells can access the cervical lymph nodes via 
drainage through Virchow-Robin spaces (20). Moreover, dendritic cells (DCs) injected into 
brain tumors have been shown to migrate to the cervical lymph nodes in a mouse glioma 
model (19, 21). In order to manifest antiglioma cellular immunity, glioma antigens have to be 
presented in major histocompatibility complex (MHC) molecules (either within the brain 
itself or in the peripheral lymphoid structures) to naïve precursor T cells and B cells. Within 
the brain, DCs and microglia (the brain‟s resident macrophages) are the main antigen-
presenting cell (APC) types, although B lymphocytes and perivascular macrophages may also 
exert this function (20). DCs and microglia are both able to cross-present intracerebral 
antigens in MHC-I context to naïve CD8
+
 T cells in vivo. A last argument in favor of the 
immunocompetent state of the CNS is the ability of antibodies and activated T cells, but not 
naïve T cells, to bypass or to penetrate the BBB to interact with their target antigens (19). 
Once arrived in the brain, these antigen-specific T cells are capable of proliferating and 
acquiring effector function.   
1.3.2 The presence of glioma-infiltrating lymphocytes and their prognostic relevance 
In order to mount effective antitumor immunity, activated lymphocytes like activated antigen-
specific CD4
+
 T helper (Th) cells, CD8
+
 cytotoxic T lymphocytes (CTLs) and natural killer 
(NK) cells must traffic into the glioma microenvironment. Several chemokines (in particular 
CXCL12) and adhesion molecules (integrins α4β1 and αEβ7) expressed by T cells can 
attribute to their CNS homing (19). Both CD4
+
 and CD8
+
 T cells make up 4 to 40% of tumor-
infiltrating immune cells in glioma (22). Moreover, it has been shown that TILs are able to 
lyse autologous tumor cells (19). It is increasingly being reported that increased number of 
TILs may correlate with improved survival in many cancer types (23). In the context of 
glioma, tumor-infiltrating CD8
+
 T cells are considered a good prognostic indicator (24-28).  
With regards to the infiltration of general CD4
+
 lymphocytes, the results are less 
straightforward. While three studies report a longer survival in patients with an enriched 
CD4
+
 T cell infiltrate (28-31), two studies contradict these results (26, 31). In line with these 
data, Yu et al. have demonstrated a higher CD8
+
/CD4
+
 T cell ratio in less aggressive brain 
tumors (Yu 2003).  These conflicting results for the CD4
+
 subset might be attributed to the 
fact that the CD4
+
 population also comprises immunosuppressive regulatory T cells (Tregs) 
and different Th subsets. The significance of Treg infiltration in HGG will be discussed in 
chapter 1.4.2.3. While the positive prognostic value of the Th1 subset has already been 
demonstrated in the context of DC vaccinated GBM patients (32), the prognostic significance 
of the Th2 subset is still not elucidated. Nevertheless, as further elaborated in chapter 1.4.2.1, 
the cytokine profiles of glioma infiltrating lymphocytes are generally skewed towards Th2-
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biased humoral immunity, suggesting a negative effect of Th2 infiltration on prognosis (19). 
The role of Th17 cells, a Th subset involved in antimicrobial inflammation and autoimmunity, 
remains controversial in most tumor types. In the setting of glioma, a recent study by Cui and 
colleagues revealed a better OS and PFS in GBM patients with high IL-17 (the main Th17 
cytokine) expression levels (33). Furthermore, this study identified IL-17 expression as an 
independent prognostic indicator in GBM patients. This result is reminiscent of that in the 
GL261 mouse model in which intracranially implanted tumors grew equally well in wildtype 
and IL-17 deficient mice (34). Along the same lines, Hu et al. showed no difference in IL-17 
expression between human low-grade and high-grade gliomas.  
NK cells consist of cytotoxic effector lymphocytes that play an important role in anti-tumor 
immune responses through apoptotic killing of tumor cells and the secretion of IFN-γ. A high 
density of NK cells was shown not to correlate with clinical outcome in non-small lung 
cancer, while it is associated with improved survival in early stages of breast cancer (23). 
Moreover, recent reports have underlined that tumor-infiltrating NK cells have an anergic 
phenotype, characterized by downregulation of activating receptors (e.g. NKp30, NKp46, 
NKp80) and upregulated expression of co-inhibitory receptors (23). These data suggest that 
NK cells may have a protective role in early stages of tumor development, while exerting 
negligible or even immunosuppressive effects in clinically apparent tumors.  When it comes 
to NK cells infiltrating in brain tumors, their suppressive role has been demonstrated both in 
vitro and in vivo (35, 36). These cells have been shown to infiltrate in HGGs as CD56
dim
CD3
-
CD16
-
 cells (25). Nevertheless, the tumor infiltration by NK cells remains low (approximately 
2% of all tumor-infiltrating immune cells) and their functionality is often harmed by tumor-
derived factors (25). As an example, tumor-derived TGF-β downregulates the expression of 
the NKG2D activating receptor on NK cells isolated from GBM patients (37).  
The role of B cells in gliomas remains enigmatic. Although these cells have been shown to 
infiltrate in HGGs, they only represent a tiny fraction (0.03 – 0.7% of all tumor-infiltrating 
immune cells) (25). As documented by Candolfi et al., B cells can function as APCs for T 
cells in a murine GBM model, suggesting their favorable prognostic impact (38). In contrast, 
several reports suggest a protumoral role of B cells relating to their ability to negatively 
regulate macrophage function through IL-10 production (37).  
1.4 Immune escape mechanisms at play in HGG  
The observation that most patients who develop HGGs are not immunocompromised 
underscores the concept of immune escape. Indeed, there is a profound local immune 
suppression in the glioma microenvironment that can provoke systemic depression of cellular 
immunity, even in a more rigorous fashion than observed in other solid tumors. A myriad of 
immunoevasive cues are at play in HGG (Table 1). These can be grouped in tumor intrinsic 
and tumor extrinsic mechanisms.  
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Table 1: Escape mechanisms involved in glioma immunoediting 
Intrinsic mechanisms establishing invisibility Therapeutic strategies 
- Escape of adaptive T cell 
recognition 
Defective MHC class I antigen 
presentation/processing, antigen 
loss (39) 
Induction of immunogenic cell 
death, DC vaccination (40) 
 Aberrant T cell costimulation 
(decreased B7-H1 and increased 
PD-L1 expression) (19, 41) 
Adjuvants (e.g. CD40 agonist, anti-
CD137), PD-1/PD-L1 blockade 
(42) 
- Evasion of innate NK cell 
recognition 
Increased expression of HLA-E 
and HLA-G (19, 41, 43) 
NKG2A blocking antibodies (44) 
 Release of soluble NKG2D ligands 
(19) 
 
Extrinsic mechanisms impairing immune cell function Therapeutic strategies 
- Lymphocyte dysfunction and Th2  
skew 
T cell anergy and lymphopenia (19, 
45, 46)  
Adoptive T cell therapy, 
checkpoint blockade (e.g. anti-
CTLA-4, anti-PD-1/PD-L1) (42, 
47-51) 
 Th2 skew in TILs and blood (52-
54) 
Adoptive T cell therapy, DC 
vaccination (40, 47, 50, 51) 
- Immunosuppressive factors Immunosuppressive enzymes (e.g. 
IDO, COX-2) (20, 44) 
IDO and COX-2 inhibitors (19, 55) 
 Immunosuppressive molecules 
(TGF-β, IL-10, PGE2, Galectin-1, 
VEGF) (19, 55) 
Anti-VEGF therapy, TGF-β 
receptor 1 inhibitors/ TGF-β 
blocking antibodies, COX-2 
inhibition (55) 
- Recruitment of immune 
suppressive populations 
Tregs (56-61) Anti-CD25 antibodies, 
cyclophosphamide, low dose TMZ, 
IDO inhibitors (20, 55, 62) 
 MDSCs (63, 64) COX-2 inihibition, CCL2 
neutralization, all-trans retinoic 
acid (20, 55, 65) 
 TAMs/Microglia (20, 66) CSF-1 receptor inhibition, CCL2 
neutralization, STAT3 inhibition 
(20, 55, 65) 
 
1.4.1 HGG intrinsic mechanisms 
HGG intrinsic mechanisms encompass intrinsic changes within the glioma cell that impair 
their recognition by the immune system (Table 1). 
1.4.1.1 Escape of adaptive T cell recognition 
To establish invisibility, glioma cells can alter their MHC class I antigen processing and 
presentation capacity, thereby impairing CTL lysis. Facoetti et al. have demonstrated the loss 
of HLA class I antigens in about 50% of GBM patients (39). Moreover, this selective antigen 
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loss correlated positively with tumor grade. On the other hand, the expression of HLA-DR, a 
major MHC class II antigen increased with increasing tumor grades, hinting towards a 
skewing of the immune response towards Th cells rather than CTLs (19, 20). Likewise, GBM 
tumor cells have been shown to downregulate key molecules in the antigen processing 
machinery like LMP2 and TAP1 or they can even completely abolish the expression of 
certain antigens as was shown for epidermal growth factor receptor variant III (EGFRvIII) 
(19, 20, 48). The EGFRvIII is an example of a tumor-specific antigen (TSA) that is expressed 
in 30 to 40% of GBM patients, but its expression is absent on nontransformed cells (67). In 
addition, GBM cells that exhibit increased levels of MHC relative to nontransformed cells, 
show impaired expression of costimulation signals belonging to the B7 family (44). 
Programmed Death Ligand-1 (PD-L1) is a member of this B7 family, but exerts primarily 
inhibitory functions when expressed on tumor cells. Upon binding to its receptor PD-1, 
expressed on antigen-specific T cells, PD-L1 can infer anergy and even apoptosis of activated 
T cells (68). Already a decade ago, Wintrelle et al. documented the constitutive expression of 
PD-L1 in glioma cell lines and tumor specimens (68). Few years later, the loss of phosphatase 
and tensin homolog (PTEN), a suppressor gene playing a role in gliomagenesis, was shown to 
enhance the expression of PD-L1 on glioma cells (41). Of note, upon stimulation of PTEN 
deficient glioma cells with IFN-γ, immune evasion was even further potentiated by increased 
expression of PD-L1 and increased T-cell apoptosis (69). PD-L1 expression is positively 
correlated with tumor grade in the context of glioma (70) and co-culturing of alloreactive T 
cells with glioma cells expressing PD-L1 significantly depressed the production of 
proinflammatory cytokines like IL-2 and IFN-γ (68).  
1.4.1.2 Evasion of innate NK cell recognition 
Besides evading recognition by T cells, glioma cells have also developed smart strategies to 
disrupt the activity and recognition by NK cells. NK cells are innate effector lymphocytes that 
play a significant role in antitumor immune responses through e.g. the apoptotic killing of 
tumor cells and priming of Th1 responses (37). The functional status of NK cells largely 
depends on the delicate balance between the signaling via activating receptors or inhibitory 
receptors expressed on this innate cell type. NKG2A is an important inhibitory receptor 
expressed on NK cells and CD8
+
 T cells. Its ligand, the non-classical MHC class I molecule 
HLA-E is overexpressed in primary GBM cell cultures, rendering them resistant to NK cell 
and CTL cytotoxicity (43). NKG2D on the other hand is an activating receptor expressed on 
NK cells, CD8
+
 T cells and γδ T cells (19). Its ligands, MICA/B and ULBP2 are expressed in 
glioma specimens and their expression correlates inversely with WHO tumor grade (19). 
Moreover, glioma cells can evade NKG2D-dependent cytotoxicity by producing soluble 
forms of these ligands or by expressing the non-classical MHC class I molecule HLA-E (19).  
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1.4.2 HGG extrinsic mechanisms 
HGG extrinsic mechanisms include the impairment of immune cells induced by the glioma 
cells (Table 1).  
1.4.2.1 Lymphocyte dysfunction and a Th2 cytokine skew 
A first extrinsic mechanism is the lymphocyte dysfunction observed in HGG patients. Several 
studies have outlined quantitative and functional deficits, specifically in the CD4
+
 T cell 
subset (19). Additionally, T cells isolated from glioma patients show decreased 
responsiveness to IL-2 signaling and defects in early T cell receptor signaling events (45, 46). 
Another critical observation encompasses the predominant expression of Th2 cytokines (e.g. 
IL-4 and IL-10) in glioma specimens, cell lines and glioma TILs (53, 54). In line with this 
notion, HGG patients show increased serum levels of IL-10 (a general immunosuppressive 
cytokine related to Th2 responses) and decreased levels of IL-12 (a pro-inflammatory 
cytokine related to Th1 responses) (52). Although the mechanism for this polarization towards 
a protumoral Th2 profile in gliomas is not elucidated yet, glioma-derived IL-10 may play a 
curcial role here. IL-10 is known to contribute to the priming of Th2 responses and to 
interfere with Th1 differentiation. Primary glioma cultures produce high levels of IL-10 and 
IL-10 expression is higher in HGGs as compared to LGGs (44, 53).  
1.4.2.2 Secretion and expression of immunosuppressive factors  
Besides the secretion of IL-10, glioma cells secrete or express a myriad of immunsuppressive 
factors like STAT3, TGF-β, PD-L1, PGE2, indoleamin 2, 3-dioxygenase (IDO), galectin-1 
and Fas ligand (FasL) (20, 44). Several of these factors are implicated in the 
induction/expansion of Tregs (e.g. TGF-β, PGE2, IDO), while others contribute to anergy 
induction in T cells (e.g. PD-L1, STAT3) or the induction of apoptosis (e.g. PD-L1, FasL and 
Galectin-1). Most of these factors have been extensively studied in experimental glioma 
mouse models, with promising drugs interfering with these pathways now being tested in 
clinical trials. For a more detailed overview of these immunoregulatory pathways, we refer to 
two recent reviews by Ahn et al. and Dunn et al. (19, 55).   
1.4.2.3 Recruitment of immunosuppressive leukocyte populations 
CD4
+
FoxP3
+
 Tregs, our natural guardians against autoimmunity, play a key role in glioma-
induced immune depression. Here, Tregs have the highest predilection for tumors of the 
astrocytic lineage and specifically in the HGGs such as GBM (58, 60). Several studies have 
meanwhile documented a worse prognosis in glioma patients with high Treg levels (26, 57, 
59, 61). Importantly, the frequency of tumor-infiltrating Tregs in GBM patients is higher than 
the blood frequency of Tregs (56, 57). This suggests that the systemic immune status does not 
accurately represent the ongoing immune reaction in the brain. Treg accumulation in the 
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blood of GBM patients has been shown to correlate with the impairment of T cell 
proliferation (71). The majority of Tregs in the context of gliomas are thymus-derived, natural 
Tregs (55). They are suggested to be recruited to the tumor site by the CC chemokines ligands 
(CCL) CCL2 and CCL22 that are abundantly produced by glioma cells (20, 60). Interaction of 
these ligands with their receptors, CCR2 and CCR4 respectively, highly expressed on glioma-
infiltrating Tregs, facilitates their recruitment to the tumor site. Although the majority of 
glioma-infiltrating Tregs are thymus-derived, induced Tregs may also contribute to glioma 
progression. Indeed, IL-10 and TGF-β, both of which are produced in significant amount by 
gliomas in vivo, have been shown to induce the induction of Tregs from conventional T cells 
in vitro (20). Tregs in glioma express a plethora of immunoregulatory molecules like CD25, 
glucocorticoid-induced TNFR family related gene (GITR), cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) and CD62L (55). The crucial role of Tregs in bolstering antiglioma 
immunity is further illustrated by Treg depletion studies in experimental glioma models. 
Several of these studies have demonstrated better tumor control in Treg depleted glioma-
bearing mice (62).  
When it comes to immunosuppressive glioma-infiltrating myeloid cells, their role in 
promoting tumor growth and invasion has gained much attention in recent years. Here, we can 
distinguish two main populations in glioma: the myeloid-derived suppressor cells (MDSCs) 
and the tumor-associated macrophages (TAMs)/microglia. Both cell types are known to 
promote tumor development via T cell suppression-dependent and independent mechanisms.  
MDSCs represent a population of highly suppressive immature myeloid cells that can 
concentrate in the tumor, secondary lymphoid structures and blood of cancer patients in 
response to tumor-derived factors (e.g. VEGF, TGF-β, IL-6, IL-10, PGE2 and CCL2) (20). In 
mice, MDSC are phenotypically characterized by the co-expression of CD11b and Gr1 (72). 
Further stratification into monocytic and granulocytic MDSCs is based on the expression of 
Ly6C and Ly6G, respectively. Human MDSC subsets are identified by the expression of 
CD11b and CD33 and by lack of expression of HLA-DR (72). Accordingly, human MDSCs 
can be subclassified into monocytic and granulocytic MDSC, based on the expression of 
CD14 and CD15, respectively. MDSCs can suppress T cell immunity through divergent 
mechanisms, including the production of nitric oxide and ROS, L-arginine and cysteine 
deprivation and the expansion of Tregs (20). In glioma context, Gielen et al. recently 
documented increased levels of monocytic and granulocytic MDSCs in the blood of glioma 
patients, while the glioma tissue showed a predominant infiltration of granulocytic MDSCs 
(63). Moreover, circulating MDSCs isolated from GBM patients have been shown to suppress 
IFN-γ production by autologous T cells (64).  
In the setting of glioma, macrophages and microglia are the predominant tumor-infiltrating 
immune cells. They can comprise up to 30% of the glioma mass (20). Depending on 
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environmental signals, they can embody pro-inflammatory/antitumoral (M1) or alternatively 
activated immunosuppressive/protumoral (M2) phenotypes. In glioma patients, macrophage 
infiltration tends to increase with increasing tumor grades, suggesting their contribution to 
tumor progression (66). Interestingly, glioma infiltrating TAMs and microglia predominantly 
show M2 characteristics (e.g. reduced expression of co-stimulatory signals, secretion of M2 
cytokines such as IL-4, IL-10 and TGF-β, and the upregulation of CD163 and CD204), 
particularly in late stage disease progression (55). TAMs are recruited and sustained in the 
glioma microenvironment via CCL2, colony-stimulating factor-1 (CSF-1) and stromal cell-
derived factor-1 (SDF-1/CXCL12) amongst others (55). Gliomas can induce TAMs and 
microglia to upregulate the expression of PD-L1, FasL and STAT3, and to significantly 
downregulate the expression of pro-inflammatory cytokines and MHC molecules (20). 
Given the substantial contribution of TAMs and MDSCs to glioma-mediated immune 
suppression, strategies targeting these myeloid populations are being exploited intensively. 
Depletion of the general CD11b
+
 myeloid subset in GL261 glioma-bearing mice delays tumor 
progression (65). This finding highlights the tumor-promoting role of tumor-infiltrating 
myeloid cells in glioma. Along the same lines, the more specific depletion of MDSCs (either 
via COX-2 inhibition, Gr-1-mediated depletion or CCL2 neutralization) and TAMs (CFS-1 
receptor blocking) has been shown to confer survival advantage in various murine glioma 
models (20, 55).  
Over the last decade, oncologists have recognized that simply debulking the tumors via a 
combination of surgery and radio- and chemotherapy is not sufficient to eradicate therapy-
resistant, heterogeneous and diffusely infiltrating glioma cells. Given the malevolent 
immunosuppressive and immunoevasive capabilities of HGGs described above, the need to 
tackle the glioma-induced immunosuppression and/or to actively stimulate antiglioma 
immune responses arose.  
1.5 Immunotherapy to tilt the balance in favor of anti-glioma immunity 
As opposed to standard cytotoxic therapies, immunotherapy is highly specific for eradicating 
cancer cells with low toxicity to surrounding normal brain tissue. Moreover, several 
immunotherapeutic strategies have been shown to evoke immunological memory. This 
memory response is considered extremely beneficial in the context of HGG, given the 
inevitable tumor relapse following standard-of care therapy.  
Box 1 summarizes the main characteristics of the two most extensively studied 
immunocompetent murine brain tumor models for testing of immunotherapeutic approaches. 
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Box 1: Characteristics of the two most widely applied immunocompetent brain tumor models 
for testing of immunotherapeutic approaches 
 CT2A GL261 
Host C57BL/6 mice C57BL/6 mice 
Induction 20-Methylcholantrene 3-Methylcholantrene 
Ease of transplantation Very good Very good 
Tumorigenesis 100%  100%  
Histologic resemblance High-grade astrocytoma Ependymoblastoma 
GBM characteristics Highly proliferative and 
invasive, pseudopalisading 
necrosis, intratumoral 
heterogeneity, angiogenesis, in 
vivo migratory patterns 
Pleomorphism, 
pseudopalisading necrosis, 
angiogenesis, invasiveness 
Grade of stemness High Moderate 
Immunogenicity Unknown Low baseline expression of 
MHC-I, but not MHC-II; 
Increased MHC-I and II 
expression upon stimulation 
with IFN-γ 
TAAs Unknown HMP/AN2, EphA2, GARC-1 
Oncogenic mutations PTEN PTEN, K-ras, P53 
MGMT promotor methylation Unknown Yes 
 
1.5.1 Checkpoint blockade to unleash the brakes of the immune system 
Inhibitory checkpoint mediators like CTLA-4 and PD-1 function as brakes to attenuate 
normal T cell responses, respectively during the priming and effector phases of T cell 
activation (47). However, cancers exploit this mechanism to depress the antitumor immune 
response. Therapeutic blockade of CTLA-4 and PD-1 or its ligands PD-L1 and PD-L2 have 
demonstrated exciting antitumor benefit in several cancer types. FDA approval of ipilimumab, 
a monoclonal antibody targeting CTLA-4, for metastatic melanoma, including patients with 
brain metastasis, has paved the way for testing checkpoint blockade in the setting of HGG 
(73). CTLA-4 blockade led to 80% long-term survival in mice bearing SMA-560 brain tumors 
and PD-1 blockade could significantly improve overall survival of intracranial GL261 tumors 
when combined with radiation therapy (47). Very recently, two mAbs targeting PD-1 receptor 
signaling (nivolumab and pembrolizumab) have joined the list of FDA-approved check-point 
blockers (respectively for the treatment of metastatic squamous non-small cell lung cancer 
and relapsed/refractory melanoma patients). Several clinical trials are currently evaluating 
ipilimumab and PD-1/PD-L1 checkpoint inhibitors in recurrent and newly diagnosed HGG 
patients (NCT02529072, NCT02311920 and NCT02017717) (47).  
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1.5.2 Passive immunization with adoptive T-cell therapy 
Adoptive T cell transfer involves the infusion of T cells with high avidity for tumor antigens. 
Originally this encompassed the administration of T cells isolated from draining lymph nodes 
from GBM patients or ex vivo expanded autologous T cells cocultured with tumor cells (47). 
A more contemporary application of this approach is the use of expanded autologous 
cytomegalovirus (CMV)-specific T cells from CMV-seropositive GBM patients (74). Indeed, 
recent studies assigning a potential association between human CMV and glioma, suggest a 
potential pool of tumor antigens of viral origin (51). Recent progress in this field has been 
made by applying genetically modified T cells engineered to express a chimeric antigen 
receptor (CAR) with high reactivity against TAAs (50). Due to their direct antigen-binding 
capacity, these so called CAR T cells can bypass MHC restriction. Preclinical experiments in 
glioma models have documented promising results with CAR T cells engineered to react with 
IL13R2α, Her2 and EphA2 (47). Moreover, clinical trials with CARs targeting EGFRvIII and 
Her2 are running for GBM patients. Major drawbacks of this type of immune therapy are 
related to the costs and the labor intensiveness of the ex vivo culturing, as well as the 
possibility of eliciting cytokine storms.  
1.5.3 Active vaccination therapy 
As opposed to passive immunization, active immunotherapy (also referred to as tumor 
vaccination) attempts to stimulate the host‟s intrinsic immune response against the 
malignancy. Several vaccination strategies have been exploited in the setting of HGGs. 
Peptide vaccines are the simplest application of this strategy. They comprise the 
administration of synthetic peptides derived from TAAs or TSAs. The majority of peptide 
vaccines currently under evaluation for glioma target the HLA-A2 haplotype (e.g. Her2, 
gp100, IL13R2α), this way limiting the application of this therapy to HLA-A2+ tumors (19). 
In contrast, the TSA EGFRvIII is a highly promising target for peptide vaccination. Sampson 
et al. developed a promising EGFRvIII vaccine that could prolong the median OS of newly 
diagnosed GBM patients in comparison to a matched control group (48). This strategy was 
proven to be safe (even in adjuvant setting after radiochemotherapy) and both humoral and 
cellular immune responses were documented. However, upon recurrence after vaccination, 
80% of the GBM tumors were EGFRvIII negative, suggestive of tumor immune editing by 
induction of tumor antigen escape (48). To overcome this antigen escape, several groups are 
exploring the use of multipeptide vaccines and autologous tumor cell vaccines. Indeed, data 
provided by Neller et al. suggest a better response rate in immunotherapies using whole tumor 
cell approaches than therapies targeting single antigens (75). A recent modification of the 
multipeptide approach involves vaccination with tumor antigens bound to 96 kD heat shock 
proteins (HSP96) (47). HSPs are natural adjuvants that can facilitate the presentation of 
peptides to circulating APCs such as DCs. Early clinical trials in recurrent GBM patients have 
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shown that this therapy can induce immunogenicity with potential survival benefit (47). 
Whole tumor cells approaches usually apply autologous tumor cells that can be irradiated, 
combined with cytokine-producing fibroblasts or transduced with Newcastle disease virus 
(76). However, due to the difficulties associated with culturing inactivated autologous tumor 
cell cultures and the impact on the immunogenicity of the tumor cells, this form of active 
immunotherapy is the least widely applied.  
In general, the success of peptide and whole tumor cells vaccines is considered limited. This 
can be attributed to the lack of immune adjuvants, resulting in poor immunization and even 
tolerance induction (75). Moreover, in vivo circulating APCs often show low MHC 
expression and frequently lack costimulatory signals in glioma-bearing individuals (20). DC 
vaccines can bypass these difficulties. DCs are positioned at the crucial interface between the 
innate and adaptive immune system as APCs capable of inducing antigen-specific CD4
+
 and 
CD8
+
 T cell responses. Therefore, they are the most frequently used cellular adjuvant in 
clinical trials. Since the publication of the first DC vaccination trial in melanoma patients in 
1995, the promise of DC immunotherapy is underlined by numerous clinical trials, frequently 
showing survival benefit in comparison to non-DC control groups (40, 77). The FDA 
approval of Sipileucel (Provenge), an autologous DC-enriched vaccine for hormone-resistant 
metastatic prostate cancer, in 2010 is considered as a milestone and proof-of-principle in this 
field (78). 
DCs reside in an immature state in most organs and tissues, specifically at sites where 
pathogen entry is very likely. This immature state allows them to sample and process antigens 
efficiently. Upon exposure to the antigens in the presence of proper danger signals (e.g. 
inflammation, pathogens), DCs upregulate their expression of adhesion, MHC and 
costimulatory molecules (like CD86, CD80 and CD40) and show enhanced expression of 
CCR7. This latter chemokine receptor drives their migration to the draining lymph nodes 
where they secrete pro-inflammatory cytokines and present the captured exogenous antigens 
in either MHC I (a process known as cross-presentation) or MHC II context to CD8
+
 CTL 
cells and CD4
+
 Th cells, respectively. Both cell types are required for the priming and 
persistence of cellular antitumor immunity. Inappropriate stimulation of DCs (e.g. in the 
absence of proper danger signaling or costimulation) may render them tolerant, resulting in 
the elimination or suppression of T cells. In view of this, ex vivo generated and antigen loaded 
DC vaccines that are activated and primed in controlled conditions, are ideal candidates to 
stimulate potent tumor-specific immunity.   
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1.6 DC-based immunotherapy for HGG: clinical status and prognostic markers 
DC vaccination constitutes the administration of autologous DCs enriched or cultured from a 
patient‟s blood and loaded with selective TAAs/TSAs, or whole tumor cell preparations. To 
date, over 20 DC clinical trials were performed in HGG patients, involving over 500 patients 
(77). Despite the notion that these early phase clinical trials differ in multiple vaccine 
parameters (e.g. site and frequency of injection, nature of the DCs, choice of antigen), DC 
vaccination in HGG patients is considered feasible as well as safe. More specifically, this 
therapy has never elicited autoimmune reactions nor demonstrated evidence of autoimmune 
encephalitis. This is in sharp contrast with the use of monoclonal antibodies or cytokine 
therapies. Ipilumumab has for instance been shown to induce immune-related adverse events 
in 60% of treated melanoma patients (73).  
DC vaccines have been shown to elicit antigen-specific cellular and humoral immune 
responses in HGG patients and several reports describe an association between DC vaccine-
induced immune responses and patient outcome (79, 80). Moreover, a recent meta-analysis 
demonstrated high IFN-γ in the peripheral blood of DC vaccinated HGG patients (77). This 
study also revealed that DC vaccination can significantly prolong the 1-, 1.5-, 2-, 3-, 4- and 5-
year OS and PFS in newly diagnosed and recurrent HGG patients as compared to a non-DC 
control group. Moreover, the objective response rate (either complete or partial response 
according to the WHO or RECIST criteria) in DC vaccinated HGG patients (15.6%) is higher 
than that observed in melanoma, prostate cancer and renal cell carcinoma patients, three other 
tumor types that are most frequently targeted with DC-based immunotherapy (40). Together 
these data indicate the susceptibility of brain tumors, despite their somehow shielded location, 
to this efficacious treatment. However, in order to evaluate if DC vaccination can confer a 
meaningful survival advantage to HGG patients, the results of ongoing large phase III 
randomized controlled (multicenter) clinical trials will have to be awaited (NCT01280552 and 
NCT00045968).  
Our increased understanding of intrinsic patient biomarkers (clinical, immunologic or 
molecular factors) that can associate with survival in DC vaccine settings may significantly 
improve the clinical results. Among clinical factors, younger patients and patients with lower 
tumor burden are more likely to respond to DC-based immunotherapy (81). In line with this 
notion, a recursive partitioning analysis model proposed by our group has identified age, 
pathology and performance status as predictors of outcome in DC vaccinated recurrent HGG 
patients (82). When it comes to molecular biomarkers, Prins et al. have recently shown that 
GBM patients that have a mesenchymal gene signature (but not patients with a proneural 
signature), show increased levels of CD8
+
 and CD3
+
 tumor-infiltrating lymphocytes, 
associated with improved survival following DC vaccination (83). Due to significant 
variability in methodology and the notion that a single immune parameter will most likely not 
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correlate with clinical outcome in all patients, clustering of several immune parameters may 
represent a promising strategy. In this regard, the immunoscore that was originally developed 
for colon cancer might be a promising tool to identify patients that will most likely benefit 
from DC vaccination. This scoring system derived from the immune contexture is a clinically 
useful prognostic marker based on the enumeration of CD3
+
 and CD8
+
 T cells in the tumor 
microenvironment (84). In the setting of glioma, the presence of pre-existing tumor antigen-
specific immune responses has been shown to correlate with response in several DC vaccine 
studies (79, 81). In line with this notion, Fadul and colleagues have demonstrated that GBM 
patients with increased postvaccination frequencies of peripheral IFN-γ+CD4+ T cells and 
IFN-γ+CD8+ T cells respond better to DC therapy (32). In contrast, a decreased frequency of 
systemic Tregs following DC vaccination has been shown to associate with improved survival 
in GBM patients (85).  
1.7 The impact of DC biology on the efficacy of DC vaccines 
Despite the notion that promising objective responses and tumor-specific T cell responses 
have been observed in DC vaccinated HGG patients (clearly providing proof-of-principle for 
DC-based immunotherapy), the clinical success of this treatment is still considered 
suboptimal. This poor clinical efficacy can in part be attributed to the severe tumor-induced 
immune suppression and the selection of patients with advanced disease status and poor 
survival prognostics (40). In addition, there is a consensus in the field that step-by-step 
optimization and standardization of the production process of DC vaccines, in order to obtain 
Th1-driven antitumor immune responses, might enhance clinical efficacy (40). The next 
section addresses some recent DC vaccine adaptations that impact DC biology. Combining 
these novel insights might bring us closer to an ideal DC vaccine product that can trigger 
potent CTL- and Th1-driven antitumor immunity (Figure 2).   
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Figure 2. DC vaccine protocol adaptations to maximize therapeutic potential.  DC-based 
immunotherapy seeks to exploit the maximal intrinsic capacity of DCs to stimulate antigen-
specific CTLs and NK cells. In recent years, several standardized steps in the production 
process of DC vaccines (as indicated in red) have been subjected to changes (as indicated in 
green) to obtain a more potent DC preparation. Besides DC vaccine parameters, intrinsic 
patient variables may also affect the therapeutic effectiveness of DC vaccines. DCi, immature 
DC; DCm, mature DC; ICD, immunogenic cell death; i.d., intradermal; i.n., intranodal; i.t., 
intratumoral; mDCs, myeloid DCs; pDC, plasmacytoid DC; TSAs, tumor-specific antigens: 
TAAs, tumor-associated antigens.  
Given the labor-intensive ex vivo culturing protocol of monocyte-derived DCs and inspired by 
the results of the Provenge study, several groups are currently exploiting the use of blood-
isolated naturally circulating DCs (86-88). In this context, De Vries et al. evaluated the use of 
antigen-loaded purified plasmacytoid DCs for intranodal injection in melanoma patients (89). 
This strategy was feasible and induced only very mild side effects. In addition, the overall 
survival of vaccinated patients was greatly enhanced as compared to historical control 
patients. However, it still remains to be determined whether this strategy is more efficacious 
than monocyte-derived DC vaccine approaches (88). In contrast, experiments in the 
preclinical GL261 HGG model have recently demonstrated that vaccination with tumor 
antigen-loaded myeloid DCs resulted in a more robust Th1 response and a stronger survival 
benefit as compared to mice vaccinated with their plasmacytoid counterparts (90).  
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In view of their strong potential to stimulate CTL responses, several groups are currently 
exploring the use of Langerhans cell-like DCs as sources for DC vaccines (91-93). These so-
called IL-15 DCs can be derived from CD14
+
 monocytes by culturing them with IL-15 
(instead of the standard IL-4). Recently it has been shown that in comparison to IL-4 DCs, 
these cells have an increased capacity to stimulate antitumor NK cell cytotoxicity in a contact- 
and IL-15-dependent manner (94). NK cells are increasingly being recognized as crucial 
contributors to antitumor immunity in DC vaccination setups (95, 96). Three clinical trials are 
currently evaluating these Langerhans cell-type DCs in melanoma patients (NCT00700167, 
NCT 01456104 and NCT01189383).  
Targeting cancer stem cells is another promising development, particularly in the setting of 
glioma (47). Glioma stem cells can foster tumor growth, radio- and chemotherapy-resistance 
and local immunosuppression in the tumor microenvironment (47, 97). On the other hand, 
glioma stem cells may express higher levels of tumor-associated antigens and MHC complex 
molecules as compared to non-stem cells (98, 99). A preclinical study in a rodent orthotopic 
GBM model has shown that DC vaccines loaded with neurospheres enriched in cancer stem 
cells could induce more immunoreactivity and survival benefit as compared to DCs loaded 
with GL261 cells grown under standard conditions (100). However, as the in vitro production 
of neurospheres can be considered a rather artificial technique to enrich for glioma stem cells, 
studies that compare DC vaccination efficacy in two glioma models with varying grades of 
stemmness (e.g., the GL261 model versus the CT2A model) will be much more informative. 
Currently there are four clinical trials ongoing in HGG patients to evaluate this approach 
(NCT00890032, NCT00846456, NCT01171469 and NCT01567202).  
Regarding the DC maturation status of the vaccine product, a phase I/II clinical trial in 
metastatic melanoma patients has confirmed the superiority of mature antigen-loaded DCs to 
elicit immunological responses as compared to their immature counterparts (101). This 
finding was further substantiated in patients diagnosed with prostate cancer and recurrent 
HGG (102, 103). Hence, DCs need to express potent costimulatory molecules and lymph 
node homing receptors in order to generate a strong T cell response. In view of this finding, 
the route of administration is another vaccine parameter that can influence the homing of the 
injected DCs to the lymph nodes. In the context of prostate cancer and renal cell carcinoma it 
has been shown that vaccination routes with access to the draining lymph nodes 
(intradermal/intranodal/intralymphatic/subcutaneous) resulted in better clinical response rates 
in comparison to intravenous injection (102). In melanoma patients, a direct comparison 
between intradermal vaccination and intranodal vaccination concluded that although more 
DCs reached the lymph nodes after intranodal vaccination, the melanoma-specific T cells 
induced by intradermal vaccination were more functional (104). Furthermore, the frequency 
of vaccination can also influence the vaccine‟s immunogenicity. Our group has shown in a 
 20 
 
cohort-comparison trial involving relapsed HGG patients that shortening the interval between 
the four inducer DC vaccines improved the PFS curves (81, 105).  
Another variable that has been systematically studied is the cytokine cocktail that is applied to 
mature the DCs. The current gold standard cocktail for DC maturation contains TNF-α, IL-1β, 
IL-6 and PGE2 (106, 107). Although this cocktail can upregulate DC maturation markers and 
the lymph node homing receptor CCR7, it failed to evoke IL-12 production by DCs (106, 
107). Nevertheless, IL-12 is a critical Th1 driving cytokine and DC-derived IL-12 has been 
shown to associate with improved survival in DC vaccinated HGG and melanoma patients 
(108, 109). Recently a novel cytokine cocktail including TNF-α, IL-1β, poly-I:C, IFN-α and 
IFN-γ was introduced (110, 111). The type 1-polarized DCs obtained with this cocktail 
produced high levels of IL-12 and could induce strong tumor-antigen specific CTL responses 
through enhanced induction of CXCL10 (108). In addition, CD40 ligand (CD40L) stimulation 
of DCs has been used to mature DCs in clinical trials (109, 112). Binding of CD40 on DCs to 
CD40L on CD4
+
 Th cells licenses DCs and enables them to prime CD8
+
 effector T cells.  
A final major determinant of the vaccine immunogenicity is the choice of antigen to load the 
DCs. Two main approaches can be applied: loading with selected TAAs or TSAs and loading 
with whole tumor cell preparations (113). The former strategy enables easier immune 
monitoring, has a lower theoretical risk of inducing auto-immunity and can provide “off-the-
shelf” availability of the antigenic cargo. Whole tumor cell-based DC vaccines on the other 
hand are not HLA-type dependent, have a reduced risk of inducing immune-escape variants 
and can elicit immunity against multiple tumor antigens. Meta-analytical data provided by 
Neller et al. have demonstrated enhanced clinical efficacy of cancer vaccines that employed 
whole tumor cells as antigens in comparison to the use of molecularly defined antigens (75). 
This finding was recently also substantiated in DC vaccinated HGG patients, although this 
study was not set-up to compare survival parameters (80).   
With regard to whole tumor cell approaches, one factor requiring more attention is the 
immunogenicity of the dying or dead cancer cells used to load the DCs. The majority of 
clinical trials that apply autologous whole tumor lysate to load DC vaccines report the 
straightforward use of multiple freeze-thaw cycles to induce primary necrosis of cancer cells 
(102, 114). In addition, this technique can easily meet the rigid clinical requirements like the 
absolute avitalization of cancer cells. However, freeze-thaw induced necrosis is considered 
non-immunogenic and has even been shown to inhibit toll-like receptor (TLR)-induced 
maturation and function of DCs (115). To this end, many research groups have focused on 
tackling this roadblock by applying immunogenic treatment modalities to induce cell death in 
the context of DC vaccines (115-119). These treatments can potentiate antitumor immunity by 
inducing immune responses against tumor neo-antigens and/or by selectively increasing the 
exposure/release of particular damage-associated molecular patterns (DAMPs) which can 
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trigger the innate immune system (116, 118, 119). The emergence of the concept of 
immunogenic cell death (ICD) might even further increase the immunogenicity of DC 
vaccines. Cancer cells undergoing ICD have been shown to exhibit excellent 
immunostimulatory capacity owing to the spatiotemporally-defined emission of a series of 
critical DAMPs acting as potent danger signals (120, 121). These danger signals are able to 
activate innate immune cells like DCs. Thus far, three DAMPs have been attributed a pivotal 
role in the immunogenic potential of nearly all ICD inducers: the surface-exposed “eat me” 
signal calreticulin (ecto-CRT), the “find me” signal ATP and the TLR ligand high-mobility 
group box 1 (HMGB1) (121). Moreover, these ICD-experiencing cancer cells have been 
shown in various mouse models to act as very potent Th1-driving anticancer vaccines, even in 
the absence of any cellular or molecular adjuvants (121, 122). The ability to reject tumors in 
syngeneic mice after vaccination with cancer cells (of the same type) undergoing ICD is a 
crucial hallmark of ICD, in addition to the molecular DAMP signature (121). The concept of 
ICD, as well as its associated DAMPs and its promising application in DC-based 
immunotherapy are further elaborated in later sections of this work. In the following section, 
we will focus on non-ICD dependent enhancers of immunogenicity and their application in 
DC vaccines.  
1.8 Immunogenic treatment modalities to establish a more productive DC-cancer cell 
interphase 
Table 2 lists some frequently applied treatment methods to enhance the immunogenic 
potential of the tumor cell cargo for DC vaccines in an ICD-independent manner (i.e. these 
treatments do not meet the molecular and/or cellular requirements of ICD). The induction of 
particular DAMPs in the dying cancer cells positively impacts DC biology (Table 2). Table 3 
summarizes the preclinical and clinical studies that investigated the in vivo potential of DC 
vaccines loaded with immunogenically killed tumor cells. Figure 3 schematically represents 
the application and the putative modes of action of these immunogenic enhancers in the 
setting of DC vaccines. 
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Figure 3. A schematic representation of immunogenic DC vaccines. Cancer cells show 
enhanced immunogenicity upon treatment with UV irradiation, oxidizing treatments and heat 
shock characterized by the release of particular danger signals and the (increased) 
production of tumor (neo-)antigens. Upon loading onto DCs, they undergo enhanced 
phagocytosis and antigen uptake and show phenotypic and partial functional maturation. 
Upon in vivo immunization, these DC vaccines elicit Th1- and cytotoxic T lymphocyte (CTL)-
driven tumor rejection.   
 23 
 
Table 2. A list of prominent enhancers of immunogenicity and ICD inducers applied in DC 
vaccine setups and their associations with DAMPs and DC biology 
 
Treatment modality Associated DAMPs Effect on DC biology 
Immunogenic treatment modalities 
UV irradiation Pre-apoptotic ecto-CRT (123); post-
apoptotic passive release of HSP70 and 
HMGB1 (124); mutation-induced neo-
antigens (125) 
Efficient engulfment; phenotypic 
maturation; increased IL-12 secretion;  
stimulate the polarization of T cells 
towards CTLs  (119, 124, 126, 127) 
Oxidation-inducing modalities 
(HOCl treatment) 
OAMPs (reactive protein carbonyls, 
peroxidized phospholipids, oxidized 
low-density 
lipoprotein) (116, 128-130); 
carbonylated protein products presented 
as neo-antigens (130, 131) 
Efficient antigen uptake and presentation; 
induction of IL-12; increased in vivo 
induction of tumor-reactive T cells (116) 
Heat shock Passive release of HSPs like 
HSP60/70/90 (118, 132); passive 
release of HMGB1 (133); increased 
expression of tumor-specific antigens 
(134) 
Upregulation of DC maturation markers 
(CD40, CD80 and CD86) and induction of 
IL-12 (132); enhanced priming of CTL 
responses (118, 134) 
Inducers of immunogenic cell death 
Radiotherapy Pre-apoptotic exposure of ecto-CRT 
(123, 124, 135); early/mid-apoptotic 
exposure of ecto-HSP70  (136); post-
apoptotic passive release of HMGB1 
(133, 135); mutation-induced neo-
antigens (125) 
Efficient phagocytosis and enhanced 
phenotypic maturation (137); increased 
infiltration in the tumor environment (138, 
139); enhanced stimulation of antigen-
specific CTL responses (140) 
Shikonin Early/mid-apoptotic induction of ecto-
HSP70, ecto-CRT and ecto-GRP78 (an 
inducer of pro-tumorigenic effects) 
(141) 
Increased phenotypic (CD40
high
, CD80
high
, 
CD86
high
) and functional maturation (IL-
12p70
high
, TGF-βhigh, IL-6high, IL-23low) but 
only in combination with LPS; increased 
capacity to induce Th1 and Th17 
differentiation (141) 
High-hydrostatic pressure Early/mid-apoptotic exposure of ecto-
HSP70, ecto-HSP90, ecto-CRT; pre-
apoptotic ATP release; post-apoptotic 
passive release of HMGB1, HSP70/90 
and CRT (142) 
Efficient phagocytosis; enhanced 
phenotypic and functional maturation; 
induction of antigen-specific T cells 
without inducing Tregs (142) 
Oncolytic viruses CVB3 and oncolytic adenovirus: 
(early-apoptotic) exposure of ecto-
CRT; (early/mid-apoptotic) secretion of 
ATP and (post-apoptotic) release of 
HMGB1 (143, 144) 
NDV: early/mid-necroptotic exposure 
of ecto-CRT and post-necroptotic 
release of HMGB1 (145) 
Enhanced expression of CD80/CD86 (144, 
146, 147) and CCR7 (144); more efficient 
priming of tumor-specific CD8
+
 CTL 
responses (143, 146, 147) and Th1 
responses (143); increased accumulation in 
tumor microenvironment (143, 144) 
Hypericin-based PDT 
 
 
 
 
 
 
Photofrin-based PDT 
Pre-apoptotic ecto-CRT, ecto-HSP70 
and secreted ATP; late apoptotic 
passive release of HSP70/90, CRT and 
HMGB1; accumulation of OAMPs like 
protein carbonyls (148-150) 
 
 
Early/mid-apoptotic exposure of CRT, 
HSP60/70, ceramide and S1P; post-
apoptotic release of HMGB1 (151, 152) 
 
 
 
Enhanced phagocytosis; phenotypic 
maturation (CD80
high 
CD86
high 
CD83
high 
MHC-II
high
) and immunogenic functional 
stimulation (NO
high 
IL-10
absent
 IL-6
high
 IL-
1βhigh IL-12p70medium); clonal expansion of 
human IFN-γ producing CD4+ and CD8+ T 
cells  (150, 153, 154) 
Increased phenotypic maturation 
(CD86
high
, MHC-II
high
) and enhanced IL-
12 production (155); increased infiltration 
in tumor draining lymph nodes after 
peritumoral vaccination (156) 
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Abbreviations: CRT, Calreticulin; CTL, Cytotoxic T lymphocyte; CVB3, Coxsacievirus B3; DAMPs, Damage-
associated molecular patterns; HMGB1, High mobility group box-1 protein; HSP, Heat shock protein; ICD, 
Immunogenic cell death; IFN, Interferon; LPS, lipopolysaccharide; NDV, Newcastle disease virus; NO, nitric 
oxide; OAMPs, oxidation-associated molecular patterns; PDT, photodynamic therapy; TGF, transforming 
growth factor; Treg, regulatory T cell 
 
Table 3. A list of preclinical tumor models and clinical studies for evaluation of the in vivo 
potency of DC vaccines loaded with immunogenically killed tumor cells 
 
Treatment modality Preclinical experience in DC 
vaccine settings  
Clinical experience in DC vaccine settings 
Immunogenic treatment modalities 
UV irradiation B16 melanoma in C57BL/6 – 
curative immunizations (119); ID8-
ova ovarian carcinoma model in 
C57BL/6 mice – weekly curative 
immunizations (116) 
Only in combination with γ-irradiation and 
heat shock in B-cell lymphoma patients (157) 
Oxidation-inducing 
modalities (HOCl) 
ID8-ova ovarian carcinoma model 
in C57BL/6 mice – weekly curative 
immunizations (116) 
Freeze-thaw cycles in combination with high-
dose irradiation are often reported in clinical 
trials involving high-grade glioma and 
melanoma patients (32, 81, 82, 114, 158-163) 
HOCl: Pilot study in 5 recurrent ovarian 
cancer patients demonstrated potent T cell 
responses against tumor antigens, decreased 
circulating Treg levels and serum IL-10 levels 
and two patients experienced durable PFS 
responses of ≥ 24 months (116) 
Heat shock PANCO2 pancreatic cancer model 
in C57BL/6 mice – curative 
vaccinations (118); in combination 
with 30 Gy irradiation in B16-ova 
model in C57BL/6 mice – 
prophylactic vaccinations (115) 
Non-randomized trial in newly diagnosed 
glioblastoma patients (164): significantly 
improved tumor control rates and survival 
rates in DC vaccine group than in control 
group; increased proportions of peripheral 
CD4
+
 and CD8
+
 T cells post vaccination 
compared to control group; In combination 
with other cell killing modalities in B-cell 
lymphoma and melanoma patients (157, 165) 
Inducers of immunogenic cell death 
Radiotherapy B16 melanoma in C57BL/6 - 
prophylactic immunization model 
with critical involvement of CD4
+
 
and CD8
+
 T cells (117, 137); E.G7 
(SCCVII) in C57BL/6 - curative 
vaccination model (140) 
Radiotherapy as a single intervention: multiple 
clinical trials in melanoma patients (114) and 
two clinical trials in high-grade glioma 
patients (166, 167). This study by Cho and 
colleagues reported a survival advantage of 
more than 15 months in the vaccinated 
glioblastoma patients in comparison to the 
control group (receiving conventional 
treatment); Radiotherapy as part of an ICD-
inducing cell death protocol in B-cell 
lymphoma patients (157) 
Shikonin B16 melanoma in C57BL/6 - 
curative immunization model with 
strong induction of CTL responses 
(141) 
Not available 
High-hydrostatic pressure Preclinical experiments are 
currently ongoing (168) 
Multiple clinical trials are initiated involving 
prostate and ovarian cancer patients (168) 
Oncolytic viruses Not applied as ICD-based DC 
vaccines yet; curative combination 
of intratumoral oncolytic virus 
Case report of breast cancer patient treated 
with combination of local hyperthermia, 
intravenously administered NDV and 
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treatment and peripheral DC 
vaccination in B16 melanoma 
(C57BL/6) (169) and in 
subcutaneous CMT64 or KNL205 
tumors (in C57BL/6 mice and 
DBA/2 DREG mice, respectively) 
(170) 
intradermal DC vaccines loaded with NDV-
oncolysate (171) 
Hypericin-based PDT 
 
 
 
Photofrin-based PDT 
Hypericin-PDT based DC vaccines 
in the ID8 ovarian carcinoma 
model (Coosemans and Baert et al., 
unpublished results) 
In vivo photofrin-PDT treatment in 
combination with curative DC 
vaccination in C-26 colon 
carcinoma (BALB/c) (172); 
curative vaccinations with  DCs 
charged with PDT-induced tumor 
lysate in EMT6, Renca and 4T1 
non-orthotopic tumor models 
(BALB/c), induction of CTL and 
Th1 responses 
Not available 
 
 
 
Not available 
Abbreviations: CRT, Calreticulin; CTL, cytotoxic T lymphocyte; ICD, Immunogenic cell death; NDV, Newcastle 
disease virus; PDT, photodynamic therapy; PFS, progression free survival 
 
1.8.1 Ultraviolet irradiation 
Ultraviolet (UV) light is considered an electromagnetic non-ionizing radiation with a 
wavelength between 100 and 400 nm. Its immunogenic potential was discovered in 1991 
when Begovic et al. demonstrated that vaccination of immunocompetent mice (but not 
immunodeficient nude mice) with UV-irradiated cancer cells could induce resistance to 
subsequent rechallenge with live tumor cells (123, 173). This antitumor effect was crucially 
mediated by NK cells and CD8
+
 T cells. UV-treated cancer cells are efficiently engulfed by 
DCs, leading to their phenotypic maturation and increased IL-12 production (119, 124, 126) 
(Table 2). Moreover, these matured DCs in turn stimulated the polarization of T cells towards 
IFN-γ producing CD8+ T cells (124, 126). Of note, human DCs that had ingested UV-
irradiated apoptotic tumor cells were shown to be more effective in generating CD8
+
 CTLs 
than DCs pulsed with freeze-thaw lysates (127). In addition, immunization with DCs loaded 
with UV-treated tumor cells could elicit effective antitumor therapeutic efficacy in a B16 
mouse melanoma model (119) (Table 3). The induction of specific DAMPs like ecto-CRT 
and the release of HSP70 and HMGB1 determines the immunogenicity of UV light (123, 124, 
133) (Table 2). Moreover, as UV light is known to affect mainly DNA, mutation-induced 
tumor neo-antigens might also contribute to increased host antitumor immune responses 
(174). Vaccination with UV-induced tumor neo-antigens might be particularly useful in UV-
induced tumors (e.g. cutaneous and uveal melanoma) that might share the ex vivo UV-induced 
tumor neo-antigens. Besides, it has previously been shown that immunization of tumor-
bearing mice with mutated melanoma-derived self-antigens can elicit efficient cross-reactive 
CD8
+
 T cell responses against multiple non-mutated epitopes of the tumor protein and against 
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the melanoma cells (175). This led to the rejection of established poorly immunogenic B16 
melanoma tumors (175).  
To the best of our knowledge, there are no reports of clinical trials that used UV irradiation as 
a single treatment for obtaining an antigen source to pulse DC vaccines (Table 3). This is 
probably related to the notion that UV light as a single treatment is not able to induce high 
levels of cancer cell death, an absolute requirement for clinical translation of DC vaccines.  
1.8.2 Oxidation-inducing modalities 
In recent years, an increased number of data were published concerning the ability of 
oxidative stress to induce oxidation-associated molecular patterns (OAMPs) like reactive 
protein carbonyls and peroxidized phospholipids which can act as DAMPs (128, 129) (Table 
2). Protein carbonylation, an indicator of irreversible protein oxidation, has for instance been 
shown to improve cancer cell immunogenicity and to facilitate the formation of immunogenic 
neo-antigens (130, 131).  
Through a series of elegant ex vivo and in vivo mouse experiments, Coukos et al. recently 
selected hypochlorous acid (HOCl)-based oxidation (to induce primary necrosis of tumor 
cells) as the method of choice (as compared to UV irradiation and freeze-thaw cycles) for 
preparing whole tumor lysate-loaded DC vaccines in the ID8 ovarian cancer model (116) 
(Table 3). In a small pilot study containing five recurrent ovarian cancer patients, these 
autologous DCs loaded with HOCl-oxidized autologous tumor lysate could produce high 
levels of IL-12, elicited strong antigen-specific T cell responses and reduced the levels of 
circulating Tregs and serum IL-10 (116). Moreover, two patients experienced durable 
progression free survival intervals of more than 24 months after vaccination (Table 3).  
One prototypical enhancer of oxidation-based immunogenicity is radiotherapy (121, 123). In 
certain tumor types like HGG and melanoma, clinical trials that apply autologous whole 
tumor lysate to load DC vaccines report the random use of freeze-thaw cycles or a 
combination of freeze-thaw cycles and subsequent high-dose γ-ray or x-ray irradiation (32, 
81, 82, 114, 158-163) (Table 3). Preclinical and clinical data comparing these two easily 
applicable treatment modalities are unfortunately lacking. In the light of the oxidation-based 
immunogenicity that is associated with radiotherapy, we however envisaged that x-ray 
irradiation might enhance the immunogenic potential of freeze-thaw necrotic tumor lysate. 
We investigated this nagging research question in the setting of HGG in chapter 3 of this 
work.  
1.8.3 Heat shock treatment 
Heat shock is a term that is applied when a cell is subjected to a temperature that is higher 
than that of the ideal body temperature of the organism from which the cell is derived. Heat 
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shock can induce apoptosis (41 to 43°C) or necrosis (> 43°C) depending on the temperature 
that is applied (176). The immunogenicity of heat shock treated cancer cells largely resides 
within their ability to produce HSPs like HSP60, HSP70 and HSP90 (118, 132) (Table 2). 
These HSPs can function as chaperones for tumor antigens, facilitating their cross-
presentation (118). Moreover, after recognition by their receptors (CD91, TLR2/4), these 
HSPs can instigate the attraction of neutrophils and monocytes and the activation of NK cells 
and DCs (177). These events are crucial for the initiation of tumor-specific immune 
responses. Independent of the induction of HSPs, heat shock treatment has also been shown to 
upregulate the transcription of TAAs (134). 
Co-incubation of heat-stressed apoptotic cancer cells with immature DCs resulted in the 
upregulation of DC maturation markers (CD40, CD80 and CD86) and higher IL-12 levels 
(132) (Table 2). Interestingly, splenocytes from mice immunized with heat-stressed apoptotic 
cancer cells got polarized towards a Th1 cytokine profile. Furthermore, DCs loaded with heat 
shock stressed melanoma cells can efficiently cross-prime tumor-antigen specific CTLs both 
in vitro and in vivo (134). Of note, direct comparison of heat shock treated tumor lysate with 
freeze-thaw tumor lysate in a DC vaccine setup demonstrated a stronger tumor regression in 
favor of heat shock lysate in a mouse model for pancreatic cancer (Table 3). Again, this was 
associated with a stronger priming of tumor-specific CTL responses (118). 
DCs loaded with heat shocked cancer cells have already been successfully applied in clinical 
practice in high-grade glioma patients (Table 3). Jie et al. recently published an open labeled 
non-randomized clinical trial in which 12 newly diagnosed GBM patients received 
conventional therapy and 13 patients received additional DC vaccines loaded with heat shock 
treated autologous GBM cells (164). The vaccinated patients had a significantly improved OS 
and PFS. Interestingly, the proportions of peripheral CD4
+
 T cells, CD8
+
 T cells and NK cells 
were significantly elevated following DC vaccination in comparison to the control group. 
Moreover, increased levels of IFN-γ, IL-2 and IL-12 were measured in the sera of DC 
vaccinated patients.  
All together, these data suggest that an immunogenic treatment of cancer cells can positively 
impact the potency of DCs interacting with them (Figure 2). In the light of this finding, the 
relatively new concept of ICD of cancer cells can be considered a promising strategy for 
loading DC-based anticancer vaccines, potentially giving rise to a next generation of potent 
Th1-driving DC vaccines (177-179) (Figure 3).  
1.9 ICD: ignited by ROS-based ER stress and executed by DAMPs 
ICD is a peculiar apoptotic demise that can trigger potent adaptive antitumor responses. It is 
accompanied by the emission of a series of immunostimulatory DAMPs in a specific 
spatiotemporal pattern (Figure 4) (121, 178). This type of cell death is considered stressor-
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dependent, as only selected agents have been shown to induce it (178, 179). Since the initial 
screening study in 2007 (this study identified mitoxantrone, the anthracyclines doxorubicin 
and idarubicin and ionizing radiation as efficient ICD inducers), the list of ICD inducers has 
been growing considerably, further highlighting their emerging therapeutic potential (123, 
179).  
 
Figure 4: Overview of the generalized DAMP profile elicited by most ICD inducers. While 
type I ICD inducers elicit ROS-based ER stress as an off-target effect, type II ICD-inducers 
instigate ER stress-mediated danger signaling and apoptosis through the selective induction 
of ER stress. Following ROS-based ER stress, CRT gets surface exposed in the pre-apopttic 
stage, followed by the externalization of phosphatidylserine (PS), the exposure of HSPs and 
the active secretion of ATP in the early apoptotic phase. Subsequently, the apoptotic process 
allows membrane permeabilization, entailing the passive release of HMGB1 and chaperones 
like CRT and HSPs (Modified adapted from (180)).  
1.9.1 ROS-based ER stress 
ICD inducers all share a common feature, being the ability to induce endoplasmatic reticulum 
(ER) stress accompanied by the production of ROS (Figure 4) (177). More specifically, their 
effects (e.g. ecto-CRT exposure and the induction of apoptosis) are abrogated in the presence 
of anti-oxidants (181). Moreover, the observation that ROS inducers (like cisplatin) need to be 
combined with ER stressors (like tunicamycin) to induce ICD further emphasizes the 
importance of ROS-based ER stress in ICD (182). However, most ICD inducers affect the ER 
as an off-target effect (177). More precisely, they trigger cell death via non-ER associated 
targets (mostly the DNA replication/repair machinery as applicable to anthracyclines, 
oxaliplatin, radiotherapy and UVC irradiation), while danger signaling is triggered via the 
collateral induction of ER stress. These ICD inducers are categorized as type I ICD inducers. 
On the other hand, type II ICD inducers selectively target the ER to induce pro-death 
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signaling and ICD-associated danger signaling (160). To date, mainly five type II inducers 
have been characterized; Hypericin-based photodynamic therapy (Hyp-PDT), three oncolytic 
virus strains (Newcastle disease viruses, adenoviruses and coxsackievirus B3) and Pt
II
 N-
heterocyclic carbene complexes (179). The collateral nature of the ER stress that is associated 
with type I ICD inducers ensures that the ICD-associated danger signaling here is milder and 
more complex (177).  
The ROS-based ER stress is crucial for activating the danger signaling pathways that lead to 
the intracellular trafficking and the subsequent surface expression/emission of DAMPs 
(Figure 4). ER stress holds an imbalance between protein-folding load and capacity as a 
consequence of pathophysiological conditions (e.g. hypoxia, ROS production, ER-Ca
2+
-
depletion and hypoglycemia) that can disturb proper protein folding. The ER then attempts to 
re-establish homeostasis by activating the unfolded protein response (UPR). This complex 
signaling cascade can originate from 3 ER-sessile proteins i.e. PERK, IRE1α and ATF6. 
However, if the ER stress is too strong, this UPR response shifts to a pro-death pathway 
(instead of a pro-survival pathway), generally resulting in mitochondrial apoptosis.  
1.9.2 DAMPs 
In homeostatic conditions, DAMPs reside within the cell where they exhibit non-
immunological functions. However, they tend to get exposed or secreted by damaged and 
dying cells in a spatiotemporally-defined manner (Figure 4), enabling them to bind pattern-
recognition receptors like Toll-like receptors (TLRs). To date, three DAMPs have been 
attributed a pivotal role in ICD i.e. CRT, ATP and HMGB1 (121). Other DAMPs like surface-
exposed or released HSPs (notably HSP70 and HSP90) have also been shown to contribute to 
the immunogenic capacity of ICD inducers (120, 121). The binding of these DAMPs to their 
respective immune receptors (CD91 for HSPs/CRT, P2RX7/P2RY2 for ATP and TLR2/4 for 
HMGB1/HSP70/HSP90) leads to the recruitment and/or activation of innate immune cells and 
facilitates the uptake of tumor antigens by antigen presenting cells and their cross-
presentation to T cells eventually leading to IL-17 and IFN-γ dependent tumor eradiation 
(122).   
1.9.2.1 Surface-exposed CRT (ecto-CRT): an established „eat-me‟ signal 
CRT is an ER protein that serves multiple functions here like chaperone activity, assistance in 
MHC assembly and regulation of Ca
2+
 homeostasis. The cell surface exposure of CRT during 
apoptosis binds to and activates LDL-receptor-related protein (LRP, also termed CD91) on 
professional phagocytes (183).  This interaction allows the activation of Rac-1 in the 
phagocytes, enabling efficient phagocytosis. Ground-breaking research by Obeid et al. has 
identified a key role for ecto-CRT in the overall immunogenicity of dying cancer cells (123). 
Here, they showed that the exposure of CRT on cancer cells undergoing ICD in response to 
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several chemotherapeutics can facilitate their phagocytosis by DCs. Hence, ecto-CRT 
exposure is considered an „eat me‟ signal for professional phagocytes. Later it was shown that 
anti-CRT antibodies could also impair the engulfment of Hyp-PDT treated cancer cells by 
murine and human DCs (150).  
CRT gets exposed in the pre-apoptotic phase of ICD, preceding apoptosis-associated exposure 
of phosphatidylserine on the outer leaflet of the plasma membrane and mitochondrial 
depolarization. The molecular mechanisms underlying this ICD hallmark have meanwhile 
been dissected for certain chemotherapeutics and Hyp-PDT, revealing some interesting 
discrepancies (177). Chemotherapy-induced ICD is highly multifactorial, involving PERK-
dependent posphorylation of eIF2α (the ER stress module), the activation of caspase-8 and the 
subsequent cleavage of BCAP31 leading to the activation of the pro-apoptotic Bcl-2 family 
members BAX and BAK proteins (the apoptotic module) and the proximal and PI3K-
regulated distal secretory pathway enabling its docking and binding to CD91 (exocytosis 
module) (121). The CRT translocation pathway induced by the type II ICD inducer Hyp-PDT 
is much simpler as it is dispensable of caspase-8 and eIF2α (150). In addition, in the setting of 
Hyp-PDT, ecto-CRT did not colocalize with ERp57 in lipid rafts, as is demonstrated for 
chemotherapy-induced ICD (150).  
1.9.2.2 ATP release: more than a „find me‟ signal 
Extracellularly released ATP can modulate different cellular functions such as death, survival, 
proliferation, adhesion and differentiation. ATP released by apoptotic cells is an established 
„find me‟ signal that facilitates the recruitment and differentiation of monocytes and 
macrophages via its interaction with the purinergic P2Y2 receptor (184). Chemotherapy-
induced ICD has been shown to induce early-apoptotic ATP secretion (during the phase of 
phosphatidyl exposure), which was vital for the generation of an effective antitumor immune 
response (185). In addition to its chemoattractant function, extracellular ATP stimulates 
P2RX7 receptors on DCs, this way activating the NLRP3 inflammasome-mediated maturation 
and consequent release of IL-1β (186). This cytokine stimulates the polarization of IFN-γ 
producing CD8
+
 CTLs and IL-17 production by Th17 cells.  
The mechanisms involved in ATP release depend on the apoptotic stage and the cell death 
stimulus involved. Pre-apoptotic secretion of ATP by Hyp-PDT treated cancer cells was 
autophagy independent and was mediated by the PERK-regulated proximal secretory pathway 
and PI3K-dependent exocytosis with no contribution of BAX or BAK (150). On the other 
hand, early apoptotic secretion as elicited by chemotherapy-induced ICD was positively 
regulated by autophagy-related genes (177).  
1.9.2.3 Passively released HMGB1: a highly context-dependent DAMP 
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HMGB1 is a nuclear chromatin-binding protein that can support the transcription of various 
genes like p53 and NF-κB. It can be passively released, however, during primary necrosis and 
immunogenic apoptosis (during secondary necrosis). Once secreted it can stimulate the 
production of pro-inflammatory cytokines (e.g. TNFα, IL-1β, IL-6 and IL-8) from innate 
immune cells, by binding to various immune receptors like TLR2, TLR4 and RAGE (177).  
Importantly, extracellular HMGB1 is crucial for the immunogenicity of chemotherapy- and 
radiotherapy-induced ICD (187, 188). More specifically, the tumor-rejecting effect of 
chemotherapy treated CT26 murine colon carcinoma cells undergoing ICD was abrogated in 
the presence of HMGB1-specific antibodies, hindering the binding of HMGB1 to TLR4 
(187). In accordance with these data, the immunogenicity of tumor cells exposed to 
anthracyclines is lost in mice presenting with genetic defects in TLR4 or its downstream 
mediator MyD88 (myeloid differentiation primary response gene 88) (187, 188). The 
TLR4/MyD88 pathway instigated by HMGB1 inhibits the fusion between lysosomes and 
phagosomes, this way encouraging antigen processing (187, 188).  
 Nonetheless, HMGB1 has also been shown to have a protumorigenic role in several murine 
models and binding of HMGB1 to TIM3 on tumor-infiltrating DCs has been shown to abolish 
nucleic-acid mediated antitumor immunity (189). To make things even more complex, the 
activity of extracellular HMGB1 is highly dependent on the redox state in the cell such that 
full oxidation of HMGB1 results in its inactivation (177). Although the tumor 
microenvironment in vivo tends to be highly pro-oxidative, in vitro this can be highly variable 
depending on the cancer cell type and it progression stage.  
1.10 ICD-based DC vaccines 
Although the list of ICD inducers is constantly growing, only few of these immunogenic 
modalities have been tested in the light of generating an immunogenic tumor cell cargo to 
load DC vaccines (Tables 2 and 3). Figure 5 schematically represents the preparation of ICD-
based DC vaccines and their putative modes of action. 
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Figure 5. A schematic representation of ICD-based DC vaccines. ICD causes cancer cells to 
emit a spatiotemporally defined pattern of danger signals. Upon loading of ICD-undergoing 
cancer cells onto DCs, they induce extensive phagocytosis and antigen uptake by DCs. 
Loaded DCs show enhanced phenotypic and functional maturation and immunization with 
these ICD-based DC vaccines instigates Th1-, Th17-, and cytotoxic T lymphocyte (CTL)-
driven antitumor immunity in vivo. 
1.10.1 Radiotherapy 
Ionizing x-ray or γ-ray irradiation exerts its anticancer effect predominantly via its capacity to 
induce DNA double-strand breaks leading to intrinsic cancer cell apoptosis (190). The idea 
that radiotherapy could also impact the immune system was derived from the observation that 
radiotherapy could induce T-cell mediated delay of tumor growth in a non-irradiated lesion 
(191). This abscopal (ab-scopus, away from the target) effect of radiotherapy was later 
explained by the ICD-inducing capacity of radiotherapy (192). Although this type I ICD 
inducer is known to induce ROS, its ER stress-inducing capability remains largely unexplored 
(177). The DAMPs that are induced following radiotherapy treatment of cancer cells include 
the exposure of ecto-CRT (123, 124, 135) and ecto-HSP70 (136) and the release of HMGB1 
(133, 135) (Table 2). Irradiated B16 melanoma cells have been shown to be efficiently 
phagocytosed by DCs and to induce phenotypic DC maturation (117, 137). In addition, 
human DCs pulsed with irradiated tumor cells could efficiently stimulate antigen-specific 
CTL responses (140) (Table 2). Furthermore, mice immunized with DCs loaded with 
irradiated cancer cells could efficiently suppress tumor growth following inoculation with live 
syngeneic tumor cells in multiple preclinical cancer models (117, 140). In this setting, 
splenocytes from vaccinated animals could efficiently prime CD4
+
 and CD8
+
 T cells and 
exerted antigen-specific cytolytic activity (117) (Table 3).  
DC vaccines exposed to irradiated cancer cells have been successfully implemented in clinical 
practice in melanoma and HGG patients (114, 166, 167) (Table 3). Cho and colleagues have 
shown that the implementation of DC vaccines loaded with irradiated autologous tumor cells 
in the conventional treatment regimen of newly diagnosed GBM patients could significantly 
prolong the median overall survival (by more than 15 months) as compared to a control group 
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receiving solely conventional treatment (167). Interestingly, Di Nicola et al. reported that 
vaccination with DCs loaded with dying autologous tumor cells after exposure to a cell death 
protocol consisting of heat shock, γ-ray and UVC ray could elicit clinical responses in 6 out of 
18 relapsed B-cell lymphoma patients (193). Later they showed the impaired ability of the 
neoplastic cells used to vaccinate non-responders to undergo ICD upon exposure to the cell 
death protocol (157). Importantly, they revealed a positive association between the extent of 
CRT and HSP90 surface expression in the DC antigenic cargo and the clinical and 
immunological responses achieved (157).  
1.10.2 Shikonin 
The phytochemical shikonin, a major component of Chinese herbal medicine, is known to 
inhibit proteasome activity. It serves multiple biological roles and can be applied as an 
antibacterial, antiviral, anti-inflammatory and anticancer treatment. The latter application has 
been shown to yield responsiveness in late-stage lung cancer patients (194). Apoptotic cell 
death elicited by this type I ICD inducer can be inhibited by anti-oxidants, suggesting a role of 
shikonin-induced ROS (195). The ICD that is induced in shikonin-treated cancer cells is 
characterized by the early induction of HSP70, HSP90, GRP78 and HMGB1 (141) (Table 2). 
Importantly, shikonin treatment could significantly improve the survival of mice bearing P388 
leukemia and this antitumor effect of shikonin was less pronounced in immunodeficient mice 
(195). Moreover, the tumor lysate from shikonin-treated B16 cells could enhance phenotypic 
and functional DC maturation and differentiation of Th1 and Th17 cells, two important 
features of ICD-associated antitumor immunity (141) (Table 2). Additionally, curative 
vaccination of B16 melanoma-inoculated mice with shikonin-lysate loaded DCs could delay 
tumor growth (141). This was associated with increased cytolytic activity of splenocytes on 
target tumor cells (Table 3). Although shikonin is administered to breast cancer patients for 
observational purposes (NCT01287468), clinical experience evaluating shikonin-lysate 
loaded DC vaccines is unfortunately still lacking (Table 3). 
1.10.3 High-hydrostatic pressure 
High-hydrostatic pressure (HHP) is an established method to sterilize pharmaceuticals, human 
transplants and food. HHP between 100 and 250 megapascal has been shown to induce 
apoptosis of murine and human (cancer) cells (196). While DNA damage does not seem to be 
induced by HHP < 1000 megapascal, HHP can disrupt membranes and denature proteins 
(197). Increased ROS production was detected in HHP-treated cancer cell lines and ER stress 
was evidenced by the rapid phosphorylation of eIF2α (142). 
The anticancer activity of HHP was already demonstrated more than 4 decades ago in bladder 
cancer patients (168). Later, preclinical experiments demonstrated in vivo immunogenicity of 
HHP-treated cancer cells in the B16 melanoma model and the 3LL-D122 lung metastasis 
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model (168). Subsequently, it was shown that HHP-treated mammalian cancer cell lines 
undergoing apoptosis can release HSP70 and HMGB1, while retaining their immunogenicity 
in vivo (198). Very recently, Spisek and colleagues have shown the ability of HHP to induce 
prototypical ICD in human prostate and ovarian cancer cell lines and in acute leukemia cells 
(142). HHP treatment induced the rapid expression of ecto-HSP70, ecto-HSP90 and ecto-CRT 
and the release of HMGB1 and ATP (Table 2). Interestingly, HHP-treated cancer cells were 
rapidly phagocytosed by DCs and induced the upregulation of CD83, CD86 and HLA-DR and 
the release of pro-inflammatory cytokines (Table 2). This led to the stimulation of high 
numbers of tumor-specific T cells without inducing Tregs. Hence, all ICD-associated 
molecular criteria are fulfilled for HHP. This group is currently testing the in vivo 
immunogenicity of HHP killed tumor cells in prophylactic and curative murine vaccination 
settings (Table 3). Moreover they have initiated multiple clinical trials to evaluate the 
potential of DC vaccines loaded with HHP-treated cancer cells in ovarian and prostate cancer 
patients (168).  
1.10.4 Oncolytic viruses 
Oncolytic viruses are self-replicating, tumor selective virus strains that can directly lyse tumor 
cells. Over the past few years, a new oncolytic paradigm has risen; entailing that, rather than 
utilizing oncolytic viruses solely for direct tumor eradication, the cell death they induce 
should be accompanied by the elicitation of antitumor immune responses to maximize their 
therapeutic efficacy (199). One way in which these oncolytic viruses can fulfill this oncolytic 
paradigm is by inducing ICD (199).  
Thus far, three oncolytic virus strains can meet the molecular requirements of ICD; 
Coxsackievirus B3 (CVB3), oncolytic adenovirus and Newcastle disease virus (NDV) (table 
2) (179). Infection of tumor cells with these viruses causes the production of viral envelop 
proteins that induce ER stress by overloading the ER. Hence, all three virus strains can be 
considered type II ICD inducers (179). While CVB3 and oncolytic adenoviruses induce the 
surface expression of CRT, followed by the release of ATP and the passive release of 
HMGB1 in apoptotic tumor cells (in non-small cell lung carcinoma and adenocarcinoma cells, 
respectively) (143, 144), NDV induces necroptosis accompanied by the surface exposure of 
ATP and the post-necroptotic release of HMGB1 in GL261 glioma cells, with no contribution 
of ATP (Table 2)(145). In addition, NDV-infected GL261 cells upregulated the expression of 
the PMEL17 tumor antigen (145).  
Intratumoral administration of CVB3 in nude mice resulted in the marked infiltration of NK 
cells, macrophages, granulocytes and mature DCs into the tumor tissue (Table 2) (144). 
Tumor-infiltrating DCs expressed significantly higher levels of costimulatory molecules 
CD80 and CD86, as well as the lymph node homing receptor CCR7 (144). CD40-ligand 
encoding oncolytic adenoviruses have also been shown to facilitate the recruitment of DCs to 
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the tumor tissue, this way entailing efficient Th1 and CD8
+
 CTL responses (Table 2) (143). 
Measles virus is another oncolytic virus that requires further investigation. Although 
extensive analysis of in vitro ICD determinants is lacking for this virus (only the release of 
HMGB1 has been documented), DCs exposed in vitro to measles-virus treated melanoma 
cells upregulated CD80 and CD86 expression levels (Table 2) (146). This resulted in the 
efficient priming of melanoma-specific cell killing by IFN-γ producing CD8+ T cells. 
Moreover, measles virus-infected melanoma cells constituted more effective tumor lysates 
(also termed oncolysates) than uninfected melanoma cell lysates as an antigen source for 
loading of DCs in terms of priming these melanoma-specific CTL responses (146). The DC 
stimulatory capacity of NDV-derived oncolysates has already been demonstrated more than a 
decade ago by the group of Schirrmacher (147). Here, DCs derived from breast cancer 
patients pulsed with NDV oncolysates showed increased expression of costimulatory 
molecules in comparison to DCs loaded with tumor lysate from non-infected breast carcinoma 
cells (Table 2). In addition, these oncolysate-loaded DCs were more effective in stimulating 
bone-marrow-derived reactive memory T cells in vitro (147).  
Oncolytic viruses hold great potential for application in ICD-based DC vaccines given their 
potential to elicit several ICD-related DAMPs. Furthermore, these viruses might directly 
affect DC maturation and activation through interaction with pathogen recognition receptors 
on the DCs. This way, biological oncolysates may render the use of an artificial maturation 
cocktail otiose. Unfortunately, there are no preclinical in vivo data available yet to evince the 
efficacy of DC vaccines loaded with immunogenic oncolysates (Table 3). Nevertheless, 
several studies have documented the beneficial effect of intratumoral application of oncolytic 
viruses in combination with tumor-directed systemic DC vaccinations (169, 170). Very 
recently, Schirrmacher et al. disclosed a case report of a breast cancer patient with liver 
metastasis that was treated with local hyperthermia, intravenously administered NDV and 
subcutaneous vaccination with DCs loaded with NDV-infected breast cancer cells 
(oncolysate) (171) (Table 3). This combination therapy led to long-lasting tumor-specific 
memory T cell responses and stable disease for more than 66 months in this particular patient 
(171). The use of autologous DCs loaded with NDV-mediated oncolysate is licensed by the 
Paul Ehrlich Institute to the Immunologic-Oncologic Centre Cologne (IOZK) since May 
2015.  
Of note, in October 2015, the FDA approved the first oncolytic virus, Imlygic (a genetically 
modified live oncolytic herpes virus) for the treatment of melanoma lesions in the skin and 
lymph nodes. This FDA approval should facilitate the approval of other oncolytic viruses as 
well as the application of oncolysates in DC vaccine settings. 
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1.10.5 Photodynamic therapy 
Photodynamic therapy (PDT) is an established, minimally invasive physico-chemical 
anticancer treatment modality. It has a two-step mode of action involving the uptake of a 
photosensitizer by the tumor tissue, followed by its activation by light of a specific 
wavelength. The absorption of photons with this specific wavelength will cause the 
photosensitizers to excite and a part of them will fall back to a more stable triplet state. These 
triplet states can undergo type I or II reactions, in the presence of oxygen, to return to their 
ground state, leading to the production of ROS (preferably singlet oxygen) (200-202). In type 
I reactions, the excited triplet state photosensitizer reacts with the neighbouring biomolecules 
(e.g. proteins or lipids) to form radical species that can react with molecular oxygen to form 
hydrogen, hydrogen radicals and superoxide (200). Type II reactions on the other hand, 
consist of the triplet state directly reacting with molecular oxygen thereby leading to the 
generation of 
1
O2 (200).  
One attractive feature of PDT is that the ROS-based oxidative stress (due to the short half-life 
and limited diffusion range of ROS species) originates in the particular subcellular location 
where the photosensitizer tends to accumulate, ultimately leading to the destruction of the 
tumor cell (203). PDT-based antitumor effects are multifactorial and depend on its abilities to 
damage the tumor vasculature, directly kill tumor cells, exert cytotoxic effects towards tumor-
infiltrating immune cells and recruit and activate immune cells that can instigate adaptive 
antitumor immune responses (202).  
Increasing preclinical information is available regarding the impact of PDT on the immune 
system. Recent studies have demonstrated that PDT can effectively generate several DAMPs. 
HSP70, the best studied DAMP associated with PDT, is exposed on the surface of cancer cells 
treated with photofrin-PDT, 5-ALA-PDT and Foscan-PDT (151, 204, 205). Of note, the 
uptake of tumor antigens and DC maturation induced by 5-ALA-PDT treated GBM spheroids 
were inhibited when HSP70 was blocked (204). Later it was reported that photofrin-PDT also 
promotes the early/mid-apoptotic surface expression of CRT and the post-apoptotic release of 
HMGB1 (152) (Table 2). Very recently, the DAMPs profile induced by Rose Bengal Acetate 
(RBAc)-based PDT was unraveled. RBAc photosensitized apoptotic/autophagic Hela cells 
were found to expose and/or release ATP, HSP70/90, HMGB1 and CRT (206). In terms of its 
immunogenicity, hypericin can be considered the best studied photosensitizer. Few years ago, 
Hyp-PDT became the first PDT modality capable of inducing prototypical ICD in cancer cells 
(Figure 6) (120, 149, 150, 177). Hypericin localizes predominantly in the ER and upon 
irradiation it causes photo-oxidative ER stress, making Hyp-PDT the only known PDT 
modality able to induce ICD through focused ROS-based ER stress (Type II ICD inducer), 
eventually culminating in mitochondrial apoptosis (150, 207). In the pre-apoptotic stage it 
induces the active emission of three crucial ICD-associated DAMPs i.e. ecto-CRT, ecto-
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HSP70 and secreted ATP, followed by the passive release of HSP70 and HMGB1 (149, 150) 
(Table 2 and Figure 6).  
The immunogenic features of Hyp-PDT-treated cancer cells have also been confirmed by ex 
vivo and in vivo experiments (Tables 2 and 3 and Figue 6). Hyp-PDT-treated cancer cells 
form a productive interface with DCs in terms of phagocytosis (CRT-dependent) and 
maturation (150) (Table 2). More specifically, the interacting DCs exhibit functional 
stimulation (NO
high
, IL-10
absent
, IL-6
high
, IL-1βhigh and IL-12p70median) and phenotypic 
maturation (CD80
high
, CD83
high
, CD86
high
 and MHC-II
high
) (150, 153). Moreover, these 
immunogenic and fully mature DCs induce the clonal expansion of human IFN-γ producing 
CD4
+
 and CD8
+
 T cells (153, 154). Consequently, this in vitro antitumor immunity induced 
by Hyp-PDT-induced ICD led to the efficient rejection of murine tumors in vivo in the 
absence of any adjuvants (both in prophylactic and curative vaccination models) – a key 
signature of antitumor immunity and ICD (150, 208). Following Hyp-PDT, photofrin-based 
PDT became the second PDT modality that is capable to fulfill this critical in vivo 
requirement for ICD characterization. Here, peritumoral curative immunization with 
benzoporphyrin-based-PDT treated squamous cell carcinoma cells constituted a potent 
anticancer vaccine (as opposed to x-ray irradiated or freeze-thawed cells) in this poorly 
immunogenic model (156).  
Importantly, inoculation of mature DCs in PDT-treated tumors resulted in the cytolytic 
activation of T cells and NK cells, leading to effective tumor eradication (172). Moreover, DC 
vaccines loaded with porphyrin PDT-induced tumor lysates have been shown to cure fully 
established solid non-orthotopic tumors. This was associated with enhanced CTL responses 
and Th1 immunity (209) (Table 3). Hyp-PDT-based DC vaccines have not been studied yet in 
preclinical tumor models. To this end, and considering the very attractive ICD-related features 
of hypericin-PDT (as elaborated chapter 1.11), we investigated the potential of Hyp-PDT-
based DC vaccines in preclinical orthotopic HGG models (chapter 4).  
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Figure 6: Photo-oxidative (Phox) ER stress induced by Hyp-PDT elicits prototypical ICD in 
cancer cells. In contrast to other ICD inducers (like doxorubicin and mitoxantrone), Hyp-
PDT induces the pre-apoptotic exposure of ecto-CRT (at higher levels as compared to 
chemotherapeutic ICD inducers) and ecto-HSP70, accompanied by the active secretion of 
ATP in the absence of plasma membrane permeabilization and prior to the externalization of 
phosphatidylserine (PS). This is followed by the passive release of HSP70, HSP90 and CRT in 
the late apoptotic phase. Overall, Hyp-PDT stressed dying/dead cancer cells cause 
phenotypic and function maturation of DCs and priming of the adaptive immune system in 
vivo upon prophylactic vaccination (Modified adapted from (180)).  
1.11 Hyp-PDT-based ICD in the spotlight 
1.11.1 Hyp-PDT: an evolutionary conserved elicitor of host-defense mechanisms? 
Hypericin is a naturally occurring photosensitizer that is exploited by plants of the genus 
Hypericum to achieve light-mediated killing of pest (203, 210). Hence, Hyp-PDT might 
constitute evolutionary conserved defense mechanisms against non-self molecules.  
As discussed previously, hypericin preferentially localizes in the ER, and upon irradiation 
with an appropriate wavelength (around 595 nm) it causes predominantly singlet oxygen 
species (210). These species can interact with proteins and lipids, thereby eliciting protein 
carbonyl derivatives or lipid hydroperoxides that can pass on this photo-oxidative damage to 
other biological targets. In particular, Hyp-PDT instigates ER dilatation and damage to 
SERCA (a sarcoplasmic reticulum Ca
2+
 ATPase), causing the exit of Ca
2+
 from the ER into 
the cytosol (211). This triggers the rapid activation of the UPR response in which PERK plays 
a central role, both in activating the danger signaling pathways responsible for the 
exposure/release of DAMPs (as discussed previously) as well as in triggering apoptosis (150, 
153, 203). In view of the latter, three pro-death signaling pathways were uncovered, 
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ultimately provoking BAX/BAK mediated mitochrondrial apoptosis accompanied by 
mitochondrial depolarization, release of cytochrome c and activation of caspase-3. In the first 
pathway, the PERK-eIF2-ATF branch robustly induces CHOP (a pro-apoptotic transcription 
factor) (212). In case of the second pathway, PERK induces the expression of Noxa (a pro-
apoptotic BH3-only protein), independent of CHOP signaling (212). In the last pathway, 
PERK functions as a component of the mitochondria-associated membranes to physically 
connect the ER to the mitochondria, allowing the ROS originated in the ER to transfer to the 
contacting mitochondria (207).  
1.11.2 Hyp-PDT as an ideal ICD inducer for application in DC vaccines?  
Recently, a list of properties of an ideal ICD inducer was proposed (177). The following of 
these requirements should also be met in the setting of ICD-based DC vaccines; the capability 
to induce efficient cell death, the ability to induce strong antitumor immunity, being non-
susceptible to drug-efflux channels, the capacity to induce severe focused ER stress, the 
ability to overcome loss of function mutations that can diminish danger signaling during 
cancer micro-evolution, the capacity to down regulate tumor-based transcription of pro-
inflammatory genes, having negligible inhibitory effects on the infiltrating antitumorigenic 
immune populations, being able to exert inhibitory effects on tumor-infiltrating 
protumorigenic immune cell. In contrast to other ICD inducers, Hyp-PDT is able to measure 
up to all of these requirements, except the last one. Indeed, the influence of Hyp-PDT on the 
tumor influx of immunosuppressive immune cells like Tregs is not investigated yet. 
Moreover, the group of Agostinis has managed to put Hyp-PDT in the spotlight when it 
comes to advantages associated with ICD and ER stress biology. More specifically, the 
number (ATP, ecto-CRT and ecto-HSP70) and relative amount of pre-apoptotically induced 
DAMPs associated with Hyp-PDT is higher than that reported for chemotherapeutics 
(mitoxantrone or doxorubicin) (203). Also the speed of their emission is unmatched.  
Moreover, as elaborated in previous sections, the Hyp-PDT induced danger signaling 
pathways involve reduced numbers of molecular components as compared to chemotherapy-
induced ICD (150, 203). This makes Hyp-PDT treated cancer cells less susceptible to tumor 
cell evasion owing to the ability of tumor cells to undergo loss of function mutations for 
several signaling molecules involved in ICD-associated danger signaling (as is demonstrated 
for caspase-8 and BAX, amongst others) (177, 203). These advantages of Hyp-PDT are 
predominantly related to its ability to induce on target photo-oxidative ER stress, able to 
trigger most potent danger signaling. Other advantages include its favorable safety profile (in 
contrast to the strong cardiotoxicity that is associated with mitoxantrone and doxorubicin) and 
its straightforward use as a single-agent ICD inducer. Additionally, unlike HHP that requires 
expensive and sophisticated HHP equipment, Hyp-PDT only needs hypericin and visible light 
in the orange region. Furthermore, Hyp-PDT is an FDA approved treatment and its in vivo 
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application in bladder carcinoma and HGG patients, amongst others, has been proven to be 
safe (178, 213).  
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2. AIMS AND OBJECTIVES 
“The scientist is not a person who gives the right answers; he's one who asks the right 
questions.”  
- Claude Lévi-Strauss 
 
Over the last decade our research group and others, have demonstrated that DC-based 
immunotherapy can be considered a promising treatment strategy in the fight against HGG. 
Nevertheless, the clinical benefit associated with this tumor-specific therapy is still considered 
suboptimal. This can in part be attributed to the strong HGG-induced immunosuppression and 
the selection of advanced disease patients. In addition, potentiating the immunogenicity of DC 
vaccines by making step-by-step protocol optimizations might also bring us closer to an 
effective CTL- and Th1-driving vaccine product. In this regard, the immunogenicity of the 
tumor lysate that is used for loading DC vaccines might constitute a crucial influencing factor.  
The general aim of this project was to increase the immunogenicity of the whole tumor cell 
preparations that are used to load DC vaccines, in the setting of preclinical HGG. Given the 
residual toxicity that might be associated with chemical inducers of cancer cell death, we 
focused here on two promising physico-chemical treatment modalities: x-ray irradiation and 
Hyp-PDT. These two cell killing modalities share the capability to generate high levels of 
ROS that can induce immunogenic OAMPs. While the former induces ROS species 
throughout the complete cell, the latter generates ROS specifically in the ER, this way 
inducing prototypical ICD, associated with the exposure/release of high levels of DAMPs.  
To study our hypothesis, we used the orthotopic murine GL261 HGG model, which is the 
most abundantly used immunocompetent mouse model to study the potency of 
immunotherapeutic strategies against intracranial HGG.  
With this background, we wished to achieve the following general aims in the two projects: 
I. To test the in vivo potency of the DC vaccine preparations in a prophylactic 
vaccination setup and to study the brain immune-contexture within this setup; 
II. To identify/develop the most clinically relevant version of the vaccine that can still 
trigger potent protective immunity against HGG; 
III. To identify the molecular and cellular determinants contributing to the vaccine‟s in 
vivo immunogenicity; 
IV. To study the efficacy of the DC vaccine preparations in a curative, more clinically 
relevant setup and to study the brain immune-contexture associated with this setup; 
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3. RESULTS – PART I 
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand 
more, so that we may fear less.”  
- Marie Curie 
 
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), 
potentiates DC vaccine-induced antitumor immunity against high-grade glioma 
OAMPs like carbonylated proteins and peroxidized phospholipids have emerged as important 
molecular determinants of cancer immunogenicity, in line with the family of DAMPs. More 
specifically, protein carbonylation has been shown to improve cancer cell immunogenicity by 
facilitating efficient Ag processing by DCs and by inducing the formation of tumor-specific 
carbonylated neo-antigens which are less susceptible to central tolerance. Most clinical 
reports involving DC vaccinated HGG patients report the ad random use of freeze-thaw 
cycles (to induce necrosis of tumor cells) or the combination of freeze-thaw cycles and high-
dose x-ray irradiation to obtain a whole tumor lysate for loading onto the DCs. There is, 
however, no consensus yet on which of the two methodologies is preferred. As radiotherapy is 
known to generate ROS that can induce OAMPs, we hypothesized that x-ray irradiation might 
potentiate the immunogenicity of freeze-thawed tumor lysates. Given that radiotherapy on its 
own is a known inducer of ICD, we also investigated the immunogenicity associated with this 
single intervention in this DC vaccine setting. Furthermore, we studied the brain immune-
contexture of vaccinated mice to identify the pivotal players of the innate and adaptive 
immune system that are contributing to the in vivo immunogenicity of the vaccines.  
With this background in mind, we wished to accomplish the following aims in the murine 
GL261 HGG model:  
I. To compare the in vivo efficacy of DC vaccines loaded with freeze-thawed GL261 
lysate (FT-DC vaccine), irradiated freeze-thawed GL261 lysate (FT+IR-DC  vaccine), 
freeze-thawed irradiated GL261 lysate (IR+FT-DC vaccine) and irradiated GL261 
cells (IR-DC vaccine) in a prophylactic DC vaccination setup; 
II.  To compare the brain immune-contexture of mice prophylactically immunized with 
FT-DC vaccines and FT+IR-DC vaccines; 
III. To unravel the molecular mechanisms behind the potentially increased 
immunogenicity (as studied in aim I) of the FT+IR-DC vaccines; 
IV. To compare the brain immune-contexture induced by FT-DC vaccines and FT+IR-DC 
vaccines in a clinically more relevant curative treatment setup; 
 
The research paper describing the results associated with this section and the 
corresponding supplementary information is presented on the following pages. 
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Abstract 
Dendritic cell (DC)-based immunotherapy has yielded 
promising results against high-grade glioma (HGG). 
However, the efficacy of DC vaccines is abated by HGG-
induced immunosuppression and lack of attention 
towards the immunogenicity of the tumor lysate/cells 
used for pulsing DCs. A literature analysis of DC 
vaccination clinical trials in HGG patients delineated the 
following two most predominantly applied methods for 
tumor lysate preparation: freeze-thaw (FT)-induced 
necrosis or FT-necrosis followed by X-ray irradiation. 
However, from the available clinical evidence, it is 
unclear which of both methodologies has superior 
immunogenic potential. Using an orthotopic HGG murine 
model (GL261-C57BL/6), we observed that prophylactic 
vaccination with DCs pulsed with irradiated FT-necrotic 
cells (compared to FT-necrotic cells only) prolonged 
overall survival by increasing tumor rejection in glioma-
challenged mice. This was associated, both in 
prophylactic and curative vaccination setups, with an 
increase in brain-infiltrating Th1 cells and cytotoxic T 
lymphocytes, paralleled by a reduced accumulation of 
regulatory T cells, tumor-associated macrophages and 
myeloid-derived suppressor cells. Further analysis 
showed that irradiation treatment of FT-necrotic cells 
considerably increased the levels of carbonylated 
proteins - a surrogate-marker of oxidation-associated 
molecular patterns (OAMPs). Through further application 
of antioxidants and hydrogen peroxide, we found a 
striking correlation between the amount of lysate-
associated protein carbonylation/OAMPs and DC 
vaccine-mediated tumor rejection capacity thereby 
suggesting for the first time a role for protein 
carbonylation/OAMPs in at least partially mediating 
antitumor immunity. Together, these data strongly 
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advocate the use of protein oxidation-inducing modalities 
like irradiation for increasing the immunogenicity of tumor 
lysate/cells used for pulsing DC vaccines.  
Introduction 
Gliomas are a group of central nervous system tumors of 
glial cell origin, accounting for at least 50% of all primary 
intrinsic brain tumors. Amongst gliomas, glioblastoma 
multiforme (GBM) is the most aggressive and most 
frequently occurring primary brain tumor in adults. 
According to the World Health Organization (WHO) it is 
classified as a grade IV tumor.1 Together with WHO 
grade III anaplastic astrocytoma, anaplastic 
oligodendroglioma and anaplastic oligoastrocytoma, 
GBM are categorized as high-grade gliomas (HGG). 
Despite multidisciplinary treatment consisting of surgical 
resection and radiochemotherapy, median overall 
survival of GBM patients is restricted to approximately 
14.6 months.2 Hence, there is an urgent need for novel, 
effective treatment strategies with minimal off-target 
effects against normal brain parenchyma.3 In this regard, 
dendritic cell (DC)-based immunotherapy can be an 
attractive option, because of its relative tumor-specific 
nature and its ability to elicit immune memory responses 
crucial for controlling or eliminating residual cancer 
cells.4, 5 A recent meta-analysis revealed that DC-based 
immunotherapy in HGG patients markedly prolonged the 
overall and the progression-free survival compared with a 
non-DC group.6 However, there is a consensus that DC 
vaccines have not yet reached their full potential. This is 
in part due to the selection of advanced disease stage 
patients and the presence of tumor-induced 
immunosuppressive mechanisms.7, 8 In addition, the lack 
of optimization and standardization of the different steps 
in the production process of DC vaccines, especially 
those pertaining to the overall immunogenicity of the 
tumor cells/lysate itself, also contributes notably to the 
limited DC vaccine efficacy.9 
HGG-induced immunosuppression is associated with a 
profound infiltration of anti-inflammatory and pro-
tumorigenic immune cells like T regulatory cells (Tregs), 
myeloid-derived suppressor cells (MDSCs) and tumor-
associated macrophages (TAMs).10-14 Therefore, an 
immunotherapeutic strategy that activates antitumor 
immunity and simultaneously tackles the infiltration of 
these immunosuppressive immune cell populations is 
highly desirable.4, 15 
DCs pulsed with whole tumor lysate tend to have 
superior efficacy over DCs pulsed with selected cancer-
associated antigen peptide(s).16 Moreover, the tumor 
specificity of the antitumor immune response elicited by 
whole tumor cell-based DC vaccination has been 
demonstrated in the preclinical GL261 HGG model.17 
Interestingly, multiple preclinical studies in different 
cancer models have convincingly demonstrated that the 
methodology utilized for tumor lysate preparation can 
influence its immunogenicity and in turn the overall 
efficacy of antitumor immunity elicited by tumor lysate 
pulsed DCs.18-21 There is, however, no consensus yet on 
the methodology of whole tumor lysate preparation; most 
clinical reports involving DC vaccinated HGG patients 
describe the use of multiple freeze-thaw (FT) cycles to 
induce necrosis of tumor cells (i.e. FT-necrosis) or a 
combination of FT-necrosis and subsequent high-dose X-
ray irradiation. The latter preparation methodology offers 
interesting, but as-yet-untested avenues in light of the 
fact that radiotherapy is a known enhancer of oxidation-
based immunogenicity.15, 22 More specifically, 
radiotherapy is known to generate reactive oxygen 
species (ROS)23 that have the ability to induce oxidation-
associated molecular patterns (OAMPs) like carbonylated 
proteins.24-29 This is important because protein 
carbonylation, a surrogate indicator of irreversible protein 
oxidation, has been shown to improve cancer cell 
immunogenicity and to facilitate the formation of neo-
immunogenic antigens.26 In addition, OAMPs like protein 
carbonylation can facilitate efficient antigen processing 
by DCs.25 
The primary goal of this study was to directly compare 
the in vivo immunogenicity of DCs pulsed with either FT-
necrotic cells or X-ray irradiated FT-necrotic cells, in the 
context of HGG. Moreover we explored the contribution 
of protein carbonylation-based OAMPs in this setting. To 
address these questions, we utilized the well-established, 
immunocompetent, orthotopic GL261 mouse HGG 
model. This model has been abundantly used to evaluate 
the potency of anti-HGG immunotherapies.30 
Results 
Clinical evidence generated from DC vaccination 
trials in HGG patients hints towards improved 
efficacy of irradiated FT-necrotic lysate 
Since 2000, over thirty phase I/II studies of DC-based 
immunotherapy for HGG have been published in which 
over 500 patients were involved.31 To this end, we 
decided to do a literature-based meta-analysis to 
ascertain the methodologies of tumor lysate preparation 
used and the associated patient responses. We found 
that 19 trials reported the use of whole tumor lysate as an 
antigen source for loading DCs (Table I). The method of 
preparing this lysate however randomly (i.e. without any 
specified reason or rationale) involved either FT-necrotic
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Figure 1. Irradiation of necrotic tumor lysate prolongs DC-vaccine induced survival of glioma-bearing mice. (A) Kaplan-Meier graph of two 
independent experiments depicting survival of mice immunized with the FT-DC vaccine (■, n = 14), the FT+IR-DC vaccine (▲, dashed 
line, n = 14) and untreated control mice (●, n = 9). *, p < 0.05; **, p < 0.01; ***, p < 0.0001 (Log-rank test). (B-D) The tumor-induced 
neurological deficit of one representative experiment is displayed graphically over time by color-coding symptom severity for (B) control 
mice (n = 4), (C) FT-DC vaccine treated mice (n = 7) and (D) FT+IR-DC vaccine immunized mice (n = 7): grade 0 (black), healthy mice; 
grade 1 (green), slight unilateral paralysis; grade 2 (yellow), moderate unilateral paralysis and/or beginning hunchback; grade 3 (orange), 
severe unilateral or bilateral paralysis and/or pronounced hunchback; grade 4 (red), moribund mice. 
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cells 16, 32-40 or irradiated FT-necrotic cells 41-49. 
Retrospective analysis of primary GBM patients‟ survival 
data with a Karnofsky performance score (KPS) of more 
than 70 revealed a trend towards prolonged overall 
survival in patients vaccinated with DCs fed with 
irradiated (IR) FT-necrotic GBM cells (FT+IR-DC vaccine, 
n = 27, median survival of 33.5 months) as compared to 
patients treated with DCs fed with FT-necrotic GBM cells 
(FT-DC vaccine, n = 34, median survival of 22.5 months, 
data not shown). These results have to be interpreted 
with due caution, as a more stringent and better powered 
meta-analysis is required to correctly compare the two 
treatment groups. Insufficient data were available for 
comparison of immunogenicity-related parameters. 
 In conclusion, this literature survey showed that several 
clinical trials utilized FT-DC vaccine and FT+IR-DC 
vaccine ad libitum for anti-HGG immunotherapy. 
Preliminary survival analysis hints towards giving 
preference to the use of irradiated necrotic lysate for 
loading DCs; however the two treatment regimens were 
indiscernible at the level of immunoscoring parameters.  
 
Irradiation of necrotic cells potentiates DC vaccine-
induced overall survival in glioma-challenged mice 
Since we were unable to reach a consensus on 
immunogenicity-related differences between the FT-DC 
vaccine and the FT+IR-DC vaccine based on above 
analysis, we decided to conduct preclinical experiments 
to directly compare the efficacy of these two DC vaccine 
„types‟. 
Using a prophylactic treatment strategy we observed a 
significant increase (p < 0.05) in the median survival of 
mice vaccinated with the FT+IR-DC vaccine (53.5 days) 
as compared to mice treated with the FT-DC vaccine (34 
days) (Figure 1A). Moreover, treatment with FT+IR-DC 
vaccine protected 5 of 14 animals (36 %) from tumor 
development, while only 2 of 14 (14 %) mice that 
received FT-DC vaccine were protected. Of note, in line 
with our previously published data, vaccination with FT-
DC vaccine induced a significant improvement in median 
survival (p < 0.01) in comparison to untreated animals 
(34 versus 23 days, respectively).50 
Consistent with the survival data, graphical 
representation of the tumor-induced neurological deficit 
scores over time revealed a delay in the onset of 
clinically-relevant symptoms and a less pronounced 
clinical manifestation in mice treated with the FT+IR-DC 
vaccine compared to FT-DC vaccine immunized animals 
(Figure 1B-D). 
As irradiation is a known enhancer of tumor cell 
immunogenicity 51, 52, we also wished to address if IR on 
its own or IR treatment prior to FT of the GL261 cells 
could impact the in vivo immunogenicity of the tumor cell 
preparations. Both treatment groups (IR-DC vaccine and 
IR+FT-DC vaccine, respectively) however failed to induce 
significant survival benefit as compared to untreated mice 
or FT+IR-DC vaccine treated mice (Suppl. Figure 1). 
Interestingly, to achieve a 90 % cell killing rate the GL261 
cells had to receive an 800 Gy X-ray dose, underlining 
the high radiotherapy resistance of this HGG cell line 
(data not shown). Of note, because of the requirement of 
100 % tumor cell avitality for clinical translation of DC 
vaccines, the IR-DC vaccine cannot be considered as a 
clinically relevant alternative for the FT+IR-DC vaccine.  
 
Increased potency of DCs pulsed with irradiated FT-
necrotic cells is associated with a favorable shift in 
brain immune contexture 
Next, we investigated whether the increased in vivo 
immunogenicity of the FT+IR-DC vaccine was associated 
with an immunostimulatory shift in the brain immune 
contexture. To this end, brain-infiltrating immune cells 
were analyzed by flow cytometry, 20 days after 
intracranial GL261 tumor inoculation (Figure 2A). Each 
graphical point (depicting one mouse) was given a color 
according to its neurological deficit score at the moment 
of sacrifice (Figure 2B-K). Evaluating the adaptive 
immune compartment, a significantly increased infiltration 
of CD3+ T cells was observed in mice vaccinated with the 
FT+IR-DC vaccine as compared to both untreated and 
FT-DC vaccine treated animals (p < 0.05, Figure 2B). We 
observed no significant differences in the percentages of 
total CD4+ brain-infiltrating T cells between the different 
groups (Figure 2C). Moreover, FT+IR-DC vaccine 
injected mice showed a reduced infiltration of 
CD4+FoxP3+ Tregs and an increase in the clinically 
relevant ratio of CD8+ T cells to CD4+FoxP3+ Tregs (p < 
0.05, Figure 2D and 2E, respectively). As IFN-γ 
production by T cells is considered crucial for the 
induction of Th1 polarization-based antitumor immunity,53 
we evaluated the intracellular levels of this cytokine in the 
brain-infiltrating lymphocytes. Only in FT+IR-DC vaccine 
treated mice the frequency of IFN-γ+CD4+ T cells i.e. Th1 
cells and IFN-γ+CD8+ T cells i.e. cytotoxic T lymphocytes 
(CTLs) was significantly higher as compared to untreated 
control mice (p < 0.05 and p < 0.01 respectively, Figure 
2F and 2G, respectively). In addition to the adaptive 
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Figure 2. Prophylactic vaccination with FT+IR-DC vaccines favorably impacts the brain immune contexture. (A) Timeline depicting the 
prophylactic treatment protocol. Mice received two weekly i.p. vaccinations with either the FT-DC vaccine (n = 8) or the FT+IR-DC vaccine 
(n = 8). One week after the last vaccination, mice were intracranially inoculated with GL261 cells. Mice not immunized with vaccines were 
used as controls (n = 5). The brain-infiltrating immune cells (BICs) were isolated on day 20 post GL261 tumor inoculation. (B-K) Flow 
cytometry of the mononuclear BICs. Each point (representing data from one mouse) is given a color according to its neurological deficit 
score: grade 0 (black), healthy mice; grade 1 (green), slight unilateral paralysis; grade 2 (yellow), moderate unilateral paralysis and/or 
beginning hunchback; grade 3 (orange), severe unilateral or bilateral paralysis and/or pronounced hunchback; grade 4 (red), moribund 
mice. (B) Percentages of CD3+ T cells (CD45high-gated), (C) CD4+ T cells (CD3+-gated), (D) FoxP3+ Tregs (CD4+-gated) and (E) the ratio of 
CD8+ T cells (CD3+-gated) over FoxP3+ Tregs (CD4+-gated). (F-G) Percentages of IFN-γ+ cells in the (F) CD4+ and (G) CD8+ T cell 
populations, analyzed by intracellular IFN-γ staining. (H) Percentages of CD11b+ myeloid cells, (I) CD11b+F4/80+ macrophages, (J) 
CD11b+Ly6C+ mononuclear MDSCs and (K) CD11b+Ly6G+ granulocytic MDSCs within the CD45high gate, thereby excluding 
CD45intCD11b+ microglia. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (one-way ANOVA). Data are presented as medians.  
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Figure 3. Curative vaccination with the FT+IR-DC vaccine induces a pro-inflammatory shift in brain immune contexture. (A) Timeline 
depicting the curative treatment protocol. Treated mice received three i.p. vaccinations with either FT-DC vaccines (n = 6) or FT+IR-DC 
vaccines (n = 5) on days 2, 9 and 17 post intracranial GL261 inoculation. Mice not immunized with vaccines were used as controls (n = 4). 
The brain-infiltrating immune cells (BICs) were isolated on day 21 post GL261 tumor inoculation. (B-K) Flow cytometry of the mononuclear 
BICs. Each point (representing data from one mouse) is given a color according to its neurological deficit score: grade 0 (black), healthy 
mice; grade 1 (green), slight unilateral paralysis; grade 2 (yellow), moderate unilateral paralysis and/or beginning hunchback; grade 3 
(orange), severe unilateral or bilateral paralysis and/or pronounced hunchback; grade 4 (red), moribund mice. (B) Percentages of CD3+ T 
cells (CD45high-gated), (C) CD4+ T cells (CD3+-gated), (D) FoxP3+ Tregs (CD4+-gated) and (E) the ratio of CD8+ T cells (CD3+-gated) over 
FoxP3+ Tregs (CD4+-gated). (F-G) Percentages of IFN-γ+ cells in the (F) CD4+ and (G) CD8+ T cell populations, analyzed by intracellular 
IFN-γ staining. (H) Percentages of CD11b+ myeloid cells, (I) CD11b+F4/80+ macrophages, (J) CD11b+Ly6C+ mononuclear MDSCs and (K) 
CD11b+Ly6G+ granulocytic MDSCs within the CD45high gate, thereby excluding CD45intCD11b+ microglia. *, p < 0.05; **, p < 0.01 (one-way 
ANOVA). Data are presented as medians. 
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immune compartment, we also evaluated the brain 
infiltration of different myeloid cell populations in tumor-
inoculated mice (Figures 2H-K). Analysis of the 
percentages of brain-infiltrating myeloid cells (CD11b+) 
revealed a significantly reduced influx of these cells in 
mice treated with the FT+IR-DC vaccine compared to 
both untreated mice (p < 0.05) and FT-DC vaccine 
immunized mice (p < 0.01, Figure 2H). A more detailed 
phenotypic characterization of the brain-infiltrating 
myeloid cells showed a significant decrease in the 
percentage of TAMs (CD11b+F4/80+, Figure 2I), 
mononuclear MDSCs (CD11b+Ly6C+, Figure 2J) and 
granulocytic MDSCs (CD11b+Ly6G+, Figure 2K) in mice 
receiving the FT+IR-DC vaccine in comparison to both 
FT-DC vaccine injected (p < 0.05, p < 0.01 and p < 0.05, 
respectively) and untreated animals (p < 0.001 for all 
three populations). Although there was a decreased 
infiltration of these myeloid cell populations in FT-DC 
vaccine treated mice as compared to untreated mice, this 
did not reach statistical significance.  
Of note, mice experiencing neurological deficits (grade 1-
4) were only present in the untreated and FT-DC vaccine 
treated groups. These mice in general showed the lowest 
infiltration of Th1 cells and CTLs, the highest infiltration of 
the different myeloid populations (especially in the FT-DC 
vaccine group) and the highest Treg levels (Figure 2).  
Together, these data suggest that prophylactic 
vaccination with FT+IR-DC vaccines leads to an 
increased accumulation of immunostimulatory, IFN-γ 
producing CD4+/CD8+ T cells while simultaneously 
impeding the infiltration of immunosuppressive Tregs, 
TAMs and MDSCs. 
Curative treatment with DC vaccines fed with 
irradiated necrotic cells establishes a shift towards 
Th1 and CTL driven antitumor immunity 
As prophylactic treatment does not really represent the 
clinical status quo, we next evaluated the in vivo 
immunogenicity of the two vaccine „types‟ in a curative 
vaccination setup. Treated mice received three weekly 
DC vaccines and all mice were sacrificed four days after 
the last vaccination to analyze the brain-infiltrating 
immune cell populations (Figure 3A). This study revealed 
an increased infiltration of CD3+ T lymphocytes and a 
reduced infiltration of CD4+ T cells in FT+IR-DC vaccine 
injected mice as compared to control mice (p < 0.05 for 
both populations, Figure 2B and 2C). However, this 
reduced infiltration of general CD4+ T cells might be 
explained by the strong significant reduction in Treg 
levels in these mice as compared to both untreated mice 
(p < 0.01) and FT-DC vaccine treated mice (p < 0.05, 
Figure 3D). Moreover vaccination with the FT+IR-DC 
vaccine resulted in a significant increase in the CD8+ T 
cell to Treg ratio (p < 0.05 versus FT-DC vaccine and p < 
0.01 versus controls, Figure 3E) and this was paralleled 
by an enhanced infiltration of Th1 cells and CTLs (Figure 
3F and 3G, respectively; p < 0.05 in comparison to FT-
DC vaccine treated mice for both populations). With 
respect to the myeloid cell populations, we observed a 
significantly reduced infiltration of total CD11b+ myeloid 
cells (Figure 3H), F4/80+ TAMs (Figure 3I) and Ly6C+ 
MDSCs (Figure 3J) in FT+IR-DC vaccine injected mice 
as compared to FT-DC vaccine immunized mice (p < 
0.01, p < 0.01 and p < 0.05, respectively). Although 
Ly6G+ MDSCs were almost absent in the brains of both 
vaccinated groups, statistical analysis revealed a lower 
infiltration of these granulocytic MDSCs only in the 
FT+IR-DC vaccine treated mice in comparison to 
untreated animals (Figure 3K, p < 0.05). Interestingly, 
also in this setting, mice injected with FT-DC vaccine 
showed no significant differences as compared to 
untreated mice for any of the studied immune cell 
populations.  
Of note, in accordance with the results obtained in the 
prophylactic setting, mice showing neurological deficits 
(predominantly present in the untreated and FT-DC 
vaccine group) in general showed the highest infiltration 
of Tregs and myeloid cell populations, while having a less 
evident infiltration of IFN-γ producing effector T cells 
(Figure 3).  
In conclusion, these remarkable results indicate that the 
productive/pro-inflammatory immune interphase between 
the tumor and its immune contexture is maintained in the 
clinically relevant setting where vaccination with FT+IR-
DC vaccine is applied in a pre-established tumor setting.  
 
Pulsing of DCs with irradiated FT-necrotic cells does 
not impact DC maturation 
Different tumor lysate preparations have been found to 
impact the phenotypic and functional maturation of DCs 
interacting with them.18, 20 To this end, we examined 
whether the pulsing of DCs with FT+IR cells could 
directly modify the DC phenotype. As shown in figure 4A, 
we observed no differences in the expression levels of 
the costimulatory proteins CD80, CD86 and CD40 and 
the MHC class I and II molecules (H-2Kb and I-A/I-E, 
respectively) between DCs constituting the FT-DC 
vaccine and the FT+IR-DC vaccine. 
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Figure 4. Loading of DCs with irradiated GL261 tumor lysate does not impact DC maturation. (A) Surface expression of CD80, CD86, I-A/I-
E, H-2Kb and CD40 on the FT-DC vaccine and the FT+IR-DC vaccine was evaluated by means of flow cytometry. Data are presented as 
the mean fluorescent intensity ± SD of 6 independent experimental determinations. (B) The conditioned media of the FT-DC vaccines and 
the FT+IR DC vaccines were collected followed by analysis for concentrations of IL-12p70, IL-10, IL-1β and IL-6. Data are presented as 
mean ± SD of 2 independent experiments, each performed in triplicate. 
 
Figure 5. Oxidation-induced protein carbonylation in GL261 tumor lysates correlates with in vivo tumor rejection. The carbonyl content 
(calculated as nmols of carbonylated proteins per mg of total proteins) was evaluated in untreated GL261 cells (controls) and in the 
following lysate conditions: FT, FT+IR, FT+IR+NAC, FT+IR+L-Hist and FT+H2O2. Data are presented as mean values ± SD from one 
experiment performed in triplicate. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (Student‟s t-test). (B) Kaplan-Meier graph of an experiment in 
which GL261 inoculated mice were either left untreated (controls, ●, n = 5) or were immunized with FT-DC vaccines (■, n = 7), FT+IR-DC 
vaccines (▲, n = 7), FT+IR+NAC-DC vaccines (○, n = 7), FT+IR+L-Hist-DC vaccines (▼, dashed line, n = 7) or FT+H2O2-DC vaccines 
(□, dashed line, n = 7). *, p < 0.05; **, p < 0.01 (Log-rank test). (C) Linear correlation between the amount of protein carbonylation in the 
different lysate preparations (as depicted in A) and the percentages of long-term surviving animals that were vaccinated with DCs pulsed 
with the respective lysate preparations (p = 0.0028, R2 = 0.96, linear regression analysis).
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In order to gain more insight into the functional status of 
the lysate-pulsed DCs, we evaluated the conditioned 
media of the FT-DC vaccine and the FT+IR-DC vaccine 
for the pattern of certain important cytokines like IL-10, 
IL-12p70, IL-6 and IL-1β (Figure 4B). The exposure of 
DCs to both lysate preparations did not induce production 
of IL-12p70. Moreover, we did not detect any differences 
in the expression levels of IL-10, IL-1β and IL-6 between 
the two vaccines. Conditioned media of the GL261 
lysates (in the absence of DCs) did not contain detectible 
levels of any of the cytokines (data not shown). 
Together, these data suggest that irradiation of FT-
necrotic cells to pulse DCs does not influence the 
phenotypic and functional maturation of DCs. 
 
Oxidation-induced protein carbonylation in tumor 
lysates in vitro, correlates with DC vaccine’s ability 
to induce tumor rejection in vivo 
Given the well described ROS-inducing features of 
irradiation,22 and the increased immunogenicity observed 
with OAMPs accumulation,54 we wondered whether 
ROS-induced OAMPs (like protein carbonylation) might 
contribute to the increased in vivo immunogenicity of 
FT+IR GL261 cells.  
To this end, we first decided to measure whether IR 
treatment can increase accumulation of protein 
carbonylation, an indicator of irreversible protein 
oxidation.55 Indeed, the level of protein carbonylation was 
significantly higher in FT+IR treated cells compared to FT 
treated cells (p < 0.01, Figure 5A). Moreover, as positive 
control, we employed the bona fide oxidizing agent 
hydrogen peroxide (H2O2)56 and as expected, H2O2 
induced even higher levels of protein carbonylation 
compared to FT+IR treated cells (p < 0.01, Figure 5A). 
Next, we wondered whether the increase in the levels of 
carbonylated proteins was caused by ROS production 
induced by exposing the FT-necrotic cells to IR. To prove 
this, we decided to employ well-established anti-oxidants 
like N-acetylcysteine (NAC)57 and L-histidine (L-Hist)55, 58 
in combination with the FT+IR treatment. We observed 
that the presence of these ROS-scavengers in 
combination with IR treatment of FT-necrotic cells 
reduced the protein carbonyl content, back to the level of 
untreated GL261 cells (Figure 5A). This result proved 
that, IR of FT-necrotic cells is associated with increased 
ROS-based biomolecule modifications. 
Next, we decided to employ our prophylactic DC 
vaccination model to address whether the increased 
OAMPs were mediating the in vivo immunogenicity of the 
FT+IR-DC vaccine (Figure 5B). Reduction of the protein 
oxidative burden in the tumor lysates used to pulse the 
DCs was able to reduce (albeit not significant) the 
median survival of FT+IR+L-Hist-DC vaccine treated 
mice (26 days) and FT+IR+NAC-DC vaccine treated 
mice (31 days) as compared to mice vaccinated with the 
FT+IR-DC vaccine only (37 days).  
Interestingly though, the percentage of mice that became 
long-term survivors was the same in the anti-oxidant 
treated groups as in the FT-DC vaccine treated group (14 
%), while 29 % of mice became long-term survivors in the 
FT+IR-DC vaccine injected group. Mice vaccinated with 
the FT+H2O2-DC vaccine showed the highest percentage 
of tumor-rejecting mice (43 %). Intriguingly, the amount of 
protein carbonylation in the different lysate preparations 
showed a highly significant linear correlation with the 
percentage of long-term surviving mice (R2 = 0.96, p = 
0.0028, Figure 5C). These data clearly indicate that the 
levels of OAMPs, like carbonylated proteins, in lysates 
used to pulse DCs, are highly associated with (and may 
partly mediate) long-term immunity in this DC vaccination 
model for murine HGG. 
Discussion 
In this study, we show the superiority of DC vaccines 
pulsed with X-ray irradiated FT-necrotic glioma cells as 
compared to DC vaccines pulsed with FT-necrotic glioma 
cells only, in terms of improving the survival of HGG-
bearing mice. Irradiation of necrotic glioma cells did not 
impact DC maturation but did, however, increase the 
amount of protein carbonylation in the lysate preparation. 
Most intriguingly, the protein carbonyl content in the 
tumor lysate preparations used to pulse the DC vaccines 
correlated significantly with the percentage of long-term 
surviving HGG-inoculated animals. 
Meta-analysis of clinical data has indicated that subtle 
differences in the production process of DC vaccines, like 
DC maturation status, DC dose and use and non-use of 
adjuvants can impact clinical parameters in human 
melanoma, prostate cancer and renal cell cancer 
patients.59, 60 Moreover, a meta-analysis of 173 
vaccination trials in a wide range of cancers concluded 
that patients vaccinated with whole tumor antigen 
vaccines had a higher rate of clinical responses 
compared to those vaccinated with defined tumor 
antigens.61 Indeed, whole tumor vaccine strategies have 
the advantage of not relying on selected haplotypes such 
that immune responses are raised against a plethora of 
tumor antigens (including neo-antigens, if any), thereby 
avoiding the risk of immune escape variants.62 
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Our literature overview of clinical studies reporting the 
use of whole tumor lysate-pulsed DCs in HGG patients 
(both adults and children) revealed that there is no 
consensus yet in how FT-necrotic tumor lysates ought to 
be prepared (Table I). However, based on our study, it 
can be hypothesized that FT-necrotic cells/lysates, if 
utilized for DC vaccines, should be preferably combined 
with high oxidation-inducing modalities. 
Moreover, to the best of our knowledge, this is the first 
preclinical study evaluating the tumor immune contexture 
in a prophylactic as well as in a curative DC vaccination 
setup. This study revealed a reduced brain infiltration of 
Tregs, TAMs and MDSCs in GL261-inoculated mice 
previously immunized with the FT+IR-DC vaccine in both 
settings. All three of the abovementioned 
immunosuppressive leukocyte populations have been 
known to accumulate in the circulation and/or in the 
tumor microenvironment of HGG patients.63 
Accumulation of CD4+FoxP3+ Tregs in the peripheral 
blood of GBM patients tends to correlate with impairment 
of T cell proliferation and the frequency of tumor-
infiltrating Tregs has been shown to correlate with tumor 
grade in astrocytomas.10, 64 Moreover, transient depletion 
of Tregs in the GL261 glioma model is capable of 
rescuing all tumor-challenged animals, however without 
the induction of immunological memory upon GL261 
rechallenge.17 Similarly, in human GBM, increased 
percentages of circulating MDSC (CD15+CD33+HLA-DR-) 
have been reported.65 Nevertheless, TAMs are the 
predominant innate immune cells infiltrating gliomas, far 
outweighing the T cells, and their (TAMs) number has 
been shown to correlate with the tumor grade.66 
Depletion of CD11b+ cells in GL261-bearing mice has 
been shown to slow down glioma progression, further 
indicating that the majority of tumor-infiltrating CD11b+ 
cells serve a tumor-promoting role in the context of 
HGG.67 Whether vaccination of GL261-inoculated mice 
with FT+IR-DC vaccine can also influence the functional 
status of Tregs, TAMs and MDSCs remains an open 
question. Additional ex vivo functional studies are 
required to address this question. 
In addition, we observed an enriched population of CD3+ 
T cells and a stronger infiltration of Th1 cells and CTLs in 
mice receiving the FT+IR-DC vaccine. This finding 
suggests that this vaccination therapy can tackle the 
suppressive immune compartment, while simultaneously 
promoting the immune stimulating arm. This shift in 
immune balance towards a more antitumorigenic immune 
contexture is further demonstrated by the increased ratio 
of CD8+ T cells to Tregs in our FT+IR-DC vaccination set-
up. Sayour and colleagues recently disclosed a positive 
correlation between the CD8+ to Treg ratio in primary 
GBM patients and survival time. 68   
Radiotherapy is a known inducer of immunogenic cell 
death (ICD) due to its combined action of generating 
ROS and inducing collateral endoplasmatic reticulum 
stress.51, 52 This ICD-inducing feature of radiotherapy 
however does not apply in the setting where FT-necrosis 
is applied before X-ray irradiation (thereby making them 
„signaling incompetent‟ from ICD‟s perspective). On the 
other hand, the ROS-inducing features of radiotherapy 
are still applicable in this situation. Accumulating 
research reveals that OAMPs like carbonylated proteins 
can act as danger signals.25-29 Irradiation of the necrotic 
GL261 cells upregulated the levels of protein 
carbonylation. Moreover, treatment of irradiated FT-cells 
with two different anti-oxidants completely abolished this 
effect. Of note, anti-oxidants based abrogation of 
irradiation-induced protein carbonylation (partially but not 
significantly) reduced overall median survival as well as 
the percentage of long-term surviving mice in our 
prophylactic vaccination model. The lack of significance 
between the different treatment conditions in this in vivo 
experiment (Figure 5B) might be due to the small survival 
benefit observed with the FT+IR-DC vaccine (as 
compared to the FT-DC vaccine), leaving a very stiff 
window for intervention. DC vaccines pulsed with tumor 
lysate treated with the chemical oxidizer H2O2 showed 
the highest level of glioma protection. These data are in 
line with a recent study of Chiang and colleagues in the 
ID8 ovarian cancer model.18 They observed an increased 
in vivo efficacy of DCs pulsed with hypochlorous acid-
oxidized tumor lysate as compared to DCs pulsed with 
FT-lysate. These findings suggest that the level of 
irreversible protein carbonylation in lysates - a convenient 
surrogate of the overall oxidative/OAMPs burden - used 
to pulse DC vaccines associates with (and possibly 
partially mediates) long-term antitumor immunity in this 
GL261 glioma model. 
Interestingly, irradiation of the GL261 cells prior to freeze-
thawing was shown to negatively affect the vaccine‟s in 
vivo immunogenicity. This could be explained by the fact 
that freeze-thawing is described to destroy carbonyl 
adducts.69  This is in accordance with our own 
observation of lower protein carbonyl content in the 
IR+FT treated cells in comparison to FT+IR treated cells 
(data not shown). 
Various oxidatively damaged components caused by the 
irradiation, including lipid (per-)oxidation products, which 
have not been investigated here, may also ultimately 
contribute to the heightened protein carbonylation status 
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of the lysates.70 This might be paralleled by formation of 
high-molecular weight aggregates of unfolded proteins 
(i.e. oxidation-induced aggregation), which can further 
enhance immunogenicity.71 
All together, these data warrant the use of X-ray 
irradiated FT necrotic lysates, over the use of FT necrotic 
lysates alone, as an antigen source to pulse DCs in 
clinical DC vaccination studies. Moreover, these data 
foster the preclinical investigation of strong oxidizing or 
OAMPs-inducing compounds to further increase the 
potency of whole tumor antigen-pulsed DC 
vaccinations.72  
 
Materials and methods 
Mice and tumor cell line 
Adult, female (8 to 10 weeks old) C57BL/6J mice were 
purchased from Harlan (Horst, The Netherlands). The 
mice were housed in conventional pathogen-free 
conditions. All animal experiments were approved by the 
bioethics committee of the KU Leuven that follows 
international guidelines. 
Methylcholanthrene-induced murine C57BL/6J syngeneic 
GL261 glioma cells were kindly provided by Dr. Eyüpoglu 
(University of Erlangen, Germany). The cells were 
maintained in DMEM supplemented with 10 % heat-
inactivated FCS (Sigma-Aldrich, F7524), 2 mM L-
glutamine, 100 U/ml penicillin and 100 mg/ml 
streptomycin (both from Lonza, BE17-605E and DE17-
602E, respectively). Cell morphology was evaluated by 
microscopic examination multiple times per week. 
Orthotopic glioma model and DC immunotherapy 
The mice were intracranially injected with 5 x 105 GL261 
tumor cells as previously described.17 Briefly, mice were 
anesthetized and fixed in a stereotactic frame (Kopf 
Instruments, Tujunga, CA), which allows for accurate 
injection at 2 mm lateral and 2 mm posterior from the 
bregma and at 3 mm below the dura mater. Stereotactic 
inoculation was performed under sterile conditions. 
DC immunotherapy was applied in the prophylactic 
setting by intraperitoneal (i.p.) injection of 1 x 106 lysate-
pulsed mature DCs on day 14 and 7 prior to GL261 
tumor inoculation. The mice were defined as long-term 
survivors when their survival exceeded three times the 
median survival of the untreated control animals. In the 
curative treatment set-up, mice received three i.p. 
administered DC vaccines on days 2, 9 and 17 after 
intracranial GL261 tumor inoculation.  
Preparation of GL261 lysates 
GL261 cells were harvested, washed and suspended in 
phosphate-buffered saline (DPBS, Lonza) supplemented 
with 1% FCS. Seven different GL261 lysate formulations 
were prepared; GL261 cells subjected to six consecutive 
freeze-thaw cycles (FT, 3 min in liquid nitrogen and 3 min 
on 56 °C, respectively), GL261 cells subjected to 6 
freeze-thaw cycles and followed by 60 Gy X-ray 
irradiation (FT+IR), GL261 cells exposed to 60 Gy X-ray 
irradiation prior to 6 freeze-thaw cycles (IR+FT), GL261 
cells subjected to 800 Gy X-ray irradiation only (IR), 
GL261 cells exposed to the anti-oxidants NAC (5 mM, 
Sigma-Aldrich, A9165) or L-Hist (250 mM, Sigma-Aldrich, 
53319) before, during and after the freeze-thaw and 
irradiation treatment (FT+IR+NAC and FT+IR+L-Hist, 
respectively) and GL261 cells incubated with the strong 
oxidizer H2O2 for 24 hours (750 µM, Sigma, H1009) after 
the freeze-thaw cycles (FT+H2O2). Protein concentrations 
were determined via colorimetric assay (Bradford protein 
assay) according to the manufacturer‟s instructions (Bio-
Rad). 
Generation and characterization of DCs 
DCs were derived from bone marrow progenitor cells as 
described.17 In short, bone-marrow progenitor cells were 
cultured for 7 days in the presence of GM-CSF (20 ng/ml, 
Peprotech, 312-03). Medium was refreshed on day 3 and 
day 5. On day 7 immature DCs were harvested using a 
cell scraper. For lysate loading, immature DCs were 
incubated with GL261 lysates at 2 mg protein per 10 x 
106 DCs per ml culture medium at 37 °C for 90 minutes. 
Immediately after loading, the DCs were transferred to 
culture flasks for 24 hours in DC medium containing 20 
ng/ml GM-CSF and 1 µg/ml Escherichia coli-derived 
lipopolysaccharide (LPS, Sigma-Aldrich, L6529-1MG) to 
induce maturation. Twenty-four hours later, the mature 
lysate-loaded DCs were harvested, counted and 
resuspended to 1 x 106 DCs in 100 µl PBS for i.p. 
injection. 
Surface expression of DC maturations markers was 
assessed on lysate-pulsed mature DCs by flow cytometry 
using the following monoclonal antibodies (mAbs): FITC-
conjugated anti-H-2Kb (Becton Dickinson (BD), 553569), 
PE-conjugated anti-I-A/I-E and anti-CD40 (BD, 557000 
and 553791, respectively) and PE-conjugated anti-CD80 
and anti-CD86 (eBioscience, 12-0862-83 and 12-0114-
83, respectively). For each staining the appropriate 
isotypes were used. Analysis was performed using the 
 57 
 
Cellquest software on a FACSort cytometer (BD, 
Erembodegem, Belgium). The conditioned media derived 
from the lysate-loaded mature DCs were collected and 
checked for cytokine levels of IL-10 (88-7104-88), IL-
12p70 (88-7121-88), IL-1β (88-7013-88) and IL-6 (88-
7064-88) by means of ELISA kits from eBioscience, 
according to the manufacturer‟s instructions. Cytokine 
levels in GL261 lysates were also evaluated to rule out 
GL261 cell-derived cytokine production. 
Isolation and characterization of brain-infiltrating 
immune cells 
Brain-infiltrating immune cells were isolated from GL261-
inoculated mice as previously described. 17 Two different 
staining panels were used respectively for the 
prophylactic and curative setup. The staining protocol 
was however exactly the same for the two experiments. 
In the prophylactic setting surface staining was 
performed with anti-CD11b PE (eBioscience, 12-0112-
83), anti-CD4 PE and anti-CD8 PE (BD, 553049 and 
553033), anti-F4/80 FITC (AbD Serotec, MCA497DB), 
anti-Ly6G FITC (eBioscience, 11-5931-83), anti-CD3 
FITC, anti-Ly6C FITC (BD, 553062 and 553104, 
respectively) and anti-CD45 PerCP-Cy5.5 mAbs 
(eBioscience, 45-0451-82). Intracellular FoxP3 was 
detected using a FoxP3-Alexa Fluor 488 staining kit 
(eBioscience, 73-5776) according to the manufacturer‟s 
protocols. For intracellular IFN-γ staining, cells were 
stimulated for 4 hours in vitro with 100 ng/ml phorbol 
myristate acetate, 1 µg/ml ionomycin and 0.7 µg/ml 
monensin (all from Sigma-Aldrich, P8139-1MG, I0634-
1MG and M5273-500MG, respectively). After 
restimulation, surface staining for CD4, CD8 and CD45 
was performed and cells were washed with a 
permeabilisation buffer containing 0.5 % saponin and 0.5 
% bovine serum albumin (BSA). Intracellular staining was 
performed with an anti-IFN-γ FITC mAb (BD, 554411). 
Data acquisition was performed on a FACSort flow 
cytometer (BD) and the Cellquest software was used for 
data analysis. 
In the curative setting surface staining was performed 
with anti-Ly6C Alexa Fluor® 647 (Bio-Rad, 
MCA2389A6457), anti-CD11b BV421, anti-Ly6G FITC, 
anti-CD8 BV421 (all three from BD, 562605, 551460 and 
563898, respectively), anti-CD45 Alexa Fluor® 700, anti-
F4/80 PE, anti-CD3 FITC and anti-CD4 PerCP-
Cyanine5.5 mAbs (all four from eBioscience, 56-0451-82, 
12-4801-80, 11-0031-82 and 45-0042-82, respectively). 
Intracellular FoxP3 was detected using an anti-FoxP3 PE 
staining set (eBioscience, 72-5775). For intracellular IFN-
γ staining, surface staining of stimulated cells was 
performed with anti-CD45 Alexa Fluor® 700, anti-CD3 
PE, anti-CD4 APC-eFluor® 780 (all three from 
eBioscience, 56-0451-82, 12-0031-82 and 47-0042-82, 
respectively) and anti-CD8 BV421 mABs (BD), followed 
by intracellular staining performed with an anti-IFN-γ 
PerCP-Cyanine5.5 mAb (BD, 560660). Data acquisition 
was performed on a LSRFortessa flow cytometer (BD 
Biosciences) and the FlowJo software was used for data 
analysis. 
Protein carbonylation detection assay 
The detection of protein carbonyl derivatives was 
performed as previously described.55 In brief, 50 µl of 
GL261 cell lysates or untreated GL261 cells, 
corresponding to a total protein concentration of 5 to 10 
mg/ml were incubated with an equal volume of 200 µM 
fluorescein-5-thiosemicarbazide (FTC, Sigma-Aldrich, 
46985-100MG-F) overnight at room temperature in the 
dark. Twenty-four hours later, proteins were precipitated 
and centrifuged after which the supernatant was 
discarded and consequently the protein precipitates were 
washed three times with acetone. The acetone 
supernatant was discarded and the precipitates were air-
dried. These precipitates were then solubilized with 50 µl 
of guanidine hydrochloride (GuHCl, 6M) and diluted with 
450 µl of NaH2PO4 (pH 7.0). Subsequently, the protein 
concentrations in these samples were measured via the 
bicinchoninic (BCA) protein assay kit from Thermo 
Scientific (23225). Fifty microliters of these samples were 
aliquoted in a black microtiter plate and fluorescence was 
measured with a FlexStation 3 microplate reader 
(Molecular Devices, Berkshire, United Kingdom, 0310-
5627). A standard curve that was prepared using 
different concentrations of FTC allowed for the 
calculation of the nanomoles of FTC-reacted carbonyls. 
These values were then divided by the respective protein 
concentrations to derive the amount of protein carbonyls 
expressed as nmol/mg protein. 
Literature search of tumor lysate-pulsed DC 
vaccination trials in HGG patients 
The studies listed in table I were identified through an 
electronic search of the PubMed database, reference 
lists of published trials and relevant review articles. The 
search strategy included the following search terms: 
“glioma” AND “dendritic cells” AND “tumor lysate”. We 
only included studies that performed freeze-thaw cycles 
to obtain tumor lysates and excluded case reports, 
articles not published in English and protocol studies. 
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Statistical analysis 
Statistical analyses were performed using GraphPad 
Prism 5 software (San Diego, USA). Survival analysis 
was performed using the log-rank test. Student‟s t-test 
was performed for statistical analysis with significance 
level set at p < 0.05. Wherever applicable (with respect to 
comparison between multiple data-sets), a one-way 
ANOVA analysis was performed. Linear regression 
analysis was performed to investigate a possible 
association between protein carbonylation levels and the 
percentages of long-term surviving mice. 
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Table I: Autologous tumor lysate-pulsed DC vaccination studies in HGG patients 
 
Author Year No. of 
patients 
(type of trial) 
Grade 
III/IV 
ND/R Lysate 
preparation 
Injection 
route 
Treatment schedule Immune response Clinical response 
Yamanaka et 
al. 32 
2003 10 (phase I-II) III /IV R FT ID and/or IT 1-10 vaccinations at 3-week 
intervals 
Increase in NK cells in 
PBMCs (5/5); positive DTH 
reaction (3/6); increased IFN-
γ ELISPOT (2/5) 
MR (2/6) 
Wheeler et al. 
33 
2003 17 (phase I) IV ND/R FT NS 3 vaccinations at 2- week 
intervals 
NS NS 
 
17 (phase II) IV ND/R FT 3 vaccinations at 2-week 
intervals; 4th vaccination 6 
weeks later 
Wheeler et al. 
34 
     2004 5 (phase I) 
and 12 
(Phase II) 
 
III/IV 
 
 
ND/R 
 
 
FT NS 3 vaccinations at 2-week 
intervals (phase I) and 4th 
vaccination 6 weeks later 
(phase II) 
In GBM patients receiving 
post-vaccine chemotherapy, 
CD8+ TRECs predicted 
longer chemotherapy 
responses 
Vaccinated patients receiving 
subsequent chemotherapy 
exhibited longer times to tumor 
recurrence after chemotherapy 
Yu et al. 35 2004 14 (phase I-II) III/IV ND/R FT SC 3 vaccinations at 2-week 
intervals; 4th vaccination 6 
weeks later 
Increased IFN-γ ELISPOT 
(6/10); expansion of CD8+ 
antigen specific T cell clones 
(4/9); systemic T cell 
cytotoxicity against tumor 
(1/1) 
OS: 133 weeks in DC-group and 
30 weeks in control-group 
(recurrent GBM) 
Rutkowski et al. 
41 
2004 12 (phase I) IV R FT + IR ID 2-7 vaccinations; 2nd vaccine 
2 weeks after 1st , then 
monthly vaccines 
Positive DTH reaction (6/8) PR (1/12); tumor-free survival 5 
year after vaccination (2/12); 
PFS: 3 months; OS: 105 months 
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Yamanaka et 
al. 36 
2005 24 (phase I-II) III/IV R FT ID or ID + IT 1-10 vaccinations at 3-week 
intervals 
Positive DTH reaction (8/17); 
positive IFN-γ ELISOT (7/16); 
positive immune monitoring 
predicts good clinical 
outcome 
PR (1/24); MR (3/24); SD 
(10/24); significantly increased 
MS 
Wheeler et al. 
37 
2008 34 (phase II) III/IV ND/R FT SC 3 vaccinations at 2-week 
intervals; 4th vaccination 6 
weeks later 
Increased IFN-γ ELISPOT 
(17/34); DTH-test resulted in 
cutaneous GBM in 1 patient 
(DTH was subsequently 
discontinued) 
Significant positive correlation 
between post-vaccine response 
magnitude and TTS; 2-year OS: 
41 % in vaccine responders 
versus 7 % in non-responders; 
patients relapsing after 
vaccination showed increased 
chemosensitivity.  
De 
Vleeschouwer 
et al. 42 
2008 56 (phase I-II) IV R FT + IR ID Cohort comparison Positive DTH (9/21 at time of 
diagnosis and 9/17 after 2 
vaccinations) 
PFS: 3 months; OS: 9.6 months; 
2-year OS: 14.8 %; total 
resection is a predictor for better 
PFS; younger age and total 
resection are predictors for 
better OS in univariable 
analysis; tendency towards 
improved PFS when faster DC 
vaccination schedule with tumor 
lysate boosting was applied 
Ardon et al. 43 2010 8 (pilot) IV ND FT + IR ID 4 weekly vaccines, 3 
monthly vaccines, then 3-
month intervals 
Increased IFN-γ ELISPOT 
(5/8), positive DTH reaction 
(3/6) 
6-month PFS: 75 %; OS: 24 
months; PFS: 18 months 
Ardon et al. 44 2010 33 children 
(phase I/II) 
III/IV R FT + IR ID Depending on the cohort NS 6-month PFS: 42 %; PFS: 4.4 
months; OS: 13.5 months 
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Fadul et al. 45 2011 10 (phase I/II) IV ND IR + FT IN 3 vaccines at 2-week 
intervals 
Increased IFN-γ ELISPOT 
(4/10) 
PFS: 9.5 months; OS: 28 
months 
Prins et al. 38 2011 23 (phase I) IV ND/R FT ID 3 vaccines at 2–week 
intervals, booster vaccines 
every 3 months (in 
combination with 
Imiquimod/Poly-ICLC) 
Mesenchymal tumors had a 
higher number of CD3+ and 
CD8+ tumor-infiltrating 
lymphocytes. 
OS: 31.4 months and a 1-, 2- 
and 3-year survival rate of 91 %, 
55 % and 47 %. Better survival 
in patients having a 
mesenchymal gene signature. 
Elens et al. 46 2012 39 (phase I/II) III R FT + IR ID Depending on the cohort NS Median PFS/OS were 3.4/20.5 
months (AA), 3.4/18.8 months 
(AOD) and 7.8/13.3 months 
(AOA) 
Ardon et al. 47 2012 77 (phase I/II) IV ND FT + IR ID 4 weekly vaccines, 3 
monthly vaccines, then 3-
month intervals 
Immunological profiling could 
not predict clinical outcome. 
6-month PFS: 70.1 %; median 
OS: 18.3 months; OS 
depending on RPA classification 
De 
Vleeschouwer 
et al. 48 
2012 117 (phase II) III/IV R FT + IR ID Changing per cohort NS OS: 6-48.4 months ( according 
to HGG-immuno RPA 
classification) 
Fong et al. 39 2012 24 (two phase 
I trials): 19 
(DC-ATL) and 
5 (DC-GAA) 
IV ND/R FT ID 3 vaccinations at 2-week 
intervals 
Decreased Treg frequency 
and decreased expression of 
CTLA-4 on T cells after DC 
vaccination was associated 
with better survival 
OS: 33.8 months (DC-ATL), 
14.5 months (DC-GAA); TTP: 
13.9 months (DC-ATL), 9.6 
months (DC-GAA) 
Valle et al. 49 2012 5 (pilot) IV ND FT + IR NS 1st vaccine one week before 
radiotherapy, 2nd  3 weeks 
after radiotherapy, 2 monthly 
vaccines and 4 every 2 
months and later quarterly 
PBMC proliferation (3/3); 
positive IFN-γ ELISA (3/3); 
positive IFN-γ ELISPOT (0/3) 
PFS: 16.1 months; OS: 27 
months 
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Lasky et al. 40 2013 7 (pilot, 
children) 
III/IV ND/R FT ID 2-week intervals Cytokine production upon in 
vitro stimulation (1/3) 
MR: 1/3; CR: 2/3 
Prins et al. 16 2013 28 (phase I) III/IV ND/R FT ID 3 vaccines at 2-week 
intervals, booster vaccines 
every 3 months 
Significant correlation 
between  decreased Treg 
ratio (post/pre-vaccination) 
and OS 
PFS: 18.1 months; OS: 34.4 
months 
 
AA, anaplastic astrocytoma; AOD, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; ATL, autologous tumor lysate; CR, complete response; CTL, cytotoxic T lymphocyte; CTLA-
4, cytotoxic T lymphocyte-associated protein 4; DC, dendritic cell; DTH, delayed-type hypersensitivity; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-linked immunosorbent 
spot assay; FT, freeze-thaw; GAA, glioma-associated antigens; GBM, glioblastoma multiforme; IFN-γ, interferon-γ; ID, intradermal; IN, intranodal; IR, irradiation; IT, intratumoral; MR, minor 
response; MS, median survival; ND, newly diagnosed; NK, natural killer; NS, not specified; OS, overall survival; PBMC, peripheral blood mononuclear cell; PFS, progression-free survival; PR, 
partial response; R, relapsed; RPA, recursive partitioning analysis; SC, subcutaneous, SD, stable disease; TREC, T cell receptor excision circle; Treg, regulatory T cell; TTP, time to 
progression; TTS, time to survival. 
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Supplemantal figure and its legend 
 
Suppl. Figure 1. Applying radiotherapy alone or prior to inducing FT-necrosis in the GL261 cells does not improve DC vaccine-induced 
antitumor immunity. Kaplan-Meier graph depicting survival of mice prophylactically immunized on days 14 and 7 prior to intracranial GL261 
tumor inoculation with FT+IR-DC vaccines (∆, dashed line, n = 17), IR+FT-DC vaccines (■, n = 9) and IR-DC vaccines (▼, n = 9). Mice 
not immunized with vaccines were used as controls (●, n = 9). *, p < 0.05 (Log-rank test).  
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4. RESULTS – PART II 
“A scientist in his laboratory is not a mere technician: he is also a child confronting natural 
phenomena that impress him as though they were fairytales.” 
- Marie Curie 
Immunotherapy with dendritic cell vaccines based on immunogenic cell death elicit 
danger signals and T cells-driven rejection of high-grade glioma 
Our research described in the previous chapter has highlighted the crucial contribution of 
oxidation, and more specifically OAMPs like carbonylated proteins, to the immunogenicity of 
whole tumor cell-based DC vaccines. This finding drove us to hypothesize that other very 
strong oxidizing treatment modalities, preferably non-chemical treatments, could further 
potentiate the immunogenicity of dying cancer cells in the setting of DC vaccines. In this 
regard, Hyp-PDT might constitute an extremely promising cancer cell killing regimen. 
Besides the strong ER-directed oxidation it confers, it is considered a prototypical inducer of 
ICD. Its capacity to emit the highest diversity and amounts of DAMPs as well as its favorable 
safety profile and many other advantages as compared to known ICD inducers (as described 
in chapter 1.11.2 of this work) make Hyp-PDT the ideal candidate to test for application in 
preclinical ICD-based DC vaccines. 
Based on these observations, we wished to address the following aims in this research project:  
I. To study the potential of Hyp-PDT to induce ICD in GL261 cancer cells;  
II. To evaluate if Hyp-PDT-based DC vaccines can induce protective immunity in a 
prophylactic vaccination setup in the GL261 model; 
III. To study the contribution of different ICD-related molecular and cellular players (i.e. 
adaptive immune cells, OAMPs, selective DAMPs, cancer cell‟s interface with DCs, 
TLR signaling) to the vaccine‟s immunogenicity; 
IV. To develop a clinically relevant version of the Hyp-PDT-based DC vaccine that still 
induces potent protective immunity against HGG; 
V. To study the brain immune-contexture of mice prophylactically vaccinated with the 
Hyp-PDT-based DC vaccine and its clinically relevant version; 
VI. To evaluate the potency of Hyp-PDT-based DC vaccines in a curative, more clinically 
relevant setup, alone and in combination with the standard-of-care chemotherapeutic 
TMZ and to study the brain immune-contexture in this setting; 
The research paper describing the results associated with this section and the corresponding 
supplementary information is presented on the following pages. 
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Abstract 
Promise of dendritic cell (DC)-based immunotherapy has 
been established by two decades of translational 
research. Of the four malignancies mostly targeted with 
clinical DC immunotherapy, high-grade glioma (HGG) 
has shown the highest susceptibility. However, HGG-
induced immunosuppression is an anti-immunotherapy 
roadblock that necessitates application of Th1 immunity-
biased, next-generation, DC immunotherapy. To this end, 
we combined DC immunotherapy with immunogenic cell 
death (ICD; a modality shown to induce Th1-immunity), 
induced by Hypericin-Photodynamic Therapy. In an 
orthotopic-HGG mouse model involving 
prophylactic/curative set-ups, both biologically and 
clinically-relevant versions of ICD-based DC vaccines 
provided strong anti-HGG survival benefit. We found that 
the ability of DC vaccines to elicit HGG rejection was 
significantly blunted if cancer cell-associated ROS and 
emanating danger signals were blocked (either singly or 
in concomitantly; showing hierarchical effect on 
immunogenicity i.e. extracellular-HMGB1>extracellular-
ATP>surface-calreticulin) or if DCs, DCs-associated 
MyD88 signal or the adaptive immune system (especially 
CD8+ T cells) were depleted. In curative setting, ICD-
based DC vaccines synergized with standard-of-care 
chemotherapy (temozolomide) to increase survival of 
HGG-bearing mice by ~300% resulting in ~50% long-
term survivors. Additionally, DC vaccines also induced an 
immunostimulatory shift in brain immune-contexture from 
Tregs to Th1/cytotoxic T lymphocytes/Th17 cells. 
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Analysis of the TCGA glioblastoma-cohort confirmed that 
increased intra-tumor prevalence of Th1/cytotoxic T 
lymphocytes/Th17 cells-linked genetic signatures 
associated with good patient prognosis. This is the first 
translational study combining a single-agent ICD inducer 
with DC immunotherapy against orthotopic HGG. We 
believe that, pending final preclinical-checks, ICD-based 
vaccines can be clinically translated for glioma treatment. 
Introduction 
Anti-cancer immunotherapy has emerged as an 
important therapeutic paradigm in recent times (1-3). Of 
the plethora of immunotherapies currently available, 
remarkable efforts have been invested in the 
development of dendritic cell (DC)-based vaccines (4). 
This is primarily because DCs are the main sentinel 
antigen-presenting cells positioned at a crucial interface 
between the innate and adaptive immune system (4). In 
therapeutic sense, DC vaccines largely act by stimulating 
tumor-specific cytotoxic T lymphocytes (CTLs) that 
recognize and eliminate malignant cells (3, 5).  
The promise of DC-based immunotherapy is backed by 
two decades of clinical studies, frequently showing 
positive association between patient survival and DC 
vaccine-induced immunity (5). DC immunotherapy has 
been applied across a wide range of cancer-types but 
most prevalently in patients of melanoma, prostate 
cancer, high-grade glioma (HGG) and renal cell cancer 
(5). A recent meta-analysis showed that of these four, the 
highest positive objective responses (15.6% of patients) 
were observed for HGG patients (5, 6), suggesting that 
HGG might be susceptible to highly efficacious 
immunotherapy (5, 6).  
It is noteworthy that existing multimodal treatments fail to 
improve HGG patient prognosis (7, 8). As many as 160 
FDA-approved oncology drugs have been applied for 
anti-HGG treatment, yet only a few (like temozolomide or 
TMZ) are used as standard-of-care (8, 9). Such standard-
of-care anti-HGG therapies, although capable of 
improving patients‟ prognosis to a certain extent, 
eventually fail due to HGG‟s brain localized invasion and 
recurrences (9). This alarmingly negative outlook means 
that HGG is in dire need for novel therapeutic 
interventions like “next-generation” DC-based 
immunotherapy (7).  
Several preclinical and clinical studies have successfully 
employed anti-HGG DC immunotherapy (10-20). 
However, current anti-HGG DC immunotherapies mostly 
employ specific antigen-peptides/RNA for pulsing DCs 
(10-12, 17-19) or whole-glioma tumor cells (autologous or 
allogeneic) (13, 14, 16, 20) killed via freeze/thawing 
(F/T)-based necrosis (7, 15, 21, 22). Here, while the 
former methodology might exhibit low efficacy due to the 
high antigenic-heterogeneity of HGG, the latter procedure 
is associated with poor immunogenic potential (7, 22). 
Thus, clearly there is a need to improve the 
immunogenicity of the dying/dead cancer cells used to 
pulse the DCs to foster development of next-generation 
anti-HGG vaccines. Moreover, it is currently recognized 
that the next-generation DC vaccines need to be biased 
towards induction of Th1-immunity, since Th1 responses 
have superior capacity in eliciting CTLs-based anti-
cancer cytotoxicity (5). To this end, we envisaged that for 
HGG, a next-generation DC vaccine could be produced 
by pulsing DCs with HGG cells undergoing immunogenic 
cell death (ICD) (1).  
Cancer cells undergoing ICD exhibit superior immune-
stimulatory capacity owing to the spatiotemporally-
defined exposure/release of damage-associated 
molecular patterns (DAMPs) acting as potent danger 
signals (23, 24). DAMPs most crucial for ICD include, 
surface-exposed calreticulin (CRT), surface-exposed 
heat shock proteins (HSP)-70/90, secreted ATP and 
passively released high mobility group box 1 (HMGB1) 
protein (23, 24). ICD is associated with highly efficacious 
anti-cancer vaccination effect that is largely biased 
towards the Th1-immunity (24, 25). Several ICD inducers 
have been characterized recently (23, 24) however very 
few prototypical ICD inducers exist thus far (26). One 
such prototypical ICD inducer is, Hypericin-based 
Photodynamic Therapy (Hyp-PDT) (27). Hyp-PDT treated 
cancer cells expose/release the highest amounts and 
diversity of DAMPs, at a rapid pace, compared to 
chemotherapy (27-32). Hyp-PDT induced ICD elicits fully 
mature immunogenic human DCs, which in turn activate 
clonal proliferation of IFN-γ producing CD4+/CD8+ human 
T cells (28, 29, 31). Moreover, cancer cells undergoing 
Hyp-PDT induced ICD act as potent anti-cancer vaccines 
in various mice vaccination models [e.g. CT26 cells-
BALB/c mice (31), B78 cells-C57BL/6 mice (29) and 
K1735 cells-C3H mice (unpublished data)].
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Figure 1. Hyp-PDT induces ROS/ER stress-based apoptosis and major ICD-associated DAMPs in murine glioma cells. (A,B) 
GL261 cells were loaded with 200 nM Hypericin (Hyp; for 2 h), followed by co-localization analysis of Hyp (red) versus ER Tracker Blue-
White (blue) via fluorescence microscopy (A); extended to co-localization defining coefficients i.e. Pearson‟s coefficient, Overlap coefficient 
and Mander‟s coefficients (M1/M2) (n=5, mean±s.e.m.) (B). (C-O) GL261 were treated with Hyp-PDT (incubation of 2 h - 200 nM Hyp, light 
fluence - 4.05 J/cm2), followed by: (C) recovery of cells 1 h post-PDT and estimation of carbonylated proteins (fold change relative to 
CNTR; n=3, mean±s.d.); (D,E) immunoblotting analysis of whole cell lysate at 1 h post-PDT using the respective antibodies as indicated; 
(F) recovery of cells 24 h post-PDT and estimation of % cellular survival via MTS assay (n=4; mean±s.d.); (G) recovery of cells 24 h post-
PDT and estimation of % dead SyGr+ cells via FACS (n=3; mean±s.d.); (H) immunoblotting of whole cell lysate at indicated time-points for 
casapase-3 cleavage; (I) recovery of cells 24 h post-PDT, as indicated the cells were pre-incubated for 1 h with, NAC (5 mM), TUDCA (500 
µg/ml) or zVAD-fmk (25 µM) followed by estimation of % cellular survival (n=3; mean±s.e.m.); (J-L) recovery of cells 1 h post-PDT and 
FACS-based analysis for surface-calreticulin (J), surface-HSP70 (K) and surface-HSP90 (L) in non-permeabilized cells (data presented as 
mean fluorescence intensity (MFI), n=3; mean±s.e.m.); (M,N) recovery of cells 1 h post-PDT and analysis for relative amounts of 
extracellular (M) and intracellular (N) ATP levels, measured in the conditioned media and cell lysates, respectively (n=6; mean±s.e.m.); 
and (O) recovery of cells at indicated time-points post-PDT, and immunoblotting analysis of concentrated conditioned media using the 
indicated antibodies. CNTR samples in these experiments were incubated with hypericin, but did not receive PDT treatment. In this figure, 
Student‟s t-test was used for statistics, *p<0.05/**p<0.01/***p<0.001 as indicated by bars; N.S. – not significant.
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Of note, Hyp-PDT has been successfully applied in the 
past, for clinical treatment of patients with non-melanoma 
skin cancer (33), cutaneous T-cell lymphoma (34) and 
basal/squamous cell carcinoma (35). 
Here, we performed a preclinical study employing a 
single-agent ICD inducer-based DC vaccine in an 
orthotopic HGG mouse model and tested its efficacy as a 
next-generation anti-HGG immunotherapy (21, 36). We 
also present a systematic assessment of the key 
molecular and signaling steps required to elicit 
immunogenicity, from cancer cell-associated signals to 
DC-associated as well as T cells-orchestrated immunity. 
Finally, we accounted for various stiff clinical operational 
and regulatory requirements (37), to produce a “clinically-
relevant version” of our ICD-based DC vaccines.  
Results 
Murine glioma cells exhibit ICD-associated molecular 
determinants following Hyp-PDT 
Considering the recent observations of contextual 
differences in ICD induction (23, 36), it was necessary to 
re-examine the ability of Hyp-PDT to elicit ICD-
associated determinants in murine GL261 glioma cells. 
(27). As found in other cellular models (31, 38, 39), 
Hypericin strongly localized at the endoplasmic reticulum 
(ER) (Fig 1A-B) and upon light-activation, caused an 
accumulation of reactive oxygen species (ROS)-induced 
(40) carbonylated proteins (Fig 1C); along with ER stress 
signatures (eIF2α phosphorylation↑ BiP↑ CHOP↑), 
culminating into loss of viability and apoptosis (e.g. 
caspase-3 cleavage (Fig 1D-H)). Moreover, attenuating 
ROS (via the anti-oxidant NAC), ER stress (via the 
chemical chaperone, TUDCA (29)) or apoptosis (via pan-
caspase inhibitor, zVAD-fmk (29)) increased the survival 
of GL261 cells following Hyp-PDT (Fig 1I) thereby 
substantiating the crucial pro-death role of these 
processes (38, 39).  
On the level of danger signals/DAMPs, Hyp-PDT caused 
rapid, (within 1 h post-treatment) surface exposure of 
CRT (Fig 1J), HSP70 (Fig 1K) and HSP90 (Fig 1L) 
accompanied by a rapid secretion of ATP (Fig 1M), in the 
absence of any changes in intracellular ATP levels (Fig 
1N). All this culminated into an extracellular exodus of 
HSP90 and HMGB1, at later time-points (e.g. 48 h), post-
treatment (Fig 1O). Moreover, murine DCs co-incubated 
with GL261 cells dying in response to Hyp-PDT exhibited 
significantly increased phenotypic maturation 
(i.e.CD80highCD86highCD40highMHC-IhighMHC-IIhigh) (Suppl. 
Fig S1). 
Interestingly, another photosensitiser i.e. 5-aminolevulinic 
acid (5-ALA, Gliolan®) is frequently used for clinical 
fluorescence-guided resection of HGG (41). Considering 
its mitochondrial (but not ER) sub-cellular localization 
(42) we compared the DAMPs-inducing capabilities of 5-
ALA-based PDT with Hyp-based PDT. At similar 
apoptosis-inducing doses (Suppl. Fig S2A), we found no 
differences in surface-HSP70 (Suppl. Fig S2B) or 
secreted ATP (Suppl. Fig S2C) between these 
photosensitizers. Yet, only Hyp-PDT induced significant 
surface-CRT (Suppl. Fig S2D), surface-HSP90 (Suppl. 
Fig S2E) and passively released-HMGB1 (Suppl. Fig 
S2F). This, along with other studies (29, 31, 43, 44), 
reiterates that higher therapeutic ER-targeting may 
translate into higher DAMPs induction. 
Taken together, these results show that GL261 murine 
glioma cells succumb to ICD induced by Hyp-PDT. 
ICD-based DC vaccines provide significant protective 
immunity against HGG 
We next tested whether Hyp-PDT induced ICD-based DC 
vaccines can induce anti-glioma protective immunity by 
utilizing the prophylactic vaccination strategy (45) (Fig 
2A). Immunocompetent, syngeneic C57BL/6 mice were 
vaccinated with either Hyp-PDT induced ICD-based DC 
vaccines or F/T-necrosis-based DC vaccines (the latter 
being a control for non-ICD and a method used pre-
dominantly for vaccine production), twice, intra-
peritoneally (with an interval of 7-8 days between 
vaccinations). Mice not immunized with the vaccines 
were used as controls (CNTR). Thereafter, immunized 
and non-immunized mice were inoculated with live 
GL261 glioma cells, intra-axially (i.e. in the brain), 7-8 
days after vaccination. Following the tumor-inoculation, 
mice were monitored for HGG-induced neurological 
deficit symptoms (45). Remarkably, approximately 70% 
of mice vaccinated with ICD-based DC vaccines resisted 
orthotopic glioma challenge and showed significantly 
higher median survival as compared to CNTR mice or 
mice vaccinated with F/T necrosis-based DC vaccines 
(Fig 2B). Consistent with this, graphical representation of 
the HGG-induced neurological deficit scores/grades 
revealed a considerable delay in the onset of clinically-
relevant symptoms in mice treated with ICD-based DC 
vaccines, compared to other cohorts (Fig 2C-E). We next 
decided to substantiate this data with magnetic 
resonance imaging (MRI)-based non-invasive monitoring 
of brain-associated glioma (Fig 2F-U). We procured the 
relevant MRI-scans of brains (Fig 2F, J, N, R) followed by 
3D rendition of the brain (Fig 2G, K, O, S), the gliomas 
(wherever visible) (Fig 2L, P) and the anterior/middle 
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ventricles (Fig 2I, M, Q, U) (respective representatives 
are shown). On day 28 post-glioma-inoculation, we 
observed that in comparison to naïve mice (Fig 2F-I), 
CNTR mice (Fig 2J-M) and mice vaccinated with F/T 
necrosis-based DC vaccine (Fig 2N-Q), exhibited 
palpable HGG masses that were capable of distorting the 
morphology of the ventricles. However, most mice 
vaccinated with ICD-based DC vaccines exhibited 
absence of visible HGG masses and normal 
brain/ventricles morphology (Fig 2R-U). We also used the 
brain 3D renditions to estimate the arbitrary alpha-
blending based relative brain volumes. Interestingly, as 
compared to naïve mice, mice vaccinated with ICD-
based DC vaccines did not exhibit any strong increase in 
brain volume (Suppl. Fig S3); whereas CNTR mice (to a 
significant extent) and F/T necrosis-based DC vaccinated 
mice (to a variable hence non-significant extent), 
exhibited increase in brain volumes (Suppl. Fig S3). 
HGGs exhibit high heterogeneity on multiple levels, 
including cellular (basal) major-histocompatibility complex 
(MHC)-based immunogenicity (46-48). GL261-tumors are 
partially immunotherapy-susceptible due to GL261‟s 
detectable MHC-based immunogenicity (46, 47).  Thus, 
we tested the potential of ICD-based DC vaccine against 
CT2A, a well-known  immunotherapy-evasive glioma 
model (47). As reported previously (47), we found that 
CT2A cells exhibited a very different morphology 
compared to GL261 cells (Suppl. Fig S4A). Moreover, 
they expressed significantly less MHC-I levels (even after 
IFN-γ stimulation; Suppl. Fig S4B) and almost negligible 
MHC-II levels (that couldn‟t be up-regulated by IFN-γ 
treatment; Suppl. Fig S4C), compared to GL261 cells. 
These observations substantiate that CT2A have very 
low immunogenicity (47, 48). Despite this disparity, CT2A 
cells in response to Hyp-PDT, exposed/released all the 
main ICD-related DAMPs (surface-CRT, surface-HSP90, 
surface-HSP70, secreted ATP and released-HMGB1) 
efficiently (Suppl. Fig S4D-H). Of note, mice vaccinated 
with ICD-based DC vaccines and orthotopically 
challenged with live CT2A cells, showed significantly 
higher median survival as compared to CNTR mice 
(although not to the same extent as in GL261 model) 
(Suppl. Fig S4I).    
Altogether, this demonstrates that ICD-based DC 
vaccines are capable of inducing potent protective 
immunity against HGG in both immunotherapy-
susceptible and to a certain extent immunotherapy-
evasive cancer models. 
Anti-tumor immunity induced by ICD-based DC 
vaccines depends on ROS, danger signals, DCs, 
intact adaptive immune system and CD8+ T cells 
The immunogenic impact of major ICD-associated 
molecular/cellular determinants (ROS and danger 
signals/DAMPs) has never been comparatively tested in 
an orthotopic HGG model (49). To this end, we employed 
relevant blockade strategies to assess the relevance of 
key molecular steps in the signaling cascade eliciting 
ICD, for the generation of efficient DC-based vaccines, 
as depicted in Fig 3A. Presence of ROS-scavenging 
molecules, NAC/L-Hist (40), significantly attenuated the 
immunogenic potential of ICD-based DC vaccine (Fig 3B-
C). Similarly, blocking different DAMPs reduced the 
vaccine‟s immunogenic potential in a hierarchical manner 
(extracellular-HMGB1>extracellular-ATP>surface-CRT) 
(Fig 3B-C). Extracellular-HMGB1 ablation by blocking 
antibodies significantly reduced both % median survival 
(Fig 3B) and % long-term survivors (Fig 3C); whereas 
degradation of extracellular-ATP by apyrase only 
significantly ablated the latter (Fig 3B-C). Surface-CRT 
blockade by blocking antibodies reduced both albeit 
insignificantly (Fig 3B-C). Remarkably, concurrent 
ablation of all three DAMPs additively reduced the mice 
median survival (30 days), more than individual DAMPs 
blockade, to nearly the same level as CNTRs (26 days) 
(Fig 3B-C). 
Cellular adjuvant like DCs (3) are often considered 
dispensable for ICD in a vaccination set-up (25, 50); 
since the cancer cells dying via ICD are considered to be 
sufficiently immunogenic (31). However in our current 
set-up, vaccination with dead/dying cancer cells 
undergoing ICD alone, without DCs, drastically reduced 
the vaccine‟s immunogenic potential (Fig 3D-E). Since 
extracellular-HMGB1 emerged as a predominant DAMP 
in this model, we decided to ablate its toll-like receptor 
(TLR)-agonist function (51), which is conveyed through 
the TLR-adaptor, myeloid differentiation primary 
response gene 88 (MyD88) for innate immune signaling 
(52). Notably, utilizing Myd88-/- DCs for making ICD-
based DC vaccine, resulted in the severe ablation of  
both % median survival (in a slightly delayed fashion) and 
especially the % long-term survivors parameters (Fig 3D-
E), thus indicating the crucial adjuvant role of proper DC-
based signaling in these settings.  
The immunogenic potential of ICD and DC vaccines 
relies upon an intact adaptive immune system and 
especially on CD8+ T cell-activity (2, 5). Remarkably, 
mice lacking an intact adaptive immune system (due to 
lack of recombination-activating gene 1 or Rag1-/-) 
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Figure 2. DC vaccines based on Hyp-PDT-induced ICD, elicit highly efficient HGG-rejecting immunity in an orthotopic model. (A) 
GL261 cells were treated to undergo ICD with Hyp-PDT and recovered 24 h post-PDT; thereafter they were co-incubated with murine DCs 
(for 24 h) to produce ICD-based DC vaccine (vacc). Alternatively, as applicable, DC vaccines were also produced with GL261 cells 
exposed to 6 cycles of F/T-based necrosis. Thereafter the vaccinations were carried out in a prophylactic vaccination set-up. (B) Kaplan-
Meier curve depicts survival of three “cohorts” (CNTR, n=5; F/T Necrosis-based DC vacc, n=7; and Hyp-PDT-based DC vacc, n=7; Log-
rank (Mantel-Cox) test; ***p<0.001 vs. CNTR (without bar) and bar indicates comparison between F/T Necrosis and Hyp-PDT-based DC 
vacc). (C-E) Graphs indicate the emergence of progressive HGG-induced neurological deficit symptoms (grade 1-3) before their sacrifice 
(grade 4) versus normal/healthy mice (grade 0), color-coded based on symptom severity. (F-U) Representative MRI-scans are shown for 
naïve/normal mice (F); i.e. mice not exposed to the procedure described in (A) and day 29 post-intra-axial GL261-inoculated mice from 
CNTR (J), F/T Necrosis-based DC vacc (N) and Hyp-PDT-based DC vacc (R) “cohorts”. Subsequently, these MRI-scans were used to 
create 3D renditions of the whole-brain (G, K, O, S), visible HGG-tumor mass wherever available (H, L, P, T) and morphology of the 
anterior brain ventricles (I, M, Q, U). 
  
 76 
 
Figure 3:  
 
  
 77 
 
Figure 3. Blockade of ROS, danger signals, DCs (or DC-associated MyD88), intact adaptive immune system and CD8+ T cells 
abrogates the ICD-based DC vaccine-induced HGG-rejection. (A) Molecular (ROS, CRT, ATP, and HMGB1) and immunological 
determinants (DCs, DC-based HMGB1-MyD88 axis, adaptive immunity especially on CD8+ T cells‟ level) were targeted through chemical, 
antibody or genetic means as specified below. (B-G) Respective vaccines (vacc) were injected twice in C57BL/6 mice. Here, the 
respective vacc were pre-treated/neutralized by NAC/L-Hist, anti-CRT or anti-HMGB1 antibodies/Abs, apyrase and a combination of the 
latter three (B,C), or the DCs were either absent or derived from Myd88-/- mice (D,E) or the mice receiving the vacc were Rag1-/- (F) or 
depleted for CD8+ cells (G). Thereafter, the immunized and non-immunized (i.e. CNTR) mice were intra-axially inoculated with live GL261 
cells. (B,C) Kaplan-Meier curve (B) depicts survival of seven “cohorts” (CNTR, n=5; Hyp-PDT based DC vacc, n=6; and Hyp-PDT-based 
DC vacc combined with - apyrase, n=8; anti-HMGB1 Ab, n=8; anti-CRT Ab, n=8; NAC/L-Hist, n=9; apyrase+anti-HMGB1/CRT Abs, n=9); 
while % glioma-free long-term surviving mice are depicted in (C). (D,E) Kaplan-Meier curve (D) depicts survival of four “cohorts” (CNTR, 
n=5; Hyp-PDT based DC vacc, n=7; and Hyp-PDT-based vacc, without DC, n=5; or with Myd88-/- DCs, n=8); while % glioma-free long-term 
surviving mice are depicted in (E). (F) Kaplan-Meier curve depicts survival of four “cohorts” (Rag1+/+ WT CNTR, n=5; Rag1+/+ WT Hyp-
PDT-based DC vacc, n=6; Rag1-/- CNTR, n=5; Rag1-/- Hyp-PDT-based DC vacc, n=6). (G) Kaplan-Meier curve depicts survival of four 
“cohorts” (CNTR, n=5; Hyp-PDT-based DC vacc, n=6; CNTR + anti-CD8 Ab, n=5; Hyp-PDT-based DC vacc + anti-CD8 Ab, n=7). In this 
figure, Log-rank (Mantel-Cox) test (B, D, F, G) or Chi-square test (C, E) were used for statistics, *p<0.05/**p<0.01/***p<0.001 as indicated 
by bars or otherwise versus respective CNTRs; N.S.: not significant. 
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completely failed to resist intra-brain glioma-inoculation 
despite immunization with ICD-based DC vaccines (Fig 
3F). Interestingly, even in CNTR settings, Rag1-/- mice 
(17 days) showed significantly, albeit marginally, reduced 
median survival as compared to Rag1+/+ mice (22 days) 
(Fig 3F), an observation reminiscent of anti-glioma 
immunosurveillance (45, 53). Next, we depleted the CD8+ 
T cells through anti-CD8 antibodies (Suppl. Fig S5). 
Depletion of CD8+ T cells (but not CD4+ T cells) was 
confirmed in various immunological compartments like 
peripheral blood and (cervical/distal) lymph nodes (Suppl. 
Fig S5). Similar to Rag1-/- mice, mice depleted of CD8+ T 
cells, also failed to resist intra-brain glioma-inoculation 
despite immunization with ICD-based DC vaccines (Fig 
3G). Of note, vaccinated mice depleted of CD8+ T cells 
(median survival: 21 days) (Fig 3G) survived only 
marginally better than similarly vaccinated Rag1-/- mice 
(median survival: 17 days) (Fig 3F).     
In conclusion, HGG-rejecting immunity elicited by ICD-
based DC vaccines is highly dependent upon ROS, 
danger signals (especially the released HMGB1-MyD88 
axis), presence of DCs as adjuvant and a CD8+ T cell-
driven adaptive immune response. 
ICD-based DC vaccines are able to withstand the 
rigid clinically-relevant operational parameters 
Two clinically-relevant operational parameters pose a 
significant challenge to the immunogenicity of anti-cancer 
vaccines i.e. avitalization (i.e. absolute absence of living 
cancer cells) and the possibility of tumor tissue material, 
to be used for vaccine preparation, being in frozen state 
(due to the clinical practice of snap-freezing the resected 
tumor) (54). In order to enable future translation towards 
the clinic we felt it was necessary to produce a clinically-
relevant version of Hyp-PDT induced ICD-based DC 
vaccine capable of withstanding such rigid operational 
parameters. 
We employed, in combination with Hyp-PDT, several 
avitalization strategies often applied in clinical vaccine 
preparation protocols i.e. high-dose radiotherapy (RT), 
mechanical necrosis (achieved here via GentleMACS® 
system i.e. GM necrosis) and the highly prevalent F/T 
necrosis. To confirm avitalization, we either estimated the 
percent cellular survival (Fig 4A) or percent clonogenic 
survival (Fig 4B). Hyp-PDT alone, Hyp-PDT+GM 
necrosis, Hyp-PDT+RT and Hyp-PDT+RT+GM necrosis, 
failed to achieve absolute avitalization (Fig 4A-B). On the 
other hand, Hyp-PDT+F/T necrosis and Hyp-
PDT+RT+F/T necrosis were found to achieve complete 
avitalization (Fig 4A-B). An analysis in the prophylactic 
treatment set-up showed that only DC vaccines based on 
GL261 cells treated with Hyp-PDT+RT, Hyp-PDT+F/T 
necrosis and Hyp-PDT+RT+F/T necrosis showed 
survivals that were not significantly different than mice 
immunized with Hyp-PDT induced ICD-based DC 
vaccines (Fig 4C). Although it is worth noting that these 
avitalization strategies did reduce the overall number of 
long-term surviving mice (Fig 4A). Overall, the most 
minimal combination that achieved both absolute 
avitalization (Fig 4A-B) and significant anti-HGG 
protective immunity in vivo (Fig 4C) was Hyp-PDT+F/T 
necrosis-based DC vaccines; and hence these were 
used subsequently as a “clinically-relevant version” along 
with the original biologically-relevant vaccine. 
Next, we tested the effect of the start-up cellular material 
having undergone a cycle of snap-freezing (overnight) 
and thawing (i.e. 1xF/T cycle, so called “frozen” cells, 
mimicking the clinical status quo) on vaccine 
immunogenicity. This F/T-step drastically reduced the 
survival of the residual cancer cells (however did not 
completely abrogate living cells) (Suppl. Fig S6). Hyp-
PDT and Hyp-PDT+F/T-necrosis treatment on these 
“frozen” cells further reduced the cellular survival 
gradually towards avitalization (Suppl. Fig S6). 
Interestingly, for Hyp-PDT+F/T necrosis-based DC 
vaccine, it did not strongly matter whether the start-up 
cellular material was live or “frozen”, as mice immunized 
with both vaccines exhibited similarly increased median 
survivals (live: 48.5 days vs. “frozen”: 60 days; as 
compared to CNTR: 26 days) and long-term survivors 
(approximately 20-30%, as compared to 0% in CNTR 
setting) (Fig 4D). On the other hand, for Hyp-PDT alone, 
the state of the start-up cellular material made a 
significant difference (Fig 4D). 
Taken together, our results show that ICD-based DC 
vaccines are capable of withstanding the rigid clinically-
relevant operational parameters such that Hyp-PDT+F/T 
necrosis based DC vaccines represent the most 
clinically-relevant version. 
ICD-based DC vaccines induce a prophylactic shift in 
brain immune-contexture from Tregs-to-
Th1/CTLs/Th17 cells 
Owing to the highly promising HGG-rejecting immunity 
induced by ICD-based DC vaccine and its clinically-
relevant version, we wondered whether this in vivo 
immunogenicity was associated with an immune 
stimulatory shift in the brain immune-contexture. To this 
end, we analyzed the brain-infiltrating immune cells in 
mice that were prophylactically vaccinated (Hyp-PDT 
based or Hyp-PDT+F/T necrosis based, DC vaccines) or 
not (CNTR setting) and inoculated within the brain with 
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live GL261 glioma cells. Remarkably, we found that 
GL261 glioma-inoculated mice prophylactically 
vaccinated with Hyp-PDT or Hyp-PDT+F/T necrosis 
based DC vaccines, exhibited significant increase (as 
compared to CNTR mice) in brain infiltration of CD3+ T 
lymphocytes (Fig 5A), CD4+ T lymphocytes (Fig 5B) and 
CD8+ T lymphocytes (Fig 5C). Moreover, GL261 glioma-
inoculated mice prophylactically vaccinated with the 
respective ICD-based DC vaccines, but not CNTR mice, 
showed increased infiltration of Th1 cells i.e. IFN-γ+CD4+ 
T cells (Fig 5D), CTLs i.e. IFN-γ+CD8+ T cells (Fig 5E) 
and Th17 cells i.e. IL-17A+CD4+ T cells (Fig 5F). 
Interestingly, whereas CNTR mice showed a higher intra-
brain infiltration of Treg cells i.e. Foxp3+CD4+ T cells, 
mice vaccinated with respective ICD-based DC vaccines, 
showed significantly reduced levels of intra-brain Tregs 
(Fig 5G). The two ICD-based vaccines did not reveal 
significant differences. However, mice vaccinated with 
Hyp-PDT+F/T necrosis based DC vaccines showed a 
trend towards slightly higher Tregs (Fig 5G) and reduced 
infiltration of Th17 cells compared to mice vaccinated 
with Hyp-PDT based DC vaccines (Fig 5F).  
Next, it was imperative to confirm whether the immune 
stimulation observed above was only a brain-localized 
reaction or whether the immune stimulation was visible 
on a systemic level, the latter being crucial for long term 
immunity. We then analyzed whether mice splenocytic 
(SPL) T cells have the ability to exhibit “immune memory” 
responses upon antigen re-exposure. Hence SPL T cells 
were isolated from GL261 glioma-inoculated CNTR mice 
or mice subjected to prophylactic vaccination with 
respective ICD-based DC vaccines (Suppl. Fig S7). 
These SPL T cells were then re-stimulated with naïve 
(i.e. untreated) GL261 lysates. We observed that SPL T 
cells isolated from respective vaccinated mice showed 
significantly higher IFN-γ production upon re-stimulation 
as compared to CNTR mice (Fig 5H).  
In conclusion, GL261-inoculated mice prophylactically 
vaccinated with ICD-based DC vaccines show a shift in 
brain contexture towards Th1/CTLs/Th17 cells and away 
from Tregs and display systemic anti-tumor immunity.  
ICD-based DC vaccines in combination with 
chemotherapy exhibit the ability to cure HGG-bearing 
mice 
Prophylaxis strategy of vaccination, although critical for 
mechanistic analysis of immunogenicity, does not 
represent the clinical status quo where vaccination is 
given in a curative setup (often in combination with 
standard-of-care chemotherapeutics like TMZ) (1, 5, 55). 
We then decided to test the immunogenicity of ICD-
based DC vaccines in a curative set-up, either alone or in 
sequential combination with prior TMZ-based 
chemotherapy. Here, mice were first inoculated 
orthotopically with live GL261 cells, followed by their 
random division into 6 “cohorts” as detailed in the Fig 6A. 
Of note, TMZ did not induce any overt signs of toxicity, as 
evident by maintenance of a healthy weight by the 
treated mice (Suppl. Fig S8). In this highly clinically-
relevant experimental set-up, we observed that both 
versions of the ICD-based DC vaccines (i.e. Hyp-PDT 
and Hyp-PDT+F/T) alone, increased the median survival 
of glioma-inoculated mice by approximately 34-41% 
(albeit statistically insignificantly), compared to CNTR 
mice (Fig 6B-C); but no long-term “cured” survivors were 
observed (Fig 6C). This reflects the well-known 
aggressiveness of this tumor model (56). On the other 
hand, TMZ-based chemotherapy alone significantly 
increased the median survival of glioma-inoculated mice 
by approximately 95% (Fig 6B-C) but failed to produce 
long-term “cured” survivors (Fig 6C). Remarkably, the 
sequential combination of TMZ treatment followed by 
immunization with the two respective ICD-based DC 
vaccines, not only strongly increased the median survival 
of glioma-inoculated mice by approximately 302-306% 
(Fig 6B-C) but also produced approximately 50% of long-
term “cured” survivors (Fig 6C). These remarkable results 
were also confirmed by MRI based non-invasive analysis 
of the brain (Fig 6D-K). At day 23, whereas the CNTR 
mice showed large intra-brain glioma/HGG masses (Fig 
6D) mice that received vaccination only (Fig 6E-F) or 
TMZ only (Fig 6G) exhibited relatively smaller but 
palpable glioma/HGG masses. On the other hand, MRI 
analysis of long-term “cured” survivors belonging to the 
“TMZ+vaccination” cohorts (Fig 6H-K), showed complete 
absence of any palpable glioma masses on days 55 (Fig 
6H, J) and 90 (Fig 6I, K) after glioma-inoculation. Further 
analysis using the equations established by Robert 
Clarke (57) revealed that TMZ and the respective ICD-
based DC vaccines synergized with each other to 
achieve this remarkable anti-glioma/HGG efficacy (Suppl. 
Fig 9). Notably, the long-term “cured” survivors from the 
respective “TMZ+vaccination” cohorts managed to 
survive significantly better (than age-matched CNTR 
mice) following a further re-challenge with intra-axial 
glioma/GL261 inoculation (Suppl. Fig 10). This 
observation proves the long-term anti-HGG immune 
memory induced by ICD-based DC vaccines. 
In conclusion, a combination of chemotherapy and ICD-
based DC vaccines provides remarkable survival benefit 
against HGG and produces long-term “cured” survivors 
with palpable anti-HGG immune memory.
 80 
 
Figure 4:  
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Figure 4. DC vaccines based on Hyp-PDT induced ICD plus F/T-necrosis, represent the most minimal combination that achieves 
absolute avitality coupled with efficient HGG-rejecting immunity. (A,B) GL261 cells were either left untreated or treated to undergo 
ICD in vitro with Hyp-PDT; thereafter they were exposed to various avitalization (i.e. live cell-eliminating) methodologies i.e. F/T-necrosis, 
GentleMACS® (GM)-necrosis, high-dose radiotherapy (RT, 60 Gy), RT+F/T-necrosis and RT+GM-necrosis. This was followed by either - 
(A) determination of percentage cellular viability through MTS assay, 10 days post-treatment (n=3; mean±s.e.m.) or (B) clonogenic assay 
after 10 days of growth (n=3; mean±s.d.). (C) Respective vaccines (vacc; +/- above avitalizations) were injected twice in C57BL/6 mice 
followed by intra-axial inoculation with live GL261 cells. Kaplan-Meier curve depicts survival of seven “cohorts” (CNTR, n=10; Hyp-PDT-
based DC vacc, n=7; Hyp-PDT+GM-Necrosis-based DC vacc, n=6; Hyp-PDT+F/T-Necrosis-based DC vacc, n=6; Hyp-PDT+RT-based DC 
vacc, n=7; Hyp-PDT+RT+GM Necrosis-based DC vacc, n=6; Hyp-PDT+RT+F/T-Necrosis-based DC vacc, n=6). (D) Frozen and then 
thawed (“Frozen” cells) or live GL261 (Live cells) were treated with Hyp-PDT or Hyp-PDT+F/T-Necrosis as described above. DC vaccines 
based on these conditions were then injected in the orthotopic HGG mice model. Kaplan-Meier curve depicts survival of five “cohorts” 
(CNTR, n=4; Live cells: Hyp-PDT-based DC vacc, n=6; Live cells: Hyp-PDT+F/T-Necrosis-based DC vacc, n=6; “Frozen” cells: Hyp-PDT-
based DC vacc, n=7; “Frozen” cells: Hyp-PDT+F/T-Necrosis-based DC vacc, n=7). In A,B, Student‟s t-test while in C,D, Log-rank (Mantel-
Cox) test were used for statistics; *p<0.05/**p<0.01/***p<0.001 as indicated by bars or otherwise versus respective CNTRs/medium 
only/background; N.S. – not significant. 
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Figure 5. ICD-based DC vaccines cause increased brain-infiltration of Th1/Th17/CTLs and decreased infiltration of Tregs. 
Respective ICD-based DC vaccines (vacc) were injected in a prophylactic orthotopic HGG murine model. Thereafter the mice were 
sacrificed at day 16 post intra-axial GL261-inoculation. Subsequently, the brains from the respective mice were isolated and processed for 
FACS-based immunophenotyping analysis for (A) T cells (CD3+ cells), (B) CD4+ T cells (CD4+CD3+ cells), (C) CD8+ T cells (CD8+CD3+ 
cells), (D) Th1 cells (IFN-γ intracellular staining in CD4+CD3+cells), (E) cytotoxic T cells/CTLs (IFN-γ intracellular staining in CD8+CD3+ 
cells), (F) Th17 cells (IL17A intracellular staining in CD4+CD3+ cells) and (G) Treg cells (Foxp3 intracellular staining in CD4+CD3+ cells). In 
A-G, n=4-6; mean±s.e.m. At the same time, spleens (H) were recovered from the above mice (enriched for T cells). Thereafter, T cell-
enriched splenocytes were co-incubated with DCs (DC:T cells ratio of 1:5) pulsed with “naïve” lysates of GL261 cells (prepared via 
GentleMACS® based mechanical disruption) for 5 days followed by estimation of IFN-γ production in respective supernatants (n=4-5; 
mean±s.e.m.). In this figure, Mann-Whitney statistical test was used; *p<0.05/**p<0.01/***p<0.001 as indicated by bars or otherwise versus 
respective CNTRs; N.S. – not significant. 
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Figure 6. DC vaccines based on Hyp-PDT induced ICD in combination with the, chemotherapeutic drug, TMZ, provides very strong survival 
benefit in a curative or therapeutic HGG set-up. (A) Firstly, C57BL/6 mice were inoculated with live GL261 cells (Day 0), intra-axially and randomly 
divided into 6 “cohorts”. Respective ICD-based DC vaccines (vacc) and TMZ were administered (40 mg/kg) as depicted. (B,C) Median Survival data and 
Percentage Change (%Δ) in median survival (Δ in median survival from CNTR group to treatment groups divided by CNTR group med ian survival and 
multiplied by 100) (B) and Kaplan-Meier curve (C) depict survival of six “cohorts”; Log-rank (Mantel-Cox) test; *p<0.05/**p<0.01/***p<0.001 vs. CNTR 
(without bar) and others are indicated by bars). (D-K) Representative MRI scans are shown for day 23 post-intra-axial GL261-inoculated mice; CNTR (D), 
Hyp-PDT-based DC vacc only (E), Hyp-PDT+F/T-Necrosis-based DC vacc (F) and TMZ only (G) “cohorts”. Scans are also shown for day 55 (H, J) and day 
90 (I, K) post-intra-axial GL261-inoculated mice from TMZ+Hyp-PDT-based DC vacc (H-I) and TMZ+Hyp-PDT+F/T-Necrosis-based DC vacc (J,K) “cohorts”. 
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ICD-based DC vaccines partially overcome the 
immune-ablating effects of chemotherapy and favor a 
shift in brain immune-contexture from Tregs to 
Th1/CTLs/Th17 cells in curative settings 
TMZ (at medium-to-high doses) has been traditionally 
found to exert immune-ablative effects on mononuclear 
immune cells leading to myelosuppression and/or 
lymphopenia (58, 59). Thus, it was imperative to confirm 
the effects of TMZ alone or in combination with vaccines 
on brain immune-contexture. In line with previous 
observations, TMZ treatment indeed severely reduced 
the absolute levels of intra-brain mononuclear immune 
cells (Fig 7A). However, combined treatment with 
respective ICD-based DC vaccines significantly rescued 
the TMZ immune-ablating effect (Fig 7A). On the 
lymphocytic level, TMZ treatment reduced the overall 
levels of intra-brain T cells (Fig 7B); however these 
lympho-ablative effects of TMZ were not targeted 
towards CD4+ T cells (Fig 7C) but rather towards CD8+ T 
cells (Fig 7D). TMZ-mediated intra-brain ablation of CD8+ 
T cells was so severe that the vaccines could not 
significantly rescue it (Fig 7D). Notably, the combination 
of TMZ with ICD-based DC vaccines was still able to 
significantly reduce intra-brain levels of 
immunosuppressive Treg cells (Fig 7E) whereas TMZ 
alone failed to do so (Fig 7E). Considering the skewing of 
the baseline levels of intra-brain mononuclear cells or 
lymphocytes by TMZ treatment alone, we decided to 
further analyze the shift in brain immune-contexture by 
estimating immune cell ratios (60) of immunostimulatory 
T cells to Tregs (i.e. Th1/Tregs, CTLs/Tregs and 
Th17/Tregs) (61, 62). TMZ alone failed to increase the 
levels of Th1 (Fig 7F), CTLs (Fig 7G) or Th17 (Fig 7H) 
cells relative to Tregs in the brain. However, combining 
the respective vaccines with TMZ caused a significant 
increase in the Th1/Treg (Fig 7F), CTLs/Treg (Fig 7G) 
and Th17/Treg (Fig 7H) ratios.     
In conclusion, in the curative settings, TMZ-induced 
immune-ablative effects are partially overcome by the 
combination with ICD-based DC vaccines, which are 
capable of eliciting a Treg to Th1/CTLs/Th17 shift in the 
brain immune-contexture.  
Increased prevalence of Th1/CTLs/Th17 cells-
associated genetic signatures, but not Tregs, 
correlates with good prognosis in glioblastoma 
patients 
An immunostimulatory tumoral immune-contexture 
associates with improved prognosis in cancer patients 
(60). Our observations that Th1/CTLs/Th17 intra-brain 
infiltrates induced by ICD-based DC vaccines associate 
with improved survival of HGG-challenged mice, created 
an important precedence for future clinical translation. 
While clinical translation of these vaccines is beyond the 
scope of the current study, we were interested to 
ascertain the prognostic impact of Th1/CTLs/Th17-based 
immune-contexture in HGG/glioblastoma (GBM) patients. 
Two technologies can be utilized to analyze this i.e. the 
“classical” direct immunophenotyping of tumor-infiltrating 
lymphocytes or the more recently emerging method of 
utilizing (pre-established) lymphocyte subpopulation-
specific mRNA signatures within the tumor (63-65). In the 
current study we utilized the latter, since this allowed us 
to analyze a very large, standardized and publicly-
available cohort of >500 GBM patients (i.e. The Cancer 
Genome Atlas/TCGA-cohort of 541 newly diagnosed 
GBM patients) (66, 67). With the former technology such 
a large-scale analysis would be practically unfeasible 
(63).  
Here, broad lymphocyte subtype-specific mRNA 
signatures available from previous studies (63-65) were 
further tailored for GBM by delineating groups of genes 
within these signatures showing strong co-expression 
(thereby acting as „metagenes‟ (68)) centered on 
standard/specific T cell markers (64). Through this 
methodology (63, 64), we produced GBM-derived gene 
co-expression profiles (based on Pearson‟s correlation 
coefficients) of different T cell subpopulation-associated 
mRNA signatures (Suppl. Fig 11A-B, Fig 8A-D). We then 
delineated a collection of GBM-tailored, T cell subtype-
associated metagenes (centered on specific markers in 
case of high co-expressional heterogeneity) e.g. CD4+ T 
cells (uncentered; Suppl. Fig 11A), CD8+ T cells 
(CD8A/CD8B-centered; Suppl. Fig 11B), Treg cells 
(CD3D/CD3G/CD2-centered; Fig 8A), Th1 cells (IFNG-
centered; Fig 8B), CTLs (CD8B-centered; Fig 8C) and 
Th17 cells (IL17A/RORC-centered; Fig 8D). 
Next, we estimated the prognostic impact of these 
metagenes‟ differential expression on patient overall 
survival (OS) in the TCGA GBM-cohort. This was further 
complemented with calculation of percent-change (%Δ) 
in median survival (MS) or %ΔMS between the high and 
low expression groups i.e. ((MShigh - MSlow)/MShigh) x100, 
as described previously (5). High expression of CD4+ T 
cell-metagene associated with slightly reduced OS 
(Suppl. Fig 11C), as evident from negative %ΔMS of -
8.37% and a hazard ratio (HR) of more than 1. However 
further analysis of CD4+ T cell subtypes showed that 
while high expression of Treg-metagene associated with 
reduced OS (Fig 8E) (%ΔMS of -7.36%) yet high 
expression of Th1-associated metagene correlated with 
prolonged OS (Fig 8F) (%ΔMS of +8.73%). On the other 
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Figure 7. ICD-based DC vaccines cause a Treg-to-Th1/Th17/CTLs shift in brain-immunofiltrates after TMZ-based HGG 
chemotherapy treatment. Firstly, C57BL/6 mice were inoculated with live GL261 cells (Day 0), intra-axially and randomly divided into 4 
“cohorts”. Thereafter a cohort was left untreated (CNTR); a cohort received 6 cycles of TMZ only (40 mg/kg; Fig 6A) and other two 
received TMZ in sequential combination with respective ICD-based DC vaccines (vacc), as depicted in Fig 6A. Thereafter the mice were 
sacrificed within 10-20 days following end of respective treatment/intra-axial challenge, as applicable. Subsequently, the brains from the 
respective mice were isolated. Initially, (A), total mononuclear immune cells were counted. Thereafter these were processed for FACS-
based immunophenotyping analysis for (B) T cells (CD3+ cells), (C) CD4+ T cells (CD4+CD3+ cells), (D) CD8+ T cells (CD8+CD3+ cells), (E) 
Treg cells (Foxp3 intracellular staining in CD4+CD3+ cells), (F) Th1-to-Treg cells ratio, (G) cytotoxic T cells/CTLs-to-Treg cells ratio, and (H) 
Th17 to Treg cells ratio. In this figure, n=5-6, mean±s.e.m., Mann-Whitney statistical test was used; *p<0.05/**p<0.01/***p<0.001 as 
indicated by bars. 
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Figure 8. Increased tumoral expression of Th1/CTLs/Th17-associated metagenes, but not Treg-associated metagene, associate 
with prolonged overall survival in glioblastoma (GBM) patients. (A-D) Metagenes associated with specific T cell-types were 
established by generating gene co-expression profiles (from TCGA GBM patient data-sets, n=541) for independently established T cells-
associated gene patterns (214, 215). Pearson‟s correlation coefficient (indicated in color-code legend) was used to analyze tendency of 
gene co-expression; and metagenes were characterized by centering the profiles (indicated by yellow line delineation) to specific T cell 
markers e.g. CD3D/CD3G/CD2 (for Treg cells, A), IFNG (for Th1 cells, B), CD8B (for CTLs, C) and IL17A/RORC (for Th17 cells, D). (E-I) 
Publicly-available TCGA cohort of GBM patients (n=541) was stratified (at 75th percentile of gene expression) into “high expression” (red; 
n=136) or “low expression” (black; n=405) groups for each metagene; followed by Kaplan-Meier plotting of patient‟s overall survival (OS; Y-
axis) versus follow-up duration in days (X-axis). This was done for metagene expressions associated with Treg (E), Th1 (F), CTLs (G), 
Th17 (H) and, combination of Th1/CTLs/Th17 (I). In all E-I graphs, respective log-rank (Mantel-Cox) test p-values and hazard ratios (HR; 
with its 95% confidence interval in parenthesis) are displayed. Two dotted lines represent approximate point of 2 and 5 year survival (y.s.) 
windows. (J) The analysis of 20 published articles studying the impact of T cell immune-infiltrates on the prognosis of glioma/GBM patients 
(Suppl. Table S1) is represented. „Good‟ refers to increased infiltrates associating with favourable patient prognosis, „Poor‟ refers to 
increased infiltrates associating with poor patient prognosis and „None‟ means lack of conclusive correlation. Enlargements of figures A-D 
are shown in supplemental figure S12.  
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hand, high expression of CD8+ T cell-metagene 
associated with slightly prolonged OS (Suppl. Fig 11D) 
(%ΔMS of +4.47%), a positive prognostic impact that 
improved further on CTLs-level. Indeed, high CTLs-
metagene expression associated with more prolonged 
OS (Fig 8G) (%ΔMS of +10.94%). Although the above 
survival trends were not significant, interestingly, high 
expression of Th17-metagene alone (Fig 8I) (%ΔMS of 
+18.76%) or combined high expression of 
Th1/CTLs/Th17-metagenes (Fig 8H) (%ΔMS of 
+17.56%), associated with significant prolongation of OS. 
It is noteworthy that, in general, GBM patients showing 
more than 2 years of survival (2 y.s.; especially between 
2 and 5 y.s. window) showed the highest 
positive/negative impact of respective T cell-associated 
metagenes. 
Next, we decided to substantiate the above results with a 
literature meta-analysis of papers employing direct 
immunophenotyping of tumor-infiltrating lymphocytes in 
GBM/HGG tumor tissue (Suppl. Table S1), as described 
previously (60). This meta-analysis revealed that, high 
tumor-infiltration of CD4+ T cells and CD8+ T cells 
associated with good prognosis in HGG/GBM patients 
(Fig 8J). Similar trend was implied for GBM/HGG-
infiltration of Th1, CTLs and Th17 cells, albeit covered by 
fewer studies (Fig 8J). On the other hand, high tumor-
infiltration of Tregs associated with poor prognosis (Fig 
8J).  
In conclusion, our TCGA- and literature meta-analysis 
revealed that increased prevalence of molecular 
signatures corresponding to Th1/CTLs/Th17 cells, but not 
Tregs, associate with good prognosis in GBM/HGG 
patients.  
 
Discussion 
To the best of our knowledge, this is the first translational 
study combining a single-agent ICD inducer with DC 
immunotherapy against a vital organ-associated cancer 
in a preclinical, orthotopic model. Previously, ICD-based 
vaccines have only been applied in either heterotopic 
subcutaneous cancer models (49, 69) or in an orthotopic 
model of non-vital organ-associated cancer (e.g. shikonin 
against breast cancer (70)). This is also the first study to, 
on one hand, test the efficacy of ICD-based DC 
immunotherapy against a highly immunosuppressive 
HGG; and, on the other hand, directly compare the 
immunogenic impact of four different ICD-essential 
molecular determinants (ROS, CRT, ATP, HMGB1) in an 
orthotopic tumor model (45, 71). This study also adds to 
the significant anti-tumor immunity inducing capabilities 
demonstrated for Hyp-PDT, in other cancer models (27, 
29, 31). Considering the previous application of Hyp-PDT 
for clinical cancer treatment (27, 72) and of Hypericin for 
clinical fluorescence-guided HGG resection (73), Hyp-
PDT based anti-cancer vaccines can be translated 
towards the clinic in near future (pending final preclinical 
checks pertaining to safety and regulatory parameters). 
We currently envisage undertaking this step for HGG. 
Our results confirm, that Hyp-PDT induced ICD-based 
DC vaccines have a high potency both in biologically- 
and clinically-relevant forms. The latter form integrated 
both absolute cellular avitalization and the possibility of 
treating “frozen” tumor material. These results are of 
general translational interest, because the rigid clinically-
relevant operational parameters (if not accounted for, in 
early stages) may lead to failure of anti-cancer vaccine in 
later stages of development. Such stiff parameters have 
facilitated usage of the low-immunogenic but operational 
parameters-satisfying procedure of F/T necrosis for cell 
death preparations (5, 7, 22, 29, 31). The current study 
shows that sequential combination of Hyp-PDT treatment 
and F/T necrosis can achieve a productive balance 
between preserving immunogenicity (to a certain degree) 
and withstanding the negative impact of stringent 
operational parameters.  
Remarkably, in prophylactic/curative set-ups, both 
biologically and clinically-relevant versions of the ICD-
based DC vaccines provided considerable survival 
benefit against HGG. Especially in the latter case, in 
combination with the standard-of-care chemotherapeutic 
TMZ, both ICD-based DC vaccines synergized to 
increase the median survival by more than 300% relative 
to CNTR. The combination with TMZ-based 
chemotherapy was essential to provide strong survival 
benefit since the vaccines alone only increased median 
survival by 34-40%. This phenomenon has been 
described previously i.e. DC immunotherapies tend to 
function sub-optimally in the presence of pre-existing 
tumors, owing to the high tumor-induced immune-
suppression (5, 74). Also clinically, an inverse 
association has been observed between tumor burden 
and immunotherapy effectiveness (74, 75). These 
observations have paved the way for combining DC 
immunotherapy with cyto/tumor-reductive anti-cancer 
chemotherapies like TMZ (5) – a rationale that we 
successfully applied in this study. It has also been 
postulated that chemotherapy preceding DC 
immunotherapy can make tumor cells more susceptible 
to immunotherapy (7, 76, 77) thereby providing 
synergistic survival benefit (78).  
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Interestingly, although in the curative set-up there was no 
significant difference between the efficacies of Hyp-PDT-
based and Hyp-PDT+F/T necrosis-based DC vaccines 
yet in prophylactic set-up, there was a distinct difference 
in the % long-term survivors between these vaccines. 
Such differences could originate from the nature of 
prophylactic vaccination. While it is widely recognized 
that prophylactic vaccination model is an adequate 
approach for the experimental testing of a vaccine‟s in 
vivo immunogenicity and the underlying mechanisms (25, 
29, 55, 79, 80) yet when it comes to clinical relevance it 
has many disadvantages e.g. the absence of a pre-
established tumor-burden based immune-suppression 
(55), possible occurrence of split immunity (81) and 
absence of systemic tolerogenicity towards 
overexpressed cancer antigens (55, 79, 80). Moreover, it 
should be also taken into consideration that pre-
established tumors (and/or its pre-treatment with 
chemotherapy) can change immunological responses 
induced by DC immunotherapy – a phenomenon that has 
also been reported in the clinic (5, 7, 76). Although our 
DC immunotherapies show potency in both prophylactic 
and curative set-up, the latter is much more important 
and relevant. 
On the molecular level, our study show that ROS and 
danger signals (extracellular HMGB1>extracellular 
ATP>surface-CRT) are major cancer cell-autonomous 
determinants of vaccine‟s immunogenicity. Clearly in 
case of Hyp-PDT or PDT in general, ROS generation is 
the most apical signaling event triggering cell death 
associated signals crucial for ICD, including ER stress 
and exposure/release of some danger signals (surface-
CRT/secreted-ATP) (27, 28, 31, 38). The immunogenic 
role of ROS may not be limited to PDT but might have 
very broad implications for all anti-cancer therapies 
operating through oxidative stress (40). Beyond ROS, 
concurrent blockade of all three ICD-relevant danger 
signals, almost completely ablated the median survival 
advantage provided by the vaccine. Thus, our studies 
show that these three danger signals account for most of 
the ICD‟s in vivo immunogenic potential in this set-up and 
further outline the predominant immunogenic role played 
by the HMGB1-MyD88 axis for generating a productive 
interface between dying cancer cells and DC. These 
results also outline that depending on the vaccination or 
therapeutic set-ups the immunogenic potential of one, or 
a few, DAMP may prevail on the others (49). It is possible 
that, in our DC- based vaccines, late-apoptotic danger 
signal like extracellular HMGB1 has a predominant role 
since the vaccines are largely composed of post-
apoptotic cells; while a danger signal like surface-CRT 
may require higher prevalence of pre-/early-apoptotic 
cells (31, 82, 83). Irrespective of this, our study supports 
the decisive role of ICD-associated DAMPs in the 
generation of novel and more powerful DC-based 
vaccines.   
The efficacy of ICD-based DC vaccines was highly 
dependent upon an intact adaptive immune system. 
Moreover, our studies identified CD8+ T cells as the 
predominant adaptive immune mediators of anti-tumor 
immunity, although this does not rule out the role of other 
immune cells. ICD-based DC vaccines also induced an 
immune-stimulatory shift in the brain immune-contexture 
i.e. increased intra-brain infiltration of Th1/CTLs/Th17 
cells relative to reduction in Tregs, in both prophylactic 
and curative set-ups (latter, in combination with TMZ). Of 
note, TMZ exerted specific (intra-brain) immune-ablative 
effects that were corrected to a certain extent by the 
vaccines to sustain a Treg-to-Th1/CTLs/Th17 
immunostimulatory shift in the brain. Hence, while on the 
level of overall survival, TMZ and ICD-based DC 
vaccines might exhibit synergism, yet on the level of 
brain immune-contexture these two strategies engage in 
partially antagonistic interactions. This further 
substantiates the largely cytotoxic or tumor-reductive role 
of TMZ in this set-up. Thus, as expected from a next-
generation DC immunotherapy (5), Hyp-PDT induced 
ICD-based DC vaccines biased the immune reactions in 
favor of Th1-type immunity. Moreover, our TCGA GBM 
patient analysis and literature meta-analysis showed that 
increased incidence of molecular signatures associated 
with Th1/CTL/Th17 relative to Tregs can have significant 
positive prognostic impact in GBM patients. Of note, 
across preclinical and clinical data, brain-infiltrating Th17 
cells (or corresponding molecular signatures) associated 
well with good prognosis in both HGG mice model and 
GBM/HGG patients. Since the role of Th17 in GBM/HGG 
remains largely enigmatic, in future, it would be 
necessary to carry out detailed studies on the anti-HGG 
immunological effects of Th17 cells and its possible 
modulators emerging from ICD and/or DCs. Of note, the 
analysis of prognostic impact of Th1/CTLs/Th17 cells-
associated metagene in GBM/HGG patients is of great 
significance, since now it joins few other cancer-types 
(melanoma, colorectal, breast and lung cancer) where 
such analysis has been accomplished (60). Such 
analysis may also be crucial in future for patient 
stratification exercises striving to delineate GBM/HGG 
patients most likely to respond to ICD-based DC 
vaccines (49, 84). 
Last but not least, our comparison between GL261 and 
CT2A glioma models shows that responsiveness to ICD-
based DC vaccines could be affected by MHC-level 
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heterogeneity in HGG tumors. It would be also crucial in 
future to characterize other immunotherapies that can be 
combined with ICD-based DC vaccines to overcome 
resistance posed by CT2A-like glioma cells in tumors 
(e.g. IDO inhibitors, anti-CTLA4/PD1/PD-L1 antibodies 
(1)).  However, the results obtained in the current study, 
using the HGG model consolidate the strength of Hyp-
PDT based anticancer vaccines observed in previous 
studies, using other cancer models (29, 31). Whether 
Hyp-PDT-induced ICD-based DC vaccines will prove to 
have similar effectiveness in other cancer-types, is a 
conjecture that needs to be experimentally tested in the 
near future.  
Materials and Methods 
Cell culture, ICD induction and DC vaccine 
production 
GL261 (received as a gift from Dr. Eyupoglu, University 
of Erlangen, Germany) and CT2A mouse glioma cells 
were cultured at 37°C under 5% CO2 in DMEM 
containing 4.5 g/L glucose and 0.11 g/L sodium pyruvate 
and supplemented with 2 mM glutamine, 100 units/ml 
penicillin, 100 µg/L streptomycin and 10% fetal calf 
serum. For induction of Hyp-PDT elicited ICD, the GL261 
cancer cells were incubated with 200 nM Hypericin (for 2 
h in serum-free media) followed by light irradiation (4.05 
J/cm2) performed as described previously (85) and 
recovered 24 h post-treatment unless otherwise 
mentioned. Of note, Hypericin was prepared, purified and 
stored as detailed elsewhere (86). Wherever applicable, 
Hypericin co-localization analysis in the endoplasmic 
reticulum was performed via fluorescence microscopy as 
described previously (31, 38). For preparation of Hyp-
PDT induced ICD-based DC vaccines, DCs derived from 
the bone marrow progenitor cells as described previously 
(45), were loaded with the above Hyp-PDT treated 
GL261/CT2A cancer cells (2 mg protein per 10 x 106 DCs 
per ml culture medium) at 37°C for 90 min. Wherever 
applicable, either the DCs were derived from Myd88-/- 
mice (Charles River Laboratories, France) or the 
respective Hyp-PDT treated cancer cells-associated 
components were neutralized with anti-CRT antibody (6 
µg/106 cells post-PDT; Abcam), anti-HMGB1 antibody 
(10 µg/106 cells post-PDT; Abcam), apyrase (13 U/106 
cells post-PDT; Sigma), a combination of these three or a 
combination of N-acetylcysteine (NAC, 5 mM; Sigma)/L-
Histidine (25 mM; Sigma) at pre-/post-PDT stages. 
Thereafter, the loaded DCs were transferred to culturing 
flasks for 24 h in DC culturing medium (consisting of 20 
ng/ml GM-CSF, from Peprotech; and 1 µg/ml E.coli-
derived LPS, from Sigma-Aldrich). Thereafter, 24 h later, 
the loaded DCs were harvested, counted and 
resuspended (1 x 106 DCs in 100 µL PBS) for intra-
peritoneal injection in mice. As applicable, surface 
expression of DC maturation markers was assessed on 
pulsed DCs via flow cytometry, using the following 
monoclonal antibodies (mAbs): FITC-conjugated anti-H-
2Kb (Becton Dickinson, BD), PE-conjugated anti-I-A/I-E 
and anti-CD40 (BD), and PE-conjugated anti-CD80 and 
anti-CD86 (eBioscience). For each staining the 
appropriate isotypes were utilized. Analysis was 
performed using the Cellquest software on a FACSort 
cytometer (BD, Erembodegem, Belgium). 
 Orthotopic high grade glioma (HGG) mice model 
For this model, female C57BL/6J mice (8 to 10 weeks 
old) were purchased from Harlan (Horst, Netherlands). 
They were housed in the conventional pathogen-free 
conditions and all the relevant experiments were carried 
out in accordance with the bioethics guidelines or 
regulations of the KU Leuven. DC immunotherapy and 
temozolomide (Schering-Plough, Brussels, Belgium; 40 
mg/kg) administration schedules are described either in 
the figures as schemas or within the figure legends. 
Temozolomide (TMZ) was dissolved in PBS with equal 
amounts of L-histidine (w/w) to improve solubility (mixture 
was sonicated for 1 h and agitated every 20 min to avoid 
precipitation). To create intra-brain HGG, the mice were 
intra-cranially/intra-axially injected with 5 x 105 GL261 or 
CT2A glioma cells as detailed elsewhere (45). Briefly, 
mice were anesthetized, fixed in a stereotactic frame 
(Kopf Instruments, Tujunga, CA) and injected (under 
sterile conditions) with the GL261/CT2A cells at 2 mm 
lateral and 2 mm posterior from the bregma and at 3 mm 
below the dura mater. After intra-cranial/brain-inoculation, 
the mice were monitored 3 times per week and clinical 
symptoms were scored with a neurological deficit grading 
scale adapted from an experimental autoimmune 
encephalomyelitis model, as described previously (45). 
Mice were defined as long-term survivors if their survival 
exceeded 3 times the median survival of the untreated 
control (CNTR) mice. Wherever applicable, the long-term 
survivors were re-challenged with GL261 cells, 
orthotopically (as described above) in the contralateral 
hemisphere, along with age-matched naïve mice serving 
as CNTR. Rag1-/- mice were kindly provided by Dr. Guy 
Boeckxstaens (KU Leuven). Also, as applicable, some 
animals received CD8+ T cells depleting antibodies, intra-
peritoneally 1 day before (200 µg) and 1 day after (100 
µg) intracranial glioma-inoculation. The hybridoma 
producing the anti-CD8 antibody was kindly provided by 
the University of Cambridge. As applicable, either 
representatives of two-three independent mice 
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experiments were shown and/or power analysis based on 
previous publications (45, 53, 71) was employed to reach 
necessary sample sizes in individual experiments. 
MRI analysis and Image processing 
MR images were procured on the 9.4 T Biospec small 
animal MR system (Bruker Biospin, Germany) using a 7 
cm linearly polarized resonator for transmission and an 
actively decoupled dedicated mouse brain surface coil 
acting as receiver (Rapid Biomedical, Germany). For 
localization, two-dimensional axial T2-weighted images 
(spin echo, TEeff = 48 ms, TR = 3500 ms) and two-
dimensional coronal T2-weighted images were obtained. 
Image acquisition was performed with the Paravision 5.0 
(Bruker BioSpin). ImageJ software was used for further 
image processing, 3D rendering, and for alpha-blending 
based brain volume calculations. 
Brain immune infiltration analysis 
Brain-infiltrating immune cells were isolated from GL261-
inoculated mice as detailed before (45). Surface staining 
was performed with anti-CD4 PerCP-Cyanine5.5, anti-
CD3 eFluor® 450 and anti-CD8a eFluor® 605NC mAbs 
(all from eBioscience). Intracellular FoxP3 was detected 
using a FoxP3-PE staining kit (eBioscience) according to 
the manufacturer‟s protocols. For intracellular IL-17A and 
IFN-γ staining, cells were stimulated for 4 h in vitro with 
100 ng/ml phorbol myristate acetate, 1 µg/ml ionomycin 
and 0.7 µg/ml monensin (all from Sigma-Aldrich). After 
restimulation, surface staining for CD4 APC-eFluor® 780, 
CD8a eFluor® 450 and CD3 PE (all from eBioscience) 
was performed and cells were washed with a 
permeabilization buffer containing 0.5% saponin and 
0.5% bovine serum albumin (BSA). Intracellular staining 
was performed with anti-IFN-γ-PerCP-Cyanine5.5 and 
anti-IL-17A-APC mAbs (eBioscience). Data acquisition 
was performed on LSRFortessa flow cytometer (BD 
Biosciences) and the FlowJo software was used for data 
analysis. 
Statistical Analysis 
All statistical analyses were performed using either Prism 
software (GraphPad Software, USA) or GraphPad 
QuickCalcs online software 
(http://www.graphpad.com/quickcalcs/index.cfm). 
Student‟s t-test, Log-rank (Mantel-Cox) test or Mann-
Whitney statistical test were used for statistical analysis, 
as applicable and unless otherwise mentioned, with 
significance level set at p<0.05. 
List of Supplementary Materials: (1) Supplementary 
methods: (a) Cell death, cell survival and clonogenic 
survival analysis, (b) 5-ALA-based PDT treatment, (c) 
Analysis of DAMPs, (d) Analysis of MHC-I and MHC-II 
expression levels, (e) Immunoblotting, (f) splenocyte 
analysis, (g) literature meta-analysis for prognostic 
impact of immune-infiltrates in glioblastoma patients and 
(h) construction of immune-infiltrate associated 
metagenes and their prognostic impact in TCGA 
glioblastoma patient data-set; (2) Supplementary 
figures: Supplementary Figure S1. DCs co-incubated 
with Hyp-PDT treated GL261 cells exhibit increased 
phenotypic maturation; Supplementary Figure S2. Hyp-
PDT induces superior enrichment of DAMPs 
exposure/release than 5-ALA-PDT from murine glioma 
cells; Supplementary Figure S3. Mice treated with ICD-
based DC vaccines maintain normal brain volume 
despite GL261-based HGG challenge; Supplementary 
Figure S4. The low immunogenic, immunotherapy-
resistant, CT2A glioma can be significantly rejected by 
Hyp-PDT induced ICD-based DC vaccine; 
Supplementary Figure S5. Anti-CD8 antibody depletes 
CD8+ T cells (but not CD4+ T cells) in various immune-
compartments like blood and (cervical/distal) lymph 
nodes; Supplementary Figure S6. Single Freezing-step 
does not completely abrogate the survival or clonogenic 
potential of murine glioma cells. Supplementary Figure 
S7. Splenocytes derived from mice are functionally 
competent; Supplementary Figure S8. Treatment of mice 
with the chemotherapeutic drug, temozolomide (TMZ), 
does not lead to general toxicity; Supplementary Figure 
S9. ICD-based DC vaccines synergize with the, 
chemotherapeutic drug, temozolomide (TMZ) in providing 
survival benefit in a curative or therapeutic HGG set-up; 
Supplementary Figure S10. Long-term survivors 
immunized previously by ICD-based DC vaccines tend to 
significantly reject re-challenge with orthotopic HGG; 
Supplementary Figure S11. Increased tumoral 
expression of CD8+ T cell-associated metagenes, but not 
CD4+ T cell-associated metagene, associate with 
prolonged overall survival in glioblastoma (GBM) 
patients. Supplemental Figure S12. Enlargements of the 
metagenes associated with specific T cell-types as 
presented in main figure 8. (3) Supplementary Table 
S1. Literature meta-analysis of, prognostic impact of, 
intra-tumoral T cell infiltration in high-grade glioma or 
glioblastoma (GBM) patients. 
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Supplemental Figures, Tables and Methods 
 
 
 
 
Supplementary Figure S1. DCs co-incubated with Hyp-PDT treated GL261 cells exhibit increased phenotypic 
maturation. GL261 cells were treated in vitro with Hyp-PDT (200 nM Hyp incubated for 2 h, followed by irradiation with light 
fluence of 4.05 J/cm2), followed by their recovery 24 h post-treatment, and co-incubation with murine DCs for another 24 h. 
Thereafter the surface expression of CD40, MHC-II (I-A/I-E), MHC-I (H2-Kb), CD80 and CD86 were evaluated by FACS-
based analysis (n=4; mean±s.e.m.; Student‟s paired t-test; *p<0.05/**p<0.01/***p<0.001 versus CNTR-GL261). 
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Supplementary Figure S2. Hyp-PDT induces superior enrichment of DAMPs exposure/release than 5-ALA-PDT from 
murine glioma cells. GL261 were treated with either Hyp-PDT (incubation of 2 h - 200 nM Hyp, light fluence – 2.70 J/cm2) 
or 5-ALA-PDT (incubation of 2 h – 0.5 mM 5-ALA, light fluence – 2.13 J/cm2), followed by: (A) recovery of cells 24 h post-
PDT and estimation of % early-apoptotic (Ann-V+/SyGr-) or % late-apoptotic/necrotic (Ann-V+/SyGr+) cells via FACS (n=3; 
mean±s.d.); (B-E) recovery of cells 1 h post-PDT and FACS-based analysis for surface-calreticulin (D), surface-HSP70 (B) 
and surface-HSP90 (E) in non-permeabilized cells (data presented as mean fluorescence intensity (MFI), n=3; 
mean±s.e.m.); (C) recovery of cells 1 h post-PDT and analysis for relative amounts of extracellular (C) ATP levels, measured 
in the conditioned media (n=5-6; mean±s.e.m.); and (F) recovery of cells at 48 h post-PDT, and immunoblotting analysis of 
concentrated conditioned media. In this figure, Student‟s t-test was used for statistics, *p<0.05/**p<0.01/***p<0.001 as 
indicated by bars; N.S. – not significant. 
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Supplementary Figure S3. Mice treated with ICD-based DC vaccines maintain normal brain volume despite GL261-
based HGG challenge. GL261 cells were treated to undergo ICD in vitro with Hyp-PDT (200 nM Hyp incubated for 2 h, 
followed by irradiation with light fluence of 4.05 J/cm2) and recovered 24 h post-PDT; thereafter they were co-incubated with 
murine DCs (for 24 h) to produce ICD-based DC vaccine. Alternatively, as applicable, DC vaccines were also produced for 
GL261 cells exposed to 6 cycles of freezing and thawing (F/T) based necrosis. These vaccines were injected twice in 
C57BL/6 mice intra-peritoneally, with an interval of 7-8 days between vaccinations. Mice not immunized with the vaccines 
were used as controls (CNTR). Thereafter, the immunized and non-immunized mice were inoculated with live GL261 cells, 
intra-axially (i.e. in the brain), 7-8 days after vaccination. Thereafter the mice were monitored for high-grade glioma (HGG)-
induced neurological deficit symptoms. Thereafter, magnetic resonance imaging (MRI) scans were carried out for 
naïve/normal mice (i.e. mice not exposed to the procedure described above) and day 29 post-intra-axial GL261-inoculated 
mice from CNTR, F/T Necrosis-based DC vaccine and Hyp-PDT-based DC vaccine “cohorts”. Subsequently, these MRI 
scans were used to create 3D renditions of the whole-brain and these 3D renditions were used to estimate alpha-blending 
based relative brain volume (n=3-4 mice; mean±s.d.; Student‟s t-test; *p<0.05 as indicated by the bars). 
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Supplementary Figure S4. The low immunogenic, immunotherapy-resistant, CT2A glioma can be significantly rejected by Hyp-
PDT induced ICD-based DC vaccine. (A) A phase-contrast microscopic analysis of confluent cultures of GL261 and CT2A cells shows 
that while GL261 exhibit a more differentiated cellular phenotype yet, the CT2A cells exhibit a more undifferentiated mesenchymal-like 
cellular morphology. (B-C) GL261/CT2A cells were either left untreated or treated with recombinant murine IFN-γ, recovered 48 h post-
treatment and analyzed for expression levels of MHC-I (B) or MHC-II (C) via flow cytometry (data presented as mean fluorescence 
intensity (MFI), n=5; mean±s.e.m.; two-way ANOVA). (D-G) CT2A were treated with Hyp-PDT (incubation of 2 h - 200 nM Hyp, light 
fluence – 4.05 J/cm2), followed by: recovery of cells 1 h post-PDT and FACS-based analysis for surface-calreticulin (D), surface-HSP90 (E) 
and surface-HSP70 (F) in non-permeabilized cells (data presented as mean fluorescence intensity (MFI), n=3; mean±s.e.m.); (G) recovery 
of cells 1 h post-PDT and analysis for relative amounts of extracellular ATP levels, measured in the conditioned media (n=5-6; 
mean±s.e.m.); and (H) recovery of cells at 48 h post-PDT, and immunoblotting analysis of concentrated conditioned media. In D-G, 
Student‟s t-test was used for statistics, *p<0.05/**p<0.01/***p<0.001 as indicated by bars; N.S. – not significant. (I) CT2A cells were treated 
to undergo ICD with Hyp-PDT and recovered 24 h post-PDT; thereafter they were co-incubated with murine DCs (for 24 h) to produce ICD-
based DC vaccine (vacc). Thereafter the vaccinations were carried out in a prophylactic vaccination set-up. Kaplan-Meier curve depicts 
survival of two “cohorts” (CNTR, n=5; and Hyp-PDT-based DC vacc, n=7; Log-rank (Mantel-Cox) test; *p<0.05 vs. CNTR). 
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Supplementary Figure S5. Anti-CD8 antibody depletes CD8+ T cells (but not CD4+ T cells) in various immune-compartments like 
blood and (cervical/distal) lymph nodes. Mice were injected with anti-CD8 antibody (Ab) one day before (D-1) and one day after (D+1) 
the intra-axial inoculation with live GL261 cells. Thirteen days post-antibody injection, the mice blood, cervical lymph nodes and distal 
lymph nodes were isolated and processed for FACS-based immunophenotyping followed by detection of CD4+ T cells (CD4+CD3+ cells), 
CD8+ T cells (CD8+CD3+ cells) and double-negative T cells (CD8-CD4-CD3+ cells) (n=2-3 mice; mean±s.e.m.; ***p<0.001 indicated by 
bars; Student‟s t-test). 
 
 
Supplementary Figure S6. Single Freezing-step does not completely abrogate the survival or clonogenic potential of murine 
glioma cells. GL261 cells were either left untreated or treated with one freezing and thawing (F/T) cycle, F/T+Hyp-PDT and F/T+Hyp-
PDT+6xF/T. This was followed by either - (A) determination of percentage cellular viability through MTS assay, 48 h post-treatment (n=4; 
mean±s.e.m.; one-way ANOVA) or (B) clonogenic assay after 10 days of growth (n=3; mean±s.d.; Student‟s t-test). In this figure, 
*p<0.05/**p<0.01/***p<0.001 is either vs. Untreated (without bars) or as indicated by bars; N.S. – not significant. 
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Supplementary Figure S7. Splenocytes derived from mice are functionally competent. GL261 cells were treated to undergo ICD in 
vitro with Hyp-PDT (200 nM Hyp incubated for 2 h, followed by irradiation with light fluence of 4.05 J/cm2); thereafter in another case as 
applicable they were also exposed to avitalization via freeze/thawing (F/T) based necrosis. Subsequently, respective treated cancer cells 
were co-incubated with murine DCs (for 24 h) to produce respective ICD-based DC vaccines. These vaccines were injected twice in 
C57BL/6 mice intra-peritoneally, with an interval of 7-8 days between vaccinations. Mice not immunized with the vaccines were used as 
controls (CNTR). Thereafter, the immunized and non-immunized mice were inoculated with live GL261 cells, intra-axially (i.e. in the brain), 
7-8 days after vaccination. Thereafter the mice were sacrificed at day 16 post intra-axial GL261-inoculation. Subsequently, spleens were 
recovered from the above mice, followed by their processing to enrich for T cells. Thereafter, the T cell-enriched splenocytes were either 
left without activation (negative control) or activated with beads associated with anti-CD3/anti-CD28 antibodies (positive control) for 5 days, 
followed by estimation of IFN-γ production in respective supernatants (n=4-5 mice; mean±s.e.m.; Mann-Whitney statistical test; *p<0.05 as 
indicated by bars; N.S. – not significant). 
 
 
Supplementary Figure S8. Treatment of mice with the chemotherapeutic drug, temozolomide (TMZ), does not lead to general 
toxicity. C57BL/6 mice were inoculated with live GL261 cells (Day 0), intra-axially (i.e. in the brain). Consequently, these HGG-inoculated 
mice were either left untreated (CNTR) or treated with 6 cycles of orally-administrated (through gavage) chemotherapeutic, TMZ (40 
mg/kg) at the indicated schedule. During TMZ treatment and until 1 week after TMZ treatment, the overall body weight of the CNTR mice 
and TMZ only mice were recorded and are presented in grams (gm) (CNTR, n=5; TMZ only, n=6; mean±s.e.m.). 
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Supplementary Figure S9. ICD-based DC vaccines synergize with the, chemotherapeutic drug, temozolomide (TMZ) in providing 
survival benefit in a curative or therapeutic HGG set-up. Firstly, C57BL/6 mice were inoculated with live GL261 cells (Day 0), intra-
axially (i.e. in the brain). Consequently, GL261 cells were treated to undergo ICD in vitro with Hyp-PDT (200 nM Hyp incubated for 2 h, 
followed by irradiation with light fluence of 4.05 J/cm2) and recovered 24 h post-PDT; thereafter in another case as applicable they were 
also exposed to avitalization via freeze/thawing (F/T) based necrosis; subsequently these cells were co-incubated with murine DCs (for 24 
h) to produce respective ICD-based DC vaccines. Thereafter the intra-axially GL261-inoculated mice were randomly divided into 6 
“cohorts” i.e. CNTR, where HGG-inoculated mice were not immunized with any vaccine; two cohorts (“vaccination only”) where the above 
two vaccines were injected thrice in HGG-inoculated mice intra-peritoneally at the indicated schedule; one cohort (“TMZ only”) where the 
HGG-inoculated mice were treated with 6 cycles of orally-administrated (through gavage) chemotherapeutic, TMZ (40 mg/kg) at the 
indicated schedule; and two cohorts (“TMZ+vaccination”) where the HGG-inoculated mice were first treated with 6 cycles of orally-
administrated (through gavage) chemotherapeutic, TMZ (40 mg/kg) at the indicated schedule and thereafter the above two vaccines were 
injected thrice, intra-peritoneally, at the indicated schedule. Thereafter the mice were monitored for HGG-induced neurological deficit 
symptoms. (A-B) Thereafter, based on respective median survival data, the calculations for antagonistic effect, additive effect and 
synergistic effect were carried out based on the Robert Clark equations (R Clarke, 1997, Breast Cancer Research and Treatment, 46:255-
278) for Hyp-PDT-based DC vacc (A) and Hyp-PDT + F/T Necrosis-based DC vacc (B).  
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Supplementary Figure S10. Long-term survivors immunized previously by ICD-based DC vaccines tend to 
significantly reject re-challenge with orthotopic HGG. Long-term surviving mice of the TMZ+Hyp-PDT-based DC vacc 
and TMZ+Hyp-PDT+F/T-necrosis based DC vacc conditions (Fig 6) were re-challenged with intra-axial inoculation with 
GL261 (along with age-matched, untreated CNTR mice). Kaplan-Meier curve depicts survival of three “cohorts” (CNTR, 
n=10; TMZ+Hyp-PDT-based DC vacc, n=6; TMZ+Hyp-PDT+F/T-necrosis based DC vac, n=5; Log-rank (Mantel-Cox) test; 
*p<0.05 vs. CNTR). 
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Supplementary Figure S11. Increased tumoral expression of CD8+ T cell-associated metagenes, but not CD4+ T cell-
associated metagene, associate with prolonged overall survival in glioblastoma (GBM) patients. (A-B) Metagenes 
associated with specific T cell-types were established by generating gene co-expression profiles (from TCGA GBM patient 
data-sets, n=541 (1, 2)) for independently established T cells-associated gene patterns (3, 4). Pearson‟s correlation 
coefficient (indicated in color-code legend) was used to analyze tendency of gene co-expression; and metagenes were 
characterized by centering the profiles (indicated by yellow line delineation) to specific T cell markers e.g. uncentered (for 
CD4+ T cells, A) or CD8A/CD8B (for CD8+ T cells, B). (C-D) Publicly-available TCGA cohort of GBM patients (n=541) was 
stratified (at 75th percentile for CD4+ T cells, or, median for CD8+ T cells, of gene expression) into “high expression” (red; 
n=136 for CD4+ T cells or n=271 for CD8+ T cells) or “low expression” (black; n=405 for CD4+ T cells or n=270 for CD8+ T 
cells) groups for each metagene; followed by Kaplan-Meier plotting of patient‟s overall survival (OS; Y-axis) versus follow-up 
duration in days (X-axis). This was done for metagene expressions associated with CD4+ T cells (C) and CD8+ T cells (D). In 
all C-D graphs, respective log-rank (Mantel-Cox) test p-values and hazard ratios (HR; with its 95% confidence interval in 
parenthesis) are displayed. Two dotted lines represent approximate point of 2 and 5 year survival (y.s.) windows. 
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Supplemental Figure S12: 
 
 
 109 
 
 
 
Supplemental Figure S12.  Enlargements of the metagenes associated with specific T cell-types as presented in 
main figure 8 A, B, C and D.  
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Supplementary Table S1. Literature meta-analysis of, prognostic impact of, intra-tumoral T cell infiltration in high-
grade glioma or glioblastoma (GBM) patients. 
 Patient Prognosis 
Untreated/Surgery or Chemo/Radio-therapy-based set-up DC vaccination-based set-
up 
T cells (CD3+ cells) Good(5-7) Poor(8) None(9-11) - - - 
CD4+ T cells Good(7, 12-14) Poor(15) None(5) Good(16) - - 
CD8+ T cells Good (5-7, 13, 15, 17, 18) - None(11, 19) Good(16) - - 
IFN-γ+CD4+ T cells - - - Good(16) - - 
IFN-γ+CD8+ T cells - - - Good(16) - - 
Foxp3+CD4+ T cells (Tregs) - Poor(5, 8, 19-
21) 
None(10, 13, 15, 22) - Poor(23) - 
IL17A+CD4+ T cells (Th17 cells) Good(24) - - - - - 
Following studies were utilized for this meta-analysis: 
  
Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, et al. 2015. Cancer Immunol Immunother DOI: 10.1007/s00262-014-1651-
7 
Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, et al. 2013. J Neuroimmunol 264: 71-83 
Wong ET, Lok E, Gautam S, Swanson KD. 2015. Br J Cancer 113: 232-41 
Wiencke JK, Accomando WP, Zheng S, Patoka J, Dou X, et al. 2012. Epigenetics 7: 1391-402 
Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. 2015. BMC Cancer 15: 617 
Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, et al. 2015. Neuro Oncol 17: 801-9 
Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, et al. 2015. Neuro Oncol 17: 1064-75 
Gousias K, Voulgaris S, Vartholomatos G, Voulgari P, Kyritsis AP, Markou M. 2014. Surg Neurol Int 5: 89 
Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, et al. 2011. Clin Cancer Res 17: 4296-308 
Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, et al. 2011. Clin Cancer Res 17: 5473-80 
Han S, Zhang C, Li Q, Dong J, Liu Y, et al. 2014. Br J Cancer 110: 2560-8 
Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, et al. 2011. J Immunother 34: 382-9 
Kim YH, Jung TY, Jung S, Jang WY, Moon KS, et al. 2012. Br J Neurosurg 26: 21-7 
Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, et al. 2010. J Clin Neurosci 17: 1381-5 
Yue Q, Zhang X, Ye HX, Wang Y, Du ZG, et al. 2014. J Neurooncol 116: 251-9 
El Andaloussi A, Lesniak MS. 2007. J Neurooncol 83: 145-52 
Jacobs JF, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJ, et al. 2010. J Neuroimmunol 225: 195-9 
Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, et al. 2008. Clin Cancer Res 14: 5166-72 
Fong B, Jin R, Wang X, Safaee M, Lisiero DN, et al. 2012. PLoS One 7: e32614 
Cui X, Xu Z, Zhao Z, Sui D, Ren X, et al. 2013. Int J Biol Sci 9: 134-41 
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Supplementary Methods: 
Protein Carbonylation Analysis: The detection of protein carbonyls was performed published previously (25). In brief, 50 µl 
of GL261 cell lysates, corresponding to a total protein concentration of 5-10 mg/ml were incubated with an equal volume of 
200 µM fluorescein-5-thiosemicarbazide (FTC, Sigma-Aldrich) overnight (at room temperature and in dark); 24 h later, 
proteins were precipitated, centrifuged and the supernatant was discarded. Consequently the protein precipitates were 
washed with acetone. The acetone supernatant was discarded followed by air drying of the precipitates. These were then 
solubilized with 50 µl of guanidine hydrochloride (GuHCl, 6M) and diluted with 450 µl of NaH2PO4 (pH 7.0). Protein 
concentrations were then measured via the bicinchoninic (BCA) protein assay kit (Thermo Scientific) and 50 µL of these 
samples were aliquoted in a black microtiter plate and fluorescence was measured with a FlexStation 3 microplate reader 
(Molecular Devices, Berkshire, UK). A standard curve prepared using pure FTC allowed for the calculation of the nanomoles 
of FTC-reacted carbonyls. These values were divided by the protein concentrations to derive the amount of protein carbonyls 
(expressed as, nmol/mg protein). 
Cell death, Cell survival and Clonogenic survival analysis: Cell death analysis was carried out via flow cytometry by 
scoring for cells staining positive for Sytox Green alone or in combination with Annexin-V-APC (BD Biosciences; as 
applicable), as described previously (26); while cell survival analysis was done via MTS assay (Promega), as per the 
manufacturer‟s instructions. Clonogenic survival analysis was carried out as described elsewhere (27). Starting plating 
efficacy was set at 500 cells per plate. Wherever applicable, Tauroursodeoxycholic acid (TUDCA) was purchased from 
Merck-Millipore (Darmstadt, Germany) while Z-Val-Ala-Asp(OMe)-fmk (zVAD-fmk) was purchased from Bachem (Weil am 
Rhein, Germany). 
5-ALA-based PDT treatment: GL261 cells were pre-incubated with 0.5 mM Gliolan® or 5-aminolevulinic acid (Medac 
GmbH, Hamburg, Germany) (for 2 h in serum-free media) followed by light irradiation (2.13 J/cm2) performed as described 
previously (28) and recovered 24 h post-treatment. 
Analysis of DAMPs: After treatment, cells were collected with TrypLE Express (Life Technologies, Belgium), washed, 
incubated for 1 hr at 4°C with anti-CRT (Abcam, Cambridge, UK) or anti-HSP90 (Stressgen) or anti-HSP70 (Santa Cruz 
Antibodies) antibodies; followed by another wash and subsequent incubation for 1 hr at 4°C with goat anti-rabbit or anti-
mouse antibodies conjugated with Alexa Fluor®647 (Invitrogen, Belgium) or DyLight 680/DyLight800 (Thermo Scientific), as 
applicable. After final washes cells were incubated in FACS (Flow Cytometry) buffer (2% FBS, 1% BSA in PBS) including 1 
µM Sytox Green (Life Technologies, S7020) for 15 min and analyzed on Attune Flow Cytometer (Life Technologies). The 
permeabilised cells (i.e. Sytox Green positive cells) were excluded from the analysis, and the mean fluorescence intensity 
(MFIs) for ecto-DAMPs was analyzed. In another case, after treatment, extracellular ATP was measured in the conditioned 
media via ATP Bioluminescent assay kit (Sigma, St. Louis, MO, USA)  as described previously (29). For analysis of passively 
released DAMPs, the „conditioned‟ culture media (5–8 ml), were collected and concentrated to manageable volumes (200–
500 µl) via centrifugation (2000 × g for 5 min) using Pierce Concentrator 7ml/9K filters (Pierce), according to the 
manufacturer‟s instructions. They were then analyzed by immunoblotting. 
Analysis of MHC-I and MHC-II expression levels: GL261 and CT-2A cells were treated (or not) with 200 U/mL 
recombinant murine IFN-γ (Roche) for 48 h. Thereafter the cells were collected, washed and incubated for 30 minutes at 4°C 
with either anti-MHC-I (H2Kb) or anti-MHC-II (I-A/I-E) antibodies conjugated with PE-cyanine 7 (eBioscience). Data 
acquisition was performed on a LSRFortessa flow cytometer (BD Biosciences); and the mean fluorescence intensities (MFI) 
were  analyzed by the FlowJo software. 
Immunoblotting: Immunoblotting was performed as described previously (30, 31). Densitometric analyses were generated 
using Image J. Anti-CHOP, anti-P-eIF2α, anti-Total eIF2α, anti-caspase 3, anti-HSP90 and anti-Bip/GRP78 antibodies were 
purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody against actin was purchased from Sigma (St. 
Louis, MO, USA) while anti-HMGB1 antibody was purchased from Abcam (Cambridge, UK). Secondary antibodies 
conjugated to horseradish peroxidase were purchased from Cell Signaling Technology (Danvers, MA, USA) or Abcam 
(Cambridge, UK). Also, the following secondary antibodies were used: goat anti-mouse-DyLight680 (Thermo Scientific, 
Belgium) and goat anti-rabbit-DyLight800 (Thermo Scientific, Belgium). Chemiluminescence detection was done using the 
Odyssey infrared-imaging system (Li-Cor Biosciences, Lincoln, NE, USA) or ChemidocTM MP system (Bio-Rad, Nazareth 
Eke, Belgium), as applicable. 
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Splenocytes analysis: Spleens were isolated and single cell suspensions were prepared by passaging through a cell 
strainer (BD Biosciences). Next, nylon wool fiber (Polysciences, Germany) was used for enriching T cell fraction. These 
splenocytic T cells were co-cultured with mouse T-activator CD3/CD28 Dynabeads® (positive control; ThermoFisher 
Scientific) or DCs (5:1 ratio) pulsed with naïve or untreated GL261 lysate (prepared via GentleMACS® system) at 200 µg 
protein/106 DCs, for 5 days. At the end of this co-incubation, the respective supernatants were harvested and analyzed for 
secreted IFN-γ levels using the CBA kit (BD Biosciences), as per the manufacturer‟s instructions.  
Literature meta-analysis for prognostic impact of immune-infiltrates in glioblastoma patients: Electronic databases 
including PubMed, Scopus and Web of Knowledge were searched for relevant studies conducted in humans, until 25 th 
November 2015. The following search keywords were used: (“glioblastoma” OR “glioma”) AND (“T lymphocytes”), (“T cells”), 
(“CD3”), (“CD4”), (“IL17A”), (“interferon gamma”), (“Foxp3”) AND (“patient”). To further recognize potentially pertinent stud ies, 
the list of articles identified in the early search, were also scanned manually. Studies or specific results within them were 
considered eligible if they met all of the following criteria: (1) explore the association or correlation between immunoinfiltrates 
and long-term clinical survival parameters like progression-free survival, overall survival or disease free survival and (2) 
explore the association or correlation between immunoinfiltrates and higher glioma/glioblastoma grade. Studies or specific 
results were excluded based on any of the following reasons: (1) not sufficient data reported, (2) letters, reviews, 
commentary, perspectives, case reports, conference abstracts, editorials or expert opinion, (3) studies where correlation was 
done with short-term clinical response determinants like clinical responders (complete or partial response) vs. non-
responders (progressive or stable disease). 
Construction of immune-infiltrate associated metagenes and their prognostic impact in TCGA glioblastoma patient 
data-set: The metagene sets (32) associated with specific immune cell types were taken from either Bindea et al. Immunity, 
2013 (3) (CD4+ T cells, CD8+ T cells, Th1 cells, Th17 cells, CTLs) or Gentles et al. Nature Medicine, 2015 (4) (Tregs). The 
co-expression of the respective genes in each metagene set was re-analysed for the glioblastoma (GBM) patients in order to 
derive GBM-specific T cells-associated metagene sets. Here, The Cancer Genome Atlas (TCGA) (33) gene expression 
dataset (transcriptome data produced by U133 microarray technology) of GBM patients (n=541) (1, 2) was utilized to 
generate correlation submatrix of respective gene‟s expression levels by estimating the respective Pearson‟s correlation 
coefficients, using the cBioPortal (34). These coefficient values were then used to carry out hierarchical clustering (32) 
through the Cluster 3.0 software (35) and the metagene was visualized as a heatmap through TreeView (36). The statistical 
parameters utilized to derive GBM-specific T cells-associated metagene were based on specific centering of highly co-
expressing gene clusters to bona fide T cell markers wherever applicable (as described previously (3, 37)) e.g. Th1 cell-
associated metagene was centred on IFNG gene, Th17 cell-associated metagene was centred on IL17A/RORC genes, 
CTLs/CD8+ T cells-associated metagenes were centred on CD8A/CD8B genes, Treg cell-associated metagene was centred 
on CD3D/CD3G/CD2 gene, while CD4+ T cell-associated metagene didn‟t require specific centering due to highly 
homogeneous expression patterns.  
Thereafter, the respective metagene expression levels in TCGA GBM patient data-set (n=541) and associated clinical 
survival information (overall survival or OS) (1, 2) was analysed through the PROGgeneV2 platform (38). This platform 
stratified the respective patients on the basis of the 75th percentile of overall gene expression profile into two risk-groups i.e. 
high risk or low risk, with respect to the mean of the collective expression of multiple genes/transcripts composing a 
metagene (32). The respective patient risk groups were plotted with respect to OS of the patients to produce respective 
Kaplan-Meier curves using the Graphpad Prism software. Hazard ratio (and its 95% confidence intervals) and log-rank 
(Mantel-Cox) P values were calculated (statistical significance threshold set at p<0.05) (3232). Patients surviving beyond the 
follow-up thresholds were censored.   
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5. FINAL DISCUSSION AND PERSPECTIVES 
“Learn from yesterday, life for today, hope for tomorrow. The important thing is not to stop 
questioning.” 
- Albert Einstein 
5.1. Oxidation in cancer cells as driver of potent DC vaccines 
Over the past five years researchers have realized that besides therapeutically exploiting 
innate or adaptive immune cells directly (e.g. through DC vaccines or adoptive T cell transfer) 
and/or improving the effector function of T cells (through check-point blockade), cancer cells 
themselves need to be made immunogenic either in vivo or ex vivo for application in cancer 
vaccines (179). Our results, as well as increasing data from other groups, point towards a 
critical involvement of oxidative modifications or OAMPs in the immunogenicity of cancer 
cells (116, 130, 131, 216). In this project, we evaluated two different physicochemical 
treatments that are known to induce oxidative stress in cancer cells (i.e. x-ray irradiation and 
Hyp-PDT), for application in DC vaccines. While the former instigates oxidative stress over 
the entire cell, the latter specifically induces it in the ER (177, 178). Our data indirectly 
suggest that ER-directed oxidative stress induced by Hyp-PDT-treatment of the GL261 cells 
might be more effective in the context of DC vaccines. Indeed, Hyp-PDT-based DC vaccines 
yielded higher levels of tumor rejection and a stronger median survival advantage as 
compared to (FT+)IR-DC vaccines or IR+FT-DC vaccines in prophylactic vaccination setups. 
This might be attributed to our observation that Hyp-PDT-treatment of GL261 cells can 
potently stimulate ICD, in addition to its ability to generate OAMPs like carbonylated 
proteins. This enables oxidation- and danger signal-mediated immunogenic signaling 
dependent CTL-, Th1- and Th17-driven glioma rejection (Figure 1). Irradiation- or H202-
based oxidation of signaling-incompetent freeze-thawed GL261 cells, on the other hand, lacks 
this ICD component. Here, the oxidation-induced OAMPs associate with the vaccines‟ 
capacity to reject tumors in a presumably Th1- and CTL-dependent manner (Figure 2).  
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Figure 1: DC vaccines based on Hyp-PDT elicit strong ROS- and DAMPs-dependent 
Th1/Th17/CTL-driven antitumor immunity against orthotopic HGG.  
As can be derived from chapters 3 and 4 and figures 1 and 2, we have put the biggest effort in 
the preclinical evaluation of the Hyp-PDT-based DC vaccines. In fact, FT+IR-DC vaccines 
are already regularly implemented in clinical practice (32, 81, 82, 114, 158-163), making 
extensive preclinical evaluation otiose. We simply wished to address their possible superior 
immunogenicity as compared to standard FT-DC vaccines, given their ability to induce 
oxidative modifications.  
 
Figure 2: OAMPs-based DC vaccines provide protective immunity associated with a 
favorable brain immune-contexture against intracranial HGG 
5.2. Are Th1/Th17-driving DC vaccines the next generation glioma vaccines?  
The data presented in this thesis highlight the importance of eliciting anti-tumor T cell 
responses for effective DC vaccination. In the setting of Hyp-PDT-based DC vaccines, the 
antitumor effects were completely abrogated in CD8
+
 T cell-depleted mice and Rag1
KO
 mice, 
suggesting the critical importance of CD8
+
 effector T cells. These results impose minimal 
contribution of innate immune cells to the antitumor effect of Hyp-PDT-based DC vaccines. 
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Our flowcytometric data confirmed these results, with increased infiltration of intrabrain 
Th1/CTL/Th17 cells relative to reduction in Tregs in prophylactic as well as curative Hyp-
PDT-based vaccination settings. Sayour and colleagues have already demonstrated the 
superior informative value of the effective balances of CD4
+
 and CD8
+
 T cells to Tregs for 
predicting clinical outcomes in GBM patients (26). Of note, TMZ treatment or combined 
chemo-immunotherapy did not affect the NK cell frequencies in our model (data not shown). 
To evaluate the clinical relevance of the T cell subpopulations contributing to the 
immunogenicity of the Hyp-PDT-based DC vaccines in our preclinical model, we performed 
a retrospective analysis based on lymphocyte subpopulation-specific immune signatures in 
541 newly diagnosed GBM patients (available in the TCGA database) (217, 218). Our results 
show a significant survival advantage in GBM patients having a strong prevalence of 
intratumoral Th1/Th17/CTL-linked genetic signatures (i.e., metagenes). Hence, this clinical 
analysis confirms the relevance of the favorable brain immune-contexture we observed in our 
DC vaccinated mice. Interestingly, the patient analysis uncovered the Th17 population (i.e. its 
corresponding molecular signatures) as being the main T cell subpopulation affecting patient 
survival. Th17 cells are known to play both protumorigenic (e.g. by inducing angiogenesis or 
exerting direct immunosuppressive effects) and antitumorigenic roles (e.g. by inducing the 
activation of macrophages and DCs and by stimulating the cytotoxic activity of CTLs and NK 
cells) in different cancer settings (219). This suggests that Th17 cells might be considered a 
double-edged sword depending on multiple factors like tumor type and tumor stage. The 
contribution of Th17 cells to antiglioma immunity is poorly characterized until now, with 
only one study linking IL-17 expression to survival in the HGG patients (33). In line with our 
data, this study designated high intratumoral IL-17A expression levels as an independent 
positive prognostic factor affecting the overall survival of 541 GBM patients. In order to 
ratify these findings, in future, detailed studies should be carried out to evaluate the anti-HGG 
immunological effect of Th17 cells and its possible mediators, especially in (ICD-based) DC 
vaccination settings.  
Together, our preclinical and clinical brain immune-contexture analyses argue that next-
generation (DC)-vaccines should ideally elicit potent combined Th1 and Th17 responses able 
to orchestrate effective cytolytic CTL responses, especially in HGG settings. In addition, our 
findings suggest that HGG patients representing with a pre-existing Th1/CTL/Th17 tumor 
immune-contexture might benefit most from (ICD-based) DC vaccination. To confirm this 
hypothesis it would be of great value to (re)analyze the immune infiltrates in FT(+IR)-DC 
vaccinated HGG patients. In the case of Hyp-PDT-based DC vaccines, new trials will have to 
be initiated. However, considering the fact that Hyp-PDT constitutes a FDA-approved therapy 
and given the notion that Hypericin has proven to be safe when used for fluorescence-guided 
resection in HGG patients, clinical trials testing Hyp-PDT-based DC vaccines in HGG 
patients can be envisaged in the near future.  
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5.3. DAMPs as molecular regulators of potent ICD-based DC vaccines 
Our preclinical study is the first demonstration of a causal association between ICD-
associated DAMPs and the efficacy of ICD-based (DC) vaccines in an orthotopic tumor 
model, especially for HGG. Here, while all three DAMPs contributed to the immunogenicity 
of the vaccine (extracellular-HMGB1>extracellular-ATP>surface-CRT), the HMGB1-MyD88 
axis can be considered the predominant molecular determinant. Moreover, our data confirm 
the necessity of DCs as a cellular adjuvant in this glioma model. While some studies 
suggested the dispensability of cellular adjuvants like DCs in the context of ICD (122), the 
severe HGG-induced immune suppression, including the low immunogenic/tolerant state of 
endogenously circulating APCs (20), might make them indispensible in the setting of HGG.  
Interestingly, through concurrent blockade of all three major ICD-associated DAMPs, we 
showed that these three DAMPs account for most of ICD‟s in vivo potential, leaving little (but 
not null) space  for contribution of other ICD-related DAMPs (like HSPs) or yet 
uncharacterized danger signals.  
Hence, with respect to ICD-based DC vaccines, intratumoral levels of ICD-related DAMPs 
might also constitute promising prognostic and predictive biomarkers (either as single 
DAMPs or as a cluster). Retrospective analysis of data retrieved from published ICD-based 
DC vaccination trials or prospective analysis of new trials (as applicable for Hyp-PDT) should 
corroborate this hypothesis. High serum or intratumoral HMGB1 levels have for instance 
been shown to correlate with improved patient survival following radiotherapy, anthracycline-
based chemotherapy and treatment with oncolytic adenoviruses (179). Interestingly, Di Nicola 
et al. showed that B cell lymphoma patients respond better to DC vaccines loaded with 
autologous cancer cells exposed to a multimodal ICD regimen (consisting of heat shock, γ-ray 
and UVC ray) if the neoplastic cancer cells emitted high amounts of CRT and HSP90 
following the cell death protocol (193).  
5.4. How to reduce the chance of clinical failure of promising preclinical DC 
vaccines? 
It needs to be highlighted that more attention should be paid to some clinically-driven 
considerations when evaluating DC vaccines in preclinical experiments. Indeed, the rigid 
clinically-relevant operational parameters are often not tested in the early stages of anti-cancer 
vaccine development. Eventually these parameters create a stiff “bottleneck” that causes 
failure of several anti-cancer vaccines that pre-clinically showed great translational promise. 
First, one should consider the requirement of 100% mortality of the tumor cells before in vivo 
application. Subcutaneous injection of irradiated tumor cells has already induced 
subcutaneous tumor growth in one GBM patient (79). In general, most single treatment 
modalities (except for non-immunogenic freeze-thawing) cannot meet this requirement, 
postulating their combination with other (potentially less immunogenic) cell killing 
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modalities. A second clinical consideration (especially in multi-center clinical trials) is the 
fact that most tumor specimens arrive in the lab in a frozen state. This implies that a 
significant number of cells have already undergone non-immunogenic necrosis before the 
experimental cell killing strategies can be applied. In case of ICD inducers, this could 
potentially hamper the immunogenicity of the tumor cells as these modalities mainly rely on 
active danger signaling pathways. We have taken these two considerations into account for 
both the OAMPs-based DC vaccines and the Hyp-PDT-based DC vaccines. Finally, for a 
more clinically relevant evaluation of the effect of immunogenic DC vaccines on tumor cell 
stromal interactions, orthotopic tumor inoculation should be preferred. As can be deduced 
from table 3, heterotopic models are most commonly used in DC vaccine settings. However, 
these models suffer from several caveats like the inability to recapitulate the early interaction 
between transformed cells and the immune system and the incompatibility between the cancer 
type and the site of transplantation. Therefore, subcutaneous non-orthotopic models could be 
questioned as the Achilles‟ heel of DC vaccination research. For this reason and others (see 
box 1), we opted for the orthotopic GL261 and CT2A models to conduct our preclinical 
experiments.  Nevertheless, it has to be admitted that no rodent model can perfectly represent 
all immunological parameters.  
5.5. Towards the clinical implementation of Hyp-PDT-based DC vaccines 
We believe that on the basis of the results described in chapter 4, pending final preclinical 
checks (relating to safety and regulatory parameters) and final human ex vivo experiments 
(with autologous patient material), Hyp-PDT-based anti-glioma vaccines can be translated 
towards the clinical in the near future. Beyond the application in glioma setting, our group is 
currently also testing Hyp-PDT-based DC vaccines in ovarian cancer.  
To allow straightforward application of Hyp-PDT-based DC vaccines in the clinical setting 
(including in multicenter clinical trials), we envisage to apply Hyp-PDT-treatment ex vivo on 
a homogenized single cell suspension derived from a snap-frozen HGG tumor specimen. In 
first instance, phase I and II clinical trials of Hyp-PDT-based DC vaccines should focus on 
safety and immune monitoring parameters. With regard to the latter, it will be imperative to 
study the basal immune contexture in the resected HGG tumor tissue (by means of 
flowcytometry/immunohistochemistry/DNA-microarrays). These studies will allow us to 
delineate the single or combined immune cell populations (e.g. formatted as an immunoscore) 
that may favorably impact patient outcome. Moreover, evaluation of pre- and postvaccination 
frequencies of systemic immune cell subtypes can be of interest for characterizing the 
immune populations mainly affected by the vaccine. In addition, it would be very informative 
to evaluate several ICD-related parameters in the ex vivo Hyp-PDT tumor cell homogenate. 
Hyp-PDT-treatment should be able to induce sufficient apoptosis, ER stress and significant 
upregulation of pivotal ICD-related DAMPs (i.e. CRT, HSP70/90, HMGGB1 and ATP). 
 120 
 
Correlating these data with patient survival or immune monitoring data could allow us to 
determine specific cut-off values for predictive purposes. Besides this quality control at the 
level of the tumor cells, the DCs will also be routinely monitored for upregulation of 
maturation markers and for their cytokine profile.  
With the clinical application of Hyp-PDT-based DC vaccines in the offing, one should also 
start envisaging how to implement this immunotherapy in the standard of care treatment 
regimen of HGG patients. Based on our therapeutic preclinical experiments, applying ICD-
based DC vaccines subsequent to a cytoreductive and lymphodepleting TMZ regimen might 
constitute a promising strategy. Indeed, several groups have already uncovered an inverse 
association between tumor burden and immunotherapy effectiveness (40, 81). Moreover, 
Sampson et al. have recently demonstrated that adjuvant TMZ regimens that induce greater 
degrees of lymphopenia (dose-intensified regimen, 100 mg/m
2
 for 21 days during each 28-day 
cycle) can boost antitumor T cell responses induced by EGFRvIII peptide vaccines to a higher 
extend as compared to TMZ regimens that induce less lymphopenia (standard regimen, 200 
mg/m
2
 for 5 days during each 28-day cycle) (220). Here, lymphodepletion, might lower the 
threshold for T cell activation and might trigger homeostatic T cell proliferation in a thymic-
independent, yet antigen-dependent manner. Additionally, TMZ-induced apoptosis can 
release an immense pool of tumor antigens and has been shown to enhance the priming of 
CD4
+
 and CD8
+
 T cells following DC vaccination in the GL26 glioma model (221).  
Unfortunately, even the most potent active immunotherapeutic strategies like (ICD-based) DC 
vaccines will be hampered by the presence of immunomodulatory checkpoint molecules (like 
PD-1 and CTLA-4) that can inhibit cytotoxic immune responses or even induce immune 
tolerance. The development of drugs that can unleash these inhibitory molecules has become 
one of the most active areas in oncology. This provides the opportunity to combine 
checkpoiunt inhibitors with DC-based immunotherapy. In the light of our findings, we believe 
that HGG patients representing with an unfavorable (Th1/Th17/CTL-low) tumor immune-
contexture might benefit most from this combination immunotherapy. The synergistic action 
of CTLA-4 blocking Abs in combination with DC therapy has already been demonstrated in 
advanced melanoma patients and several other trials evaluating this approach are on the 
horizon (40, 222, 223). In August 2015, a phase I clinical trial was set-up to evaluate the 
safety profile of combined nivolumab (a fully human anti-PD-1 antibody) and DC vaccine 
treatment in recurrent HGG patients (NCT02529072). Hence, it would be interesting to test 
the combination of Hyp-PDT-based DC vaccines and checkpoint blockade in our preclinical 
HGG models.  
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Abstract 
HGG represents a highly aggressive CNS malignancy with mortality rates matching incidence 
rates. DC vaccines aiming to stimulate the endogenous antiglioma immune response 
constitute a safe and promising treatment modality. Thus far, the efficacy of DC vaccines is 
considered suboptimal, in part owing to a lack of attention towards the immunogenicity of the 
tumor lysate used as an antigen source for loading the DC vaccines. Given the recent evidence 
that oxidation and the resultant oxidation-associated molecular patterns (OAMPs) can impact 
tumor cell immunogenicity, we applied two physico-chemical oxidizing therapies to obtain a 
more immunogenic tumor cell cargo: x-ray irradiation and hypericin-based photodynamic 
therapy (Hyp-PDT).  
DC vaccine immunogenicity was investigated in the orthotopic, syngeneic GL261 HGG 
model. Mice prophylactically immunized with DC vaccines loaded with x-ray irradiated 
freeze-thawed lysates survived significantly longer as compared to mice vaccinated with DCs 
loaded with freeze-thaw lysate only. This was associated, both in prophylactic and curative 
vaccination setups, with increased intrabrain infiltration of Th1 cells/CTLs and reduced 
infiltration of Tregs, MDSCs and TAMs. Through further application of anti-oxidants and 
hydrogenperoxide, we found a striking correlation between the amount of lysate-associated 
protein carbonylation/OAMPs and the capacity of the DC vaccines to mediate glioma 
rejection. This result fostered the preclinical investigation of other strong oxidizers like Hyp-
PDT, a potent type II inducer of ICD, in our HGG model. Hyp-PDT induced prototypical ICD 
in the GL261 cell line. In prophylactic as well as curative vaccination settings, both 
biologically and clinically-relevant versions of Hyp-PDT-based ICD-based DC vaccines 
provided strong anti-HGG survival benefit. The ability of DC vaccines to elicit HGG rejection 
was significantly blunted if cancer cell-associated ROS and emanating danger signals were 
blocked (either singly or concomitantly; showing hierarchical effect on immunogenicity i.e. 
extracellular-HMGB1>extracellular-ATP>ecto-calreticulin) or if DCs, the DCs-associated 
MyD88 signal or the adaptive immune system (especially CD8
+
 T cells) were depleted. In a 
curative setting, ICD-based DC vaccines synergized with standard-of-care chemotherapy 
(temozolomide) to increase survival of HGG-bearing mice by ~300% resulting in ~50% long-
term survivors. Additionally, DC vaccines also induced an immunostimulatory shift in the 
brain immune-contexture from Tregs to Th1/cytotoxic T lymphocytes/Th17 cells. Analysis of 
the TCGA glioblastoma-cohort confirmed that increased intra-tumor prevalence of 
Th1/cytotoxic T lymphocytes/Th17 cells-linked genetic signatures associated with good 
patient prognosis. 
Our research demonstrates that combining DC vaccination with oxidizing treatment 
modalities can induce Th1-driven antitumor immune responses, enabling CTL-mediated 
 122 
 
glioma rejection. ICD-based DC vaccines exploiting ER-directed oxidative stress might be 
considered next generation DC vaccines.   
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Summary 
In this project, we investigated two approaches to enhance the immunogenicity of tumor 
lysate preparations used for loading dendritic cell (DC) vaccines as a treatment strategy for 
malignant brain tumors (i.e. high-grade gliomas). DC vaccines aim to stimulate the 
endogenous antitumor immune response. This therapy is safe and has been shown to elicit 
antitumor T cell responses and survival benefit in glioma patients. Nevertheless, its efficacy is 
still considered suboptimal, owing to the severe tumor-induced immunosuppression and, 
amongst other DC vaccine parameters, a lack of attention towards the immunogenicity (i.e. 
the ability to provoke an immune response) of the tumor lysate used as an antigen source for 
loading DC vaccines.  
Given the recent evidence that oxidation and the related oxidation-associated molecular 
patterns (OAMPs) can impact tumor cell immunogenicity, we applied two physico-chemical 
oxidizing therapies to obtain an immunogenic tumor cell cargo: x-ray irradiation and 
hypericin-based photodynamic therapy (Hyp-PDT). While the former instigates oxidative 
stress over the entire cancer cell, the latter specifically induces it in the endoplasmatic 
reticulum (ER), this way triggering prototypical immunogenic cell death (ICD). ICD is a cell 
death subroutine which is apoptotic in nature, but associated with enhanced immunogenicity, 
owing to the emission of certain immune activating factors, also called damage-associated 
molecular patterns (DAMPs). 
During my PhD research we have shown that irradiation can enhance the in vivo 
immunogenicity of freeze-thawed necrotic cancer cells used as an antigen source for loading 
DCs. This was demonstrated in an orthotopic mouse glioma model. This survival advantage 
was associated with increased infiltration of antitumor immune cells (i.e., Th1 cells and 
cytotoxic T lymphocytes) in the tumor environment of vaccinated mice (both in 
preventive/prophylactic as well as therapeutic/curative vaccination settings). At the same 
time, the infiltration of certain immunosuppressive immune cells (like Tregs and myeloid-
derived suppressor cells) in the brain was reduced. The increased immunogenicity of DC 
vaccines loaded with irradiated freeze-thaw lysate was, at least in part, mediated by 
irradiation-induced OAMPs like protein carbonylation. Indeed, through further application of 
antioxidants and hydrogenperoxide (a strong oxidizer), we found a striking correlation 
between the amount of lysate-associated protein carbonylation/OAMPs and the capacity of 
the DC vaccines to mediate glioma rejection. 
Previous research has demonstrated that ER-directed oxidative stress, as elicited by Hyp-PDT, 
might be more immunogenic in nature than collateral ER stress, this way inducing more 
potent ICD. Hence, ICD triggered by Hyp-PDT might constitute a very attractive treatment 
modality to increase the efficacy of DC vaccines. In this project, we have shown that Hyp-
PDT can induce prototypical ICD in glioma cell lines. In our mouse glioma model (involving 
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prophylactic as well as curative settings) we have shown that both biologically and clinically-
relevant versions of ICD-based DC vaccines provided a strong antiglioma survival benefit. 
Interestingly, curative treatment with the ICD-based DC vaccines synergized with standard-
of-care chemotherapy (temozolomide), resulting in 50% tumor rejection.  
This ability of the ICD-based DC vaccines to elicit glioma rejection was blunted if cancer 
cell-associated oxidation or emanating danger signals were blocked. Additionally, HGG 
rejection was dependent on an intact adaptive immune system and upon a productive 
(MyD88-signalling dependent) cancer cell-DC interface. Additionally, our ICD-based DC 
vaccines induced infiltration of immune effector T cells (i.e. Th1 cells, cytotoxic T 
lymphocytes and Th17 cells) in the tumor environment, while at the same time reducing the 
accumulation of immunosuppressive Tregs. Analysis of patient data, collected in the TCGA 
(The Cancer Genome Atlas) glioblastoma cohort, confirmed the clinical relevance of this 
immunostimulatory shift in brain immune contexture. This patient analysis revealed that an 
increased intratumor prevalence of genetic signatures associated with Th1/cytotoxic T 
lymphocytes/Th17 cells correlated with good patient prognosis.  
This research highlights the importance of oxidation-driven tumor cell immunogenicity in the 
context of DC vaccines. This finding has important socio-economic impact as it should incite 
researchers to step away from standard non-immunogenic freeze-thaw lysates. At the same 
time it may stimulate researchers to test other strong oxidizers or ICD-inducers in 
combination with DC vaccines. Moreover, the potent Th1/Th17-driven antitumor immunity 
induced by Hyp-PDT-based DC vaccines warrants urgent clinical investigation of this therapy 
in glioma patients, but also in other cancer settings. Given the favorable safety profile of 
Hypericin and its approval by the Food and Drug Administration (in the United States), this 
can be envisaged for the near future.  
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Samenvatting 
In dit project hebben we twee benaderingen bestudeerd om de immunogeniciteit van 
tumorlysaat-bereidingen te verbeteren. Dit tumorlysaat wordt vervolgens gebruikt om 
dendritische cel (DC) vaccins te beladen als behandelingsstrategie voor kwaadaardige 
hersentumoren (i.e. hooggradige gliomen). DC-vaccins beogen het stimuleren van een 
endogene immuunrespons tegen de tumor. Deze therapie is veilig bevonden en kan T-cel-
reacties en een verbeterde overleving bewerkstelligen in gliomapatiënten. Toch wordt de 
werkzaamheid van DC-vaccins nog steeds ondermaats bevonden. Dit is te wijten aan de 
ernstige immuunsuppressie die wordt geïnduceerd door het glioom, alsook aan een gebrek aan 
aandacht voor de immunogeniciteit (i.e. de mogelijkheid om een immuunrespons uit te  
lokken) van het tumorlysaat dat gebruikt wordt als bron van antigenen om de DCs te beladen.  
Gezien het recente bewijs dat oxidatie en de gerelateerde oxidatie-geassocieerde moleculaire 
patronen (OAMPs) de immunogeniciteit van tumorcellen kunnen beïnvloeden, hebben we 
twee fysico-chemische therapieën toegepast om een meer immunogeen tumorlysaat te 
bekomen: bestraling met x-stralen en fotodynamische therapie met hypericine (Hyp-PDT). 
Terwijl de eerste therapie oxidatieve stress induceert over de gehele cel, induceert Hyp-PDT 
dit specifiek in het endoplasmatisch reticulum (ER). Op deze manier veroorzaakt Hyp-PDT 
een immunogene celdood (ICD). Deze vorm van celdood, die apoptotisch is van aard, gaat 
samen met een versterkte immunogeniciteit en dit door een verhoogde vrijzetting van factoren 
die het immuunsysteem activeren, ook wel DAMPs genoemd.  
Tijdens mijn doctoraatsproject hebben we aangetoond dat het bestralen van gevries-dooide 
necrotische kankercellen (die gebruikt worden voor het beladen van de DC vaccins) de 
immunogeniciteit van de DC-vaccins kan verhogen. Dit werd onderzocht in een orthotoop 
muismodel voor glioma. Het overlevingsvoordeel van de muizen ging gepaard met een 
verhoogde infiltratie van antitumorale immuuncellen (i.e. Th1 cellen en cytotoxische T cellen) 
in de omgeving van de tumor van gevaccineerde muizen. Gelijktijdig leidde dit tot een 
verminderde infiltratie van immuunsuppressieve cellen (zoals regulatoire T cellen en tumor-
geassocieerde macrofagen) in de hersenen. De verhoogde immunogeniciteit van de DC-
vaccins beladen met bestraald vries-dooi lysaat werd, tenminste deels, gemedieerd door de 
door bestraling geïnduceerde OAMPs zoals gecarbonyleerde proteïnen. Door verdere 
toepassing van antioxidanten en waterstofperoxide (een sterke oxidator) konden we een sterke 
correlatie aantonen tussen de hoeveelheid gecarbonyleerde proteïnen in het tumorlysaat en de 
capaciteit van de DC-vaccins om de gliomen af te weren.  
Voorgaand onderzoek heeft aangetoond dat oxidatieve stress gericht op het ER, zoals 
uitgelokt wordt door Hyp-PDT, sterker immunogeen kan zijn dan collaterale stress in het ER. 
Oxidatieve stress gericht tot het ER zou ook een krachtige vorm van ICD kunnen uitlokken. 
Vandaar dat ICD, in dit geval veroorzaakt door Hyp-PDT, een zeer aantrekkelijke 
behandelingsmethode zou kunnen zijn om de werkzaamheid van DC-vaccins te verhogen. In 
dit project hebben we aangetoond dat Hyp-PDT een prototypische vorm van ICD kan 
uitlokken in de gliomacellijnen. We hebben in onze muis gliomamodellen aangetoond dat 
zowel biologisch als klinisch relevante versies van de op ICD-gebaseerde DC vaccins een 
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sterk overlevingsvoordeel opleverden in de glioma-dragende muizen. Meer nog, curatieve 
behandeling met deze Hyp-PDT DC-vaccins leidde tot synergie in combinatie met het 
chemotherapeuticum temozolomide. Deze combinatietherapie kon 50% van de muizen 
genezen van glioma.  
De mogelijkheid van ICD-gebaseerde DC vaccins om gliomen af te weren kon onderdrukt 
worden door de oxidatie in de kankercellen of de vrijgestelde DAMPs te blokkeren. 
Bovendien was de glioma-afweer afhankelijk van een intact adaptief immuunsysteem en een 
productieve interfase tussen de kankercel en de DCs (op een MyD88-afhankelijke manier). 
Verder induceerden de op ICD-gebaseerde DC-vaccins een verhoogde infiltratie van 
antitumorale T-cellen (Th1 cellen, cytotoxische T cellen en Th17 cellen) in de omgeving van 
de tumor. Gelijktijdig accumuleerder er mincer immuunsuppressieve regulatoire T-cellen. Een 
analyse van patiëntendata, verzameld in een TCGA glioblastoma-databank van de TCGA 
(The Cancer Genome Atlas), bevestigde de relevantie van deze immuunstimulerende shift in 
de hersenen. Deze patiëntenanalyse onthulde dat een verhoogde prevalentie van 
Th1/cytotoxische T cellen/Th17 genetische handtekeningen in de tumor associeert met een 
betere prognose van gliomapatiënten.  
Dit onderzoek belicht het belang van een door oxidatie gedreven immunogeniciteit van de 
tumorcellen in de context van DC vaccins. Deze bevindingen hebben een aanzienlijke socio-
economische impact, aangezien ze wetenschappers zouden moeten aanzetten om af te stappen 
van het gebruik van standaard (niet immunogeen) vries-dooi lysaat. Tegelijkertijd zou het 
wetenschappers moeten overtuigen om andere sterk oxiderende behandelingen of uitlokkers 
van ICD te testen in combinatie met DC vaccins. Bovendien vraagt de krachtige Th1/Th17-
gedreven antitumorale immuunrespons, die we konden uitlokken met de op Hyp-PDT-
gebaseerde DC vaccins, om een dringende klinische evaluatie van deze therapie. Gezien het 
gunstige veiligheidsprofiel van hypericine en de goedkeuring van dit geneesmiddel door de 
Food and Drug Administration (een overheidsorgaan in de Verenigde Staten), kan dit 
voorzien worden voor de nabije toekomst.  
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